{"PMC7107171": [["INTRODUCTIONInfectious bronchitis is a highly contagious viral disease that may be associated with multi-systemic clinical signs (respiratory, renal, enteric, and reproductive) and reduced production in poultry commercial flocks.", [["respiratory", "ANATOMY", 130, 141], ["renal", "ANATOMY", 143, 148], ["bronchitis", "DISEASE", 23, 33], ["viral disease", "DISEASE", 57, 70], ["respiratory, renal, enteric, and reproductive)", "DISEASE", 130, 176], ["renal", "ORGAN", 143, 148], ["INTRODUCTIONInfectious bronchitis", "PROBLEM", 0, 33], ["a highly contagious viral disease", "PROBLEM", 37, 70], ["multi-systemic clinical signs (respiratory, renal, enteric, and reproductive)", "PROBLEM", 99, 176], ["reduced production in poultry commercial flocks", "PROBLEM", 181, 228], ["bronchitis", "OBSERVATION", 23, 33], ["highly", "OBSERVATION_MODIFIER", 39, 45], ["contagious", "OBSERVATION_MODIFIER", 46, 56], ["viral disease", "OBSERVATION", 57, 70], ["may be associated with", "UNCERTAINTY", 76, 98], ["multi-systemic", "OBSERVATION_MODIFIER", 99, 113], ["renal", "ANATOMY", 143, 148], ["enteric", "ANATOMY", 150, 157], ["reduced", "OBSERVATION_MODIFIER", 181, 188], ["production", "OBSERVATION_MODIFIER", 189, 199], ["commercial flocks", "OBSERVATION", 211, 228]]], ["Besides these, airsacculitis due to co-infection withMycoplasma orEscherichia coli is responsible for the condemnation of a large number of carcasses in slaughterhouses, generating great economic impact on the poultry industry (Cavanagh and Gelb, 2008).", [["airsacculitis", "DISEASE", 15, 28], ["co-infection", "DISEASE", 36, 48], ["withMycoplasma orEscherichia coli", "ORGANISM", 49, 82], ["withMycoplasma orEscherichia coli", "SPECIES", 49, 82], ["withMycoplasma orEscherichia coli", "SPECIES", 49, 82], ["airsacculitis", "PROBLEM", 15, 28], ["co-infection withMycoplasma orEscherichia coli", "PROBLEM", 36, 82], ["co-infection", "OBSERVATION", 36, 48], ["large", "OBSERVATION_MODIFIER", 124, 129], ["number", "OBSERVATION_MODIFIER", 130, 136], ["carcasses", "OBSERVATION", 140, 149], ["great", "OBSERVATION_MODIFIER", 181, 186], ["economic", "OBSERVATION_MODIFIER", 187, 195], ["impact", "OBSERVATION_MODIFIER", 196, 202]]], ["Infectious bronchitis virus (IBV) is a member of theCoronaviridae family and has a single-strand positive sense RNA genome with approximately 27 kb.", [["Infectious bronchitis virus", "DISEASE", 0, 27], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["IBV", "ORGANISM", 29, 32], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 52, 65], ["single-strand positive sense RNA genome", "RNA", 83, 122], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["IBV", "SPECIES", 29, 32], ["Infectious bronchitis virus", "PROBLEM", 0, 27], ["RNA genome", "OBSERVATION", 112, 122]]], ["The IBV has 4 structural proteins: nucleocapsid, membrane, envelope, and spike (S), and this last protein is cleaved in the S1 and S2 subunits after translation (Cavanagh, 2007).", [["membrane", "ANATOMY", 49, 57], ["IBV", "ORGANISM", 4, 7], ["nucleocapsid", "CELLULAR_COMPONENT", 35, 47], ["membrane", "CELLULAR_COMPONENT", 49, 57], ["spike (S)", "GENE_OR_GENE_PRODUCT", 73, 82], ["S1", "GENE_OR_GENE_PRODUCT", 124, 126], ["S2", "GENE_OR_GENE_PRODUCT", 131, 133], ["structural proteins", "PROTEIN", 14, 33], ["nucleocapsid, membrane, envelope, and spike (S)", "PROTEIN", 35, 82], ["S1 and S2 subunits", "PROTEIN", 124, 142], ["IBV", "SPECIES", 4, 7], ["nucleocapsid", "PROBLEM", 35, 47], ["spike (S)", "PROBLEM", 73, 82], ["4 structural", "OBSERVATION_MODIFIER", 12, 24], ["proteins", "OBSERVATION", 25, 33], ["nucleocapsid", "OBSERVATION", 35, 47]]], ["The S gene is highly polymorphic and is the main responsible for the antigenic variation of the virus (Jackwood et al., 2012).INTRODUCTIONInfectious bronchitis virus has tropism for several avian cell types and presents different clinical signs and pathogenic forms according to the affected tissue (Di F\u00e1bio and Buitrago, 2009;Fan et al., 2012).", [["cell", "ANATOMY", 196, 200], ["tissue", "ANATOMY", 292, 298], ["bronchitis", "DISEASE", 149, 159], ["INTRODUCTIONInfectious bronchitis virus", "ORGANISM", 126, 165], ["cell", "CELL", 196, 200], ["tissue", "TISSUE", 292, 298], ["S gene", "DNA", 4, 10], ["INTRODUCTIONInfectious bronchitis virus", "SPECIES", 126, 165], ["the virus", "PROBLEM", 92, 101], ["INTRODUCTIONInfectious bronchitis virus", "PROBLEM", 126, 165], ["tropism", "PROBLEM", 170, 177], ["several avian cell types", "PROBLEM", 182, 206], ["different clinical signs and pathogenic forms", "PROBLEM", 220, 265], ["highly", "OBSERVATION_MODIFIER", 14, 20], ["polymorphic", "OBSERVATION", 21, 32], ["bronchitis", "OBSERVATION", 149, 159], ["several avian cell types", "OBSERVATION", 182, 206]]], ["Initial IBV replication occurs in the respiratory tract, usually in epithelial cells of trachea (eventually also in nasal turbinates, lungs, and air sacs) and the main clinical signs are of a cold.", [["respiratory tract", "ANATOMY", 38, 55], ["epithelial cells", "ANATOMY", 68, 84], ["trachea", "ANATOMY", 88, 95], ["nasal turbinates", "ANATOMY", 116, 132], ["lungs", "ANATOMY", 134, 139], ["air sacs", "ANATOMY", 145, 153], ["IBV", "ORGANISM", 8, 11], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["epithelial cells", "CELL", 68, 84], ["trachea", "ORGAN", 88, 95], ["nasal turbinates", "MULTI-TISSUE_STRUCTURE", 116, 132], ["lungs", "ORGAN", 134, 139], ["air sacs", "MULTI-TISSUE_STRUCTURE", 145, 153], ["epithelial cells", "CELL_TYPE", 68, 84], ["IBV", "SPECIES", 8, 11], ["Initial IBV replication", "TREATMENT", 0, 23], ["nasal turbinates, lungs, and air sacs", "PROBLEM", 116, 153], ["a cold", "PROBLEM", 190, 196], ["IBV replication", "OBSERVATION", 8, 23], ["respiratory tract", "ANATOMY", 38, 55], ["epithelial cells", "OBSERVATION", 68, 84], ["trachea", "ANATOMY", 88, 95], ["nasal turbinates", "ANATOMY", 116, 132], ["lungs", "ANATOMY", 134, 139], ["air sacs", "OBSERVATION", 145, 153], ["main", "OBSERVATION_MODIFIER", 163, 167]]], ["Afterward, the virus replicates in other parts of the body, as the oviduct of the female reproductive tract, urinary system (renal tubular epithelial cells), and several organs of the digestive tract (esophagus, proventriculus, duodenum, jejunum, cloacal bursa, cecal tonsils, rectum, and cloaca).", [["body", "ANATOMY", 54, 58], ["oviduct", "ANATOMY", 67, 74], ["reproductive tract", "ANATOMY", 89, 107], ["urinary system", "ANATOMY", 109, 123], ["renal tubular epithelial cells", "ANATOMY", 125, 155], ["organs", "ANATOMY", 170, 176], ["digestive tract", "ANATOMY", 184, 199], ["esophagus", "ANATOMY", 201, 210], ["proventriculus", "ANATOMY", 212, 226], ["duodenum", "ANATOMY", 228, 236], ["jejunum", "ANATOMY", 238, 245], ["cloacal bursa", "ANATOMY", 247, 260], ["cecal tonsils", "ANATOMY", 262, 275], ["rectum", "ANATOMY", 277, 283], ["cloaca", "ANATOMY", 289, 295], ["body", "ORGANISM_SUBDIVISION", 54, 58], ["oviduct", "ORGAN", 67, 74], ["female reproductive tract", "ANATOMICAL_SYSTEM", 82, 107], ["urinary system", "CELL", 109, 123], ["renal tubular epithelial cells", "CELL", 125, 155], ["organs", "ORGAN", 170, 176], ["digestive tract", "ORGAN", 184, 199], ["esophagus", "ORGAN", 201, 210], ["proventriculus", "ORGAN", 212, 226], ["duodenum", "MULTI-TISSUE_STRUCTURE", 228, 236], ["jejunum", "MULTI-TISSUE_STRUCTURE", 238, 245], ["cloacal bursa", "MULTI-TISSUE_STRUCTURE", 247, 260], ["cecal tonsils", "MULTI-TISSUE_STRUCTURE", 262, 275], ["rectum", "ORGAN", 277, 283], ["cloaca", "ORGAN", 289, 295], ["renal tubular epithelial cells", "CELL_TYPE", 125, 155], ["the virus", "PROBLEM", 11, 20], ["renal tubular epithelial cells", "PROBLEM", 125, 155], ["several organs of the digestive tract (esophagus, proventriculus, duodenum, jejunum, cloacal bursa, cecal tonsils, rectum, and cloaca)", "PROBLEM", 162, 296], ["virus", "OBSERVATION", 15, 20], ["parts", "ANATOMY_MODIFIER", 41, 46], ["body", "ANATOMY_MODIFIER", 54, 58], ["oviduct", "ANATOMY_MODIFIER", 67, 74], ["female", "OBSERVATION", 82, 88], ["reproductive tract", "OBSERVATION", 89, 107], ["urinary system", "ANATOMY", 109, 123], ["renal", "ANATOMY", 125, 130], ["tubular", "ANATOMY_MODIFIER", 131, 138], ["epithelial cells", "OBSERVATION", 139, 155], ["digestive tract", "ANATOMY", 184, 199], ["esophagus", "ANATOMY", 201, 210], ["proventriculus", "ANATOMY_MODIFIER", 212, 226], ["duodenum", "ANATOMY", 228, 236], ["jejunum", "ANATOMY", 238, 245], ["cloacal bursa", "ANATOMY", 247, 260], ["cecal tonsils", "ANATOMY", 262, 275], ["rectum", "ANATOMY", 277, 283], ["cloaca", "ANATOMY", 289, 295]]], ["According to the physiological system affected by IBV, the chickens can present evident clinical signs as respiratory disease, false layers syndrome, decreased egg production, nephritis, and enteric disorders.", [["respiratory", "ANATOMY", 106, 117], ["egg", "ANATOMY", 160, 163], ["respiratory disease", "DISEASE", 106, 125], ["false layers syndrome", "DISEASE", 127, 148], ["decreased egg production", "DISEASE", 150, 174], ["nephritis", "DISEASE", 176, 185], ["enteric disorders", "DISEASE", 191, 208], ["IBV", "ORGANISM", 50, 53], ["chickens", "ORGANISM", 59, 67], ["egg", "ORGANISM_SUBSTANCE", 160, 163], ["chickens", "SPECIES", 59, 67], ["IBV", "SPECIES", 50, 53], ["chickens", "SPECIES", 59, 67], ["respiratory disease", "PROBLEM", 106, 125], ["false layers syndrome", "PROBLEM", 127, 148], ["decreased egg production", "PROBLEM", 150, 174], ["nephritis", "PROBLEM", 176, 185], ["enteric disorders", "PROBLEM", 191, 208], ["respiratory disease", "OBSERVATION", 106, 125], ["false layers syndrome", "OBSERVATION", 127, 148], ["decreased", "OBSERVATION_MODIFIER", 150, 159], ["egg production", "OBSERVATION", 160, 174], ["nephritis", "OBSERVATION", 176, 185], ["enteric disorders", "OBSERVATION", 191, 208]]], ["All these different pathogenic forms have been reported in different poultry producing regions of the world, including Brazil (Cavanagh, 2007;Villarreal et al., 2007;Cavanagh and Gelb, 2008;Di F\u00e1bio and Buitrago, 2009;Cook et al., 2012).INTRODUCTIONConfirmation of the IBV infection must be carried out by laboratory testing.", [["IBV infection", "DISEASE", 269, 282], ["IBV", "ORGANISM", 269, 272], ["IBV", "SPECIES", 269, 272], ["the IBV infection", "PROBLEM", 265, 282], ["laboratory testing", "TEST", 306, 324], ["different", "OBSERVATION_MODIFIER", 10, 19], ["pathogenic", "OBSERVATION", 20, 30], ["IBV", "OBSERVATION_MODIFIER", 269, 272], ["infection", "OBSERVATION", 273, 282]]], ["Classical methodology includes virus isolation in embryonated SPF eggs and subsequent identification by serum neutralization.", [["eggs", "ANATOMY", 66, 70], ["serum", "ANATOMY", 104, 109], ["SPF", "ORGANISM", 62, 65], ["eggs", "ORGANISM", 66, 70], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["SPF", "SPECIES", 62, 65], ["virus isolation", "TREATMENT", 31, 46], ["embryonated SPF eggs", "TREATMENT", 50, 70], ["serum neutralization", "TEST", 104, 124]]], ["The whole process is lengthy and laborious because field isolates usually require more passages to cultivate the virus in embryonated eggs (De Wit, 2000;Cavanagh and Gelb, 2008).", [["the virus", "PROBLEM", 109, 118], ["lengthy", "OBSERVATION_MODIFIER", 21, 28]]], ["Molecular techniques, such as reverse transcription (RT) followed by PCR, do not require prior isolation and therefore have been widely used for detection and genotyping the virus directly from clinical samples (Cavanagh and Gelb, 2008).", [["samples", "ANATOMY", 203, 210], ["Molecular techniques", "TREATMENT", 0, 20], ["reverse transcription", "TREATMENT", 30, 51], ["PCR", "TEST", 69, 72], ["prior isolation", "TREATMENT", 89, 104], ["detection", "TEST", 145, 154], ["genotyping the virus", "PROBLEM", 159, 179]]], ["The main clinical specimen for this analysis is traditionally the trachea, considered the first replication site in the beginning of the infection.", [["specimen", "ANATOMY", 18, 26], ["trachea", "ANATOMY", 66, 73], ["infection", "DISEASE", 137, 146], ["trachea", "ORGAN", 66, 73], ["this analysis", "TEST", 31, 44], ["the first replication site", "PROBLEM", 86, 112], ["the infection", "PROBLEM", 133, 146], ["main", "OBSERVATION_MODIFIER", 4, 8], ["trachea", "ANATOMY", 66, 73], ["infection", "OBSERVATION", 137, 146]]], ["However, the cloaca and cecal tonsils are also recommended because IBV can replicate in the digestive tract in later stages of the infection (De Wit, 2000;Cavanagh and Gelb, 2008).INTRODUCTIONInfectious bronchitis virus control is usually performed with the use of live attenuated or inactivated vaccines (or both) in commercial poultry flocks.", [["cloaca", "ANATOMY", 13, 19], ["cecal tonsils", "ANATOMY", 24, 37], ["digestive tract", "ANATOMY", 92, 107], ["infection", "DISEASE", 131, 140], ["bronchitis", "DISEASE", 203, 213], ["cloaca", "ORGAN", 13, 19], ["cecal tonsils", "ORGAN", 24, 37], ["IBV", "ORGANISM", 67, 70], ["digestive tract", "ORGANISM_SUBDIVISION", 92, 107], ["IBV", "SPECIES", 67, 70], ["the cloaca and cecal tonsils", "PROBLEM", 9, 37], ["IBV", "PROBLEM", 67, 70], ["the infection", "PROBLEM", 127, 140], ["INTRODUCTIONInfectious bronchitis virus control", "TREATMENT", 180, 227], ["inactivated vaccines", "TREATMENT", 284, 304], ["cloaca", "ANATOMY", 13, 19], ["cecal tonsils", "ANATOMY", 24, 37], ["digestive tract", "ANATOMY", 92, 107], ["infection", "OBSERVATION", 131, 140], ["bronchitis", "OBSERVATION", 203, 213], ["poultry flocks", "OBSERVATION", 329, 343]]], ["In Brazil, only Massachusetts (Mass) derived strains are allowed in commercial vaccine production by the Ministry of Agriculture, Livestock and Food Supply (Minist\u00e9rio da Agricultura, Pecu\u00e1ria e Abastecimento).", [["derived strains", "PROBLEM", 37, 52], ["Pecu\u00e1ria e Abastecimento", "TREATMENT", 184, 208], ["Mass", "OBSERVATION", 31, 35]]], ["However, this approach may not be effective when the field strains are different from the vaccine (Cavanagh, 2007).", [["the field strains", "PROBLEM", 49, 66], ["may not be", "UNCERTAINTY", 23, 33]]], ["Further, new serotypes/genotypes (antigenic variants) are continuously emerging in the field due to genetic events (recombination or point mutations) within field and vaccine strains (Jackwood et al., 2012).INTRODUCTIONThe first IBV isolate in Brazil was from the Mass serotype (Hip\u00f3lito, 1957).", [["IBV", "ORGANISM", 229, 232], ["IBV", "SPECIES", 229, 232], ["new serotypes/genotypes (antigenic variants", "TREATMENT", 9, 52], ["genetic events", "PROBLEM", 100, 114], ["point mutations", "PROBLEM", 133, 148], ["new", "OBSERVATION_MODIFIER", 9, 12], ["serotypes", "OBSERVATION", 13, 22], ["Mass", "OBSERVATION", 264, 268]]], ["Three decades later, IBV isolates of at least 5 different antigenic types were found in commercial chickens throughout Brazil (Di F\u00e1bio et al., 2000).", [["IBV", "ORGANISM", 21, 24], ["chickens", "ORGANISM", 99, 107], ["chickens", "SPECIES", 99, 107], ["IBV", "SPECIES", 21, 24], ["chickens", "SPECIES", 99, 107], ["IBV isolates", "TREATMENT", 21, 33], ["antigenic types", "OBSERVATION", 58, 73]]], ["More recent molecular epidemiological studies revealed the predominance of local field variants (identified asBR genotypes) in the majority of the important poultry-producing regions in Brazil (Villarreal et al., 2007;Felippe et al., 2010;Villarreal et al., 2010;Chac\u00f3n et al., 2011;Fraga et al., 2013).", [["molecular epidemiological studies", "TEST", 12, 45], ["local field variants", "PROBLEM", 75, 95], ["asBR genotypes", "PROBLEM", 108, 122], ["local", "OBSERVATION_MODIFIER", 75, 80], ["field variants", "OBSERVATION", 81, 95]]], ["In this period, an IBV strain similar to genotype 4/91 was also described in southeastern Brazil (Villarreal et al., 2010).", [["IBV", "ORGANISM", 19, 22], ["IBV", "SPECIES", 19, 22], ["an IBV strain", "PROBLEM", 16, 29], ["IBV", "OBSERVATION", 19, 22]]], ["Despite these previous works, information about the frequency and distribution of IBV in geographic regions with an increase in poultry production (such as northeast and midwest) as well as the spread of the different genotypes in the physiological systems of the chickens is still scarce and not available, hindering the control and prevention of disease.", [["IBV", "DISEASE", 82, 85], ["IBV", "ORGANISM", 82, 85], ["chickens", "ORGANISM", 264, 272], ["chickens", "SPECIES", 264, 272], ["IBV", "SPECIES", 82, 85], ["chickens", "SPECIES", 264, 272], ["IBV", "PROBLEM", 82, 85], ["an increase in poultry production", "PROBLEM", 113, 146], ["disease", "PROBLEM", 348, 355], ["IBV", "OBSERVATION", 82, 85], ["increase", "OBSERVATION_MODIFIER", 116, 124], ["poultry production", "OBSERVATION", 128, 146], ["disease", "OBSERVATION", 348, 355]]], ["This field study aimed to evaluate the occurrence of IBV in commercial poultry flocks from 3 important producing regions in Brazil and to determine the tropism of this virus (and the main circulating genotypes) to 3 different avian physiological systems (respiratory, digestive, urinary/reproductive) in commercial poultry flocks (broilers and breeders).Clinical Samples ::: MATERIALS AND METHODSSamples were collected from poultry flocks with clinical signs of infectious bronchitis (234 breeders and 198 broilers) in the period of January of 2010 to December of 2011.", [["respiratory", "ANATOMY", 255, 266], ["digestive", "ANATOMY", 268, 277], ["urinary", "ANATOMY", 279, 286], ["infectious bronchitis", "DISEASE", 462, 483], ["IBV", "ORGANISM", 53, 56], ["digestive", "ORGANISM_SUBDIVISION", 268, 277], ["urinary", "ORGANISM_SUBDIVISION", 279, 286], ["broilers", "ORGANISM_SUBDIVISION", 331, 339], ["broilers", "SPECIES", 331, 339], ["broilers", "SPECIES", 506, 514], ["IBV", "SPECIES", 53, 56], ["This field study", "TEST", 0, 16], ["IBV", "PROBLEM", 53, 56], ["this virus", "PROBLEM", 163, 173], ["respiratory, digestive, urinary/reproductive)", "PROBLEM", 255, 300], ["METHODSSamples", "TEST", 389, 403], ["infectious bronchitis", "PROBLEM", 462, 483], ["IBV", "OBSERVATION", 53, 56], ["poultry flocks", "OBSERVATION", 71, 85], ["urinary", "ANATOMY", 279, 286], ["poultry flocks", "OBSERVATION", 315, 329], ["infectious", "OBSERVATION_MODIFIER", 462, 472], ["bronchitis", "OBSERVATION", 473, 483]]], ["These flocks were from farms located in cities of 7 different states in the south (235 flocks), midwest (94 flocks), and northeast (103 flocks) regions from Brazil.", [["These flocks", "PROBLEM", 0, 12], ["flocks", "OBSERVATION", 6, 12]]], ["All the samples were analyzed in pools (set of organs collected from 3 to 5 birds).", [["samples", "ANATOMY", 8, 15], ["organs", "ANATOMY", 47, 53], ["organs", "ORGAN", 47, 53], ["All the samples", "TEST", 0, 15]]], ["Each pool contained organs from specific physiological systems: respiratory (lung, trachea, tracheal swabs), digestive (cecal tonsil and intestine), and urinary/reproductive (kidney, ovary, oviduct).RNA Extraction ::: MATERIALS AND METHODSViral RNA extraction was performed with commercial kits NewGene (Preamp and Prep) according to the protocol of the supplier (Simbios Biotechnology, Cachoeirinha, RS, Brazil).", [["organs", "ANATOMY", 20, 26], ["respiratory", "ANATOMY", 64, 75], ["lung", "ANATOMY", 77, 81], ["trachea", "ANATOMY", 83, 90], ["tracheal swabs", "ANATOMY", 92, 106], ["digestive", "ANATOMY", 109, 118], ["cecal tonsil", "ANATOMY", 120, 132], ["intestine", "ANATOMY", 137, 146], ["urinary", "ANATOMY", 153, 160], ["kidney", "ANATOMY", 175, 181], ["ovary", "ANATOMY", 183, 188], ["oviduct", "ANATOMY", 190, 197], ["organs", "ORGAN", 20, 26], ["lung", "ORGAN", 77, 81], ["trachea", "MULTI-TISSUE_STRUCTURE", 83, 90], ["tracheal swabs", "MULTI-TISSUE_STRUCTURE", 92, 106], ["digestive", "ORGAN", 109, 118], ["cecal tonsil", "MULTI-TISSUE_STRUCTURE", 120, 132], ["intestine", "ORGAN", 137, 146], ["urinary", "ORGANISM_SUBDIVISION", 153, 160], ["kidney", "ORGAN", 175, 181], ["ovary", "ORGAN", 183, 188], ["oviduct", "ORGAN", 190, 197], ["respiratory (lung, trachea, tracheal swabs", "PROBLEM", 64, 106], ["digestive (cecal tonsil and intestine", "PROBLEM", 109, 146], ["urinary/reproductive (kidney, ovary, oviduct", "PROBLEM", 153, 197], ["METHODSViral RNA extraction", "TREATMENT", 232, 259], ["commercial kits NewGene (Preamp and Prep)", "TREATMENT", 279, 320], ["respiratory", "ANATOMY", 64, 75], ["lung", "ANATOMY", 77, 81], ["trachea", "ANATOMY", 83, 90], ["tracheal", "ANATOMY", 92, 100], ["digestive", "ANATOMY", 109, 118], ["cecal tonsil", "ANATOMY", 120, 132], ["intestine", "ANATOMY", 137, 146], ["urinary", "ANATOMY", 153, 160], ["reproductive", "OBSERVATION", 161, 173], ["kidney", "ANATOMY", 175, 181], ["ovary", "ANATOMY", 183, 188], ["oviduct", "ANATOMY", 190, 197]]], ["Briefly, swabs and macerated organs from each pool were placed in 1 mL of lysis solution (Preamp) and incubated for 10 min at 60\u00b0C. After centrifugation for 1 min (8,609 \u00d7g at room temperature), 0.5 mL was removed and added to a new tube containing 20 \u00b5L of silica suspension.", [["swabs", "ANATOMY", 9, 14], ["organs", "ANATOMY", 29, 35], ["silica", "CHEMICAL", 258, 264], ["silica", "CHEMICAL", 258, 264], ["organs", "ORGAN", 29, 35], ["tube", "TISSUE", 233, 237], ["silica", "SIMPLE_CHEMICAL", 258, 264], ["swabs", "TREATMENT", 9, 14], ["lysis solution", "TREATMENT", 74, 88], ["a new tube", "TREATMENT", 227, 237], ["silica suspension", "TREATMENT", 258, 275], ["tube", "OBSERVATION", 233, 237], ["silica suspension", "OBSERVATION", 258, 275]]], ["The tube was again centrifuged for 1 min (8,609 \u00d7g at room temperature).", [["tube", "ANATOMY", 4, 8], ["tube", "TISSUE", 4, 8], ["The tube", "TREATMENT", 0, 8], ["tube", "OBSERVATION", 4, 8]]], ["The supernatant was discarded and the pellet washed successively with 150 \u00b5L of wash solutions A, B, and C (Prep).", [["supernatant", "ANATOMY", 4, 15], ["pellet", "ANATOMY", 38, 44], ["B", "SIMPLE_CHEMICAL", 98, 99], ["C", "SIMPLE_CHEMICAL", 105, 106], ["The supernatant", "TREATMENT", 0, 15], ["the pellet", "TREATMENT", 34, 44], ["wash solutions", "TREATMENT", 80, 94], ["B, and C (Prep", "TREATMENT", 98, 112]]], ["After the last wash, the silica was dried at 60\u00b0C and total RNA was eluted with 50 \u00b5L of elution buffer.IBV Detection ::: MATERIALS AND METHODSInfectious bronchitis virus was detected by reverse transcription followed by real-time TaqMan PCR (RT-qPCR) as previously described (Callison et al., 2006).", [["silica", "CHEMICAL", 25, 31], ["bronchitis", "DISEASE", 154, 164], ["silica", "CHEMICAL", 25, 31], ["silica", "SIMPLE_CHEMICAL", 25, 31], ["C", "GENE_OR_GENE_PRODUCT", 48, 49], ["METHODSInfectious bronchitis virus", "ORGANISM", 136, 170], ["IBV", "SPECIES", 104, 107], ["bronchitis virus", "SPECIES", 154, 170], ["the silica", "TREATMENT", 21, 31], ["total RNA", "TREATMENT", 54, 63], ["elution buffer", "TREATMENT", 89, 103], ["METHODSInfectious bronchitis virus", "PROBLEM", 136, 170], ["TaqMan PCR", "TEST", 231, 241], ["silica", "ANATOMY", 25, 31], ["bronchitis", "OBSERVATION", 154, 164]]], ["All the amplification reactions were performed in a StepOnePlus Real Time PCR System (Applied Biosystems, Norwalk, CT) under the following conditions: 1 cycle of 37\u00b0C for 30 min, followed by 40 cycles at 95\u00b0C for 15 s and 60\u00b0C for 1 min.IBV Genotyping ::: MATERIALS AND METHODSSome RT-qPCR-positive samples were randomly selected for IBV genotyping.", [["samples", "ANATOMY", 299, 306], ["IBV", "ORGANISM", 334, 337], ["IBV", "SPECIES", 237, 240], ["IBV", "SPECIES", 334, 337], ["CT", "TEST", 115, 117], ["MATERIALS", "TEST", 256, 265], ["METHODSSome RT-qPCR", "TEST", 270, 289], ["positive samples", "PROBLEM", 290, 306], ["IBV genotyping", "TREATMENT", 334, 348]]], ["The RNA from these samples was subjected to RT-nested-PCR amplification and sequencing of the S1 IBV gene as previously described (Fraga et al., 2013).", [["samples", "ANATOMY", 19, 26], ["samples", "CANCER", 19, 26], ["IBV", "ORGANISM", 97, 100], ["S1 IBV gene", "DNA", 94, 105], ["IBV", "SPECIES", 97, 100], ["these samples", "TEST", 13, 26], ["RT", "TEST", 44, 46], ["PCR amplification", "TEST", 54, 71], ["S1 IBV", "ANATOMY", 94, 100]]], ["Phylogenetic analysis was performed based on the nucleotide sequence, and the samples were classified in genotypes Mass and BR, the latter including the Brazilian variant genotypes BR-I and BR-II (Fraga et al., 2013).Statistical Analysis ::: MATERIALS AND METHODSChi-squared test was used to compare the frequencies of IBV-positive flocks (and also the main genotypes) in the different geographic regions, age categories, and physiological systems.", [["samples", "ANATOMY", 78, 85], ["nucleotide", "CHEMICAL", 49, 59], ["BR-I", "GENE_OR_GENE_PRODUCT", 181, 185], ["BR-II", "GENE_OR_GENE_PRODUCT", 190, 195], ["IBV", "ORGANISM", 319, 322], ["IBV", "SPECIES", 319, 322], ["Phylogenetic analysis", "TEST", 0, 21], ["the nucleotide sequence", "TEST", 45, 68], ["the samples", "TEST", 74, 85], ["genotypes Mass", "PROBLEM", 105, 119], ["METHODSChi-squared test", "TEST", 256, 279], ["IBV", "PROBLEM", 319, 322], ["positive flocks", "PROBLEM", 323, 338], ["Mass", "OBSERVATION", 115, 119], ["positive flocks", "OBSERVATION", 323, 338], ["main", "OBSERVATION_MODIFIER", 353, 357]]], ["Poultry flocks were classified according to the geographic origin in 3 groups: midwest (centro-oeste), northeast (nordeste), and south (sul).", [["Poultry flocks", "PROBLEM", 0, 14]]], ["They were also classified into 4 categories for age comparison analysis: young broilers (0 to 4.5 wk), old broilers (4.6 to 9.0 wk), young breeders (0 to 33 wk), and old breeders (33.1 to 66 wk).", [["broilers", "ORGANISM", 107, 115], ["broilers", "SPECIES", 79, 87], ["broilers", "SPECIES", 107, 115]]], ["The clinical samples were finally divided in 3 groups according to the analyzed specimen: respiratory (lung, trachea, tracheal swabs), digestive (cecal tonsils and intestines), and urinary/reproductive (kidney, ovary, oviduct).", [["samples", "ANATOMY", 13, 20], ["specimen", "ANATOMY", 80, 88], ["respiratory", "ANATOMY", 90, 101], ["lung", "ANATOMY", 103, 107], ["trachea", "ANATOMY", 109, 116], ["tracheal swabs", "ANATOMY", 118, 132], ["digestive", "ANATOMY", 135, 144], ["cecal tonsils", "ANATOMY", 146, 159], ["intestines", "ANATOMY", 164, 174], ["urinary", "ANATOMY", 181, 188], ["kidney", "ANATOMY", 203, 209], ["ovary", "ANATOMY", 211, 216], ["oviduct", "ANATOMY", 218, 225], ["lung", "ORGAN", 103, 107], ["trachea", "MULTI-TISSUE_STRUCTURE", 109, 116], ["tracheal swabs", "MULTI-TISSUE_STRUCTURE", 118, 132], ["digestive", "ORGAN", 135, 144], ["cecal tonsils", "MULTI-TISSUE_STRUCTURE", 146, 159], ["intestines", "ORGAN", 164, 174], ["urinary", "ORGANISM_SUBDIVISION", 181, 188], ["kidney", "ORGAN", 203, 209], ["ovary", "ORGAN", 211, 216], ["oviduct", "ORGAN", 218, 225], ["The clinical samples", "TEST", 0, 20], ["respiratory (lung, trachea, tracheal swabs", "PROBLEM", 90, 132], ["digestive (cecal tonsils and intestines", "PROBLEM", 135, 174], ["urinary/reproductive (kidney, ovary, oviduct", "PROBLEM", 181, 225], ["respiratory", "ANATOMY", 90, 101], ["lung", "ANATOMY", 103, 107], ["trachea", "ANATOMY", 109, 116], ["tracheal", "ANATOMY", 118, 126], ["cecal tonsils", "ANATOMY", 146, 159], ["intestines", "ANATOMY", 164, 174], ["urinary", "ANATOMY", 181, 188], ["kidney", "ANATOMY", 203, 209], ["ovary", "ANATOMY", 211, 216], ["oviduct", "ANATOMY", 218, 225]]], ["Differences were considered significant whenP < 0.05.IBV in Different Brazilian Regions ::: RESULTSIn this study, 1,294 organ pools were analyzed with a total of 382 broiler pools (from 198 different flocks) and 912 breeder pools (from 234 flocks).", [["organ", "ANATOMY", 120, 125], ["IBV", "ORGANISM", 53, 56], ["organ", "ORGAN", 120, 125], ["IBV", "SPECIES", 53, 56], ["this study", "TEST", 102, 112], ["organ pools", "TEST", 120, 131]]], ["Breeders were usually more sampled (average 3.9 samples / flock) than broilers (average 1.9 samples/flock).", [["broilers", "ORGANISM_SUBDIVISION", 70, 78], ["broilers", "SPECIES", 70, 78], ["broilers", "SPECIES", 70, 78], ["broilers", "TREATMENT", 70, 78]]], ["The flock was considered IBV positive when at least one pool of the different systems (respiratory, digestive, urinary/reproductive) presented a positive amplification result by RT-qPCR.", [["respiratory", "ANATOMY", 87, 98], ["digestive", "ANATOMY", 100, 109], ["urinary", "ANATOMY", 111, 118], ["IBV", "ORGANISM", 25, 28], ["digestive", "ORGAN", 100, 109], ["urinary", "ORGANISM_SUBDIVISION", 111, 118], ["IBV", "SPECIES", 25, 28], ["The flock", "TREATMENT", 0, 9], ["IBV positive", "PROBLEM", 25, 37], ["respiratory", "ANATOMY", 87, 98], ["urinary", "ANATOMY", 111, 118]]], ["A total of 179 flocks (41.4%) presented positive result for IBV, 107 (24.8%) from broilers and 72 (16.8%) from breeders.", [["IBV", "ORGANISM", 60, 63], ["broilers", "SPECIES", 82, 90], ["IBV", "SPECIES", 60, 63], ["flocks", "TEST", 15, 21], ["IBV", "TEST", 60, 63], ["broilers", "TEST", 82, 90]]], ["There was no significant difference in the IBV frequency in breeder (30.8 \u00b1 5.4%) and broiler (54% \u00b1 8.4%) flocks from different geographical regions, but the higher IBV frequency in broiler than in breeder flocks was observed in the 3 geographic regions (Figure 1).IBV in Different Brazilian Regions ::: RESULTSInfectious bronchitis virus from 79 randomly selected flocks (45 broilers and 34 breeders) was genotyped by performing S1 gene partial sequencing.", [["bronchitis", "DISEASE", 323, 333], ["IBV", "ORGANISM", 266, 269], ["S1 gene", "DNA", 431, 438], ["broilers", "SPECIES", 377, 385], ["IBV", "SPECIES", 43, 46], ["IBV", "SPECIES", 166, 169], ["breeder", "SPECIES", 199, 206], ["IBV", "SPECIES", 266, 269], ["RESULTSInfectious bronchitis virus", "SPECIES", 305, 339], ["significant difference", "PROBLEM", 13, 35], ["the IBV frequency", "TEST", 39, 56], ["broiler", "TEST", 86, 93], ["flocks from different geographical regions", "PROBLEM", 107, 149], ["the higher IBV frequency", "PROBLEM", 155, 179], ["breeder flocks", "PROBLEM", 199, 213], ["RESULTSInfectious bronchitis virus", "PROBLEM", 305, 339], ["S1 gene partial sequencing", "TREATMENT", 431, 457], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["IBV", "OBSERVATION", 43, 46], ["higher", "OBSERVATION_MODIFIER", 159, 165], ["IBV frequency", "OBSERVATION", 166, 179], ["breeder flocks", "OBSERVATION", 199, 213], ["bronchitis", "OBSERVATION", 323, 333]]], ["Sequence analysis showed the occurrence of 3 genotypes, 23 samples (29.1%) of the Mass vaccine, 52 samples (65.8%) of the field variant BR-I (Chac\u00f3n et al., 2011;Fraga et al., 2013), and 4 samples (5.1%) of the field variant BR-II (Fraga et al., 2013).", [["samples", "ANATOMY", 59, 66], ["samples", "ANATOMY", 99, 106], ["Sequence analysis", "TEST", 0, 17], ["3 genotypes", "PROBLEM", 43, 54], ["23 samples", "TEST", 56, 66], ["the Mass vaccine", "TEST", 78, 94], ["samples", "TEST", 99, 106], ["Mass", "OBSERVATION", 82, 86]]], ["The 2 Brazilian genotypes (BR-I and BR-II) were grouped as BR variants for the subsequent analyses.", [["BR-I", "GENE_OR_GENE_PRODUCT", 27, 31], ["BR-II", "GENE_OR_GENE_PRODUCT", 36, 41], ["BR", "PROTEIN", 27, 29], ["BR variants", "DNA", 59, 70], ["The 2 Brazilian genotypes", "TREATMENT", 0, 25], ["the subsequent analyses", "TEST", 75, 98]]], ["Genotypes Mass and BR were detected in broiler and breeder flocks from the 3 regions.", [["BR", "GENE_OR_GENE_PRODUCT", 19, 21], ["broiler", "ORGANISM_SUBDIVISION", 39, 46], ["Genotypes Mass", "PROBLEM", 0, 14], ["Mass", "OBSERVATION", 10, 14], ["BR", "ANATOMY", 19, 21], ["breeder flocks", "OBSERVATION", 51, 65]]], ["Mass genotype was identified in 20 broiler flocks and in 3 breeder flocks.", [["Mass genotype", "PROBLEM", 0, 13], ["20 broiler", "OBSERVATION_MODIFIER", 32, 42], ["flocks", "OBSERVATION", 43, 49], ["breeder flocks", "OBSERVATION", 59, 73]]], ["The BR was more frequent and widespread than Mass genotype, being detected in 25 broiler and 31 breeder flocks.", [["BR", "GENE_OR_GENE_PRODUCT", 4, 6], ["BR", "PROTEIN", 4, 6], ["Mass genotype", "PROBLEM", 45, 58], ["BR", "ANATOMY", 4, 6], ["more frequent", "OBSERVATION_MODIFIER", 11, 24], ["widespread", "OBSERVATION_MODIFIER", 29, 39], ["Mass", "OBSERVATION", 45, 49]]], ["The proportion of Mass genotype in broilers was significantly higher than that observed in breeders (P < 0.05).IBV in Flocks with Different Ages ::: RESULTSAge information was available for 174 broiler and 227 breeder flocks (these data were missing in 24 broiler and 5 breeder flocks).", [["broilers", "ORGANISM", 35, 43], ["IBV", "ORGANISM", 111, 114], ["broilers", "SPECIES", 35, 43], ["IBV", "SPECIES", 111, 114], ["Mass genotype in broilers", "PROBLEM", 18, 43], ["these data", "TEST", 226, 236], ["Mass", "OBSERVATION", 18, 22], ["broilers", "OBSERVATION_MODIFIER", 35, 43], ["significantly", "OBSERVATION_MODIFIER", 48, 61], ["higher", "OBSERVATION_MODIFIER", 62, 68]]], ["Infectious bronchitis virus was detected in 101 (58%) broiler flocks, 36 (35.6%) between 0 and 4.5 wk (younger broilers) and 65 (64.4%) between 4.6 and 9.0 wk (older broilers).", [["Infectious bronchitis virus", "DISEASE", 0, 27], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["broilers", "ORGANISM_SUBDIVISION", 166, 174], ["broilers", "SPECIES", 111, 119], ["broilers", "SPECIES", 166, 174], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["Infectious bronchitis virus", "PROBLEM", 0, 27], ["broiler flocks", "TEST", 54, 68]]], ["In breeders, 70 (30.8%) were IBV positive, 43 (61.4%) between 0 and 33 wk (younger breeders) and 27 (38.6%) between 33.1 and 66 wk of age (older breeders; difference not significant).", [["IBV", "ORGANISM", 29, 32], ["IBV", "SPECIES", 29, 32], ["IBV", "TEST", 29, 32]]], ["In addition, age and genotype (Mass or BR) were available for 74 flocks (41 broilers and 33 breeders).", [["broilers", "SPECIES", 76, 84], ["genotype (Mass or BR)", "PROBLEM", 21, 42]]], ["In broilers, the Mass genotype was detected more often in younger ages (0.0 to 4.5 wk) than BR strains (62.5 \u00d7 37.5%), whereas BR genotypes were largely predominant (88.2%) in the older ages (4.6 to 9 wk;P < 0.05).", [["broilers", "ORGANISM", 3, 11], ["BR", "GENE_OR_GENE_PRODUCT", 127, 129], ["broilers", "SPECIES", 3, 11], ["the Mass genotype", "PROBLEM", 13, 30], ["BR strains", "TEST", 92, 102], ["BR genotypes", "TEST", 127, 139], ["P", "TEST", 204, 205], ["Mass", "OBSERVATION", 17, 21], ["predominant", "OBSERVATION_MODIFIER", 153, 164]]], ["In breeders, BR strains were predominant (90.9%) in all ages (Table 1).IBV in Different Avian Physiological Systems ::: RESULTSBroiler and breeder flocks were classified into 7 groups according to the availability of the IBV results from the different physiological systems: digestive, respiratory, and urinary/reproductive (these last 2 were grouped together;Table 2).", [["digestive", "ANATOMY", 275, 284], ["respiratory", "ANATOMY", 286, 297], ["urinary", "ANATOMY", 303, 310], ["BR strains", "ORGANISM", 13, 23], ["IBV", "ORGANISM", 71, 74], ["IBV", "ORGANISM", 221, 224], ["digestive", "ORGAN", 275, 284], ["urinary", "ORGANISM_SUBDIVISION", 303, 310], ["IBV", "SPECIES", 71, 74], ["IBV", "SPECIES", 221, 224], ["BR strains", "TEST", 13, 23], ["breeder flocks", "TREATMENT", 139, 153], ["urinary/reproductive", "PROBLEM", 303, 323], ["digestive", "ANATOMY", 275, 284], ["respiratory", "ANATOMY", 286, 297], ["urinary", "ANATOMY", 303, 310]]], ["The results from 73 flocks (59 broiler and 14 breeder flocks) could not be compared because the organs from different systems were mixed in a unique pool for the analysis.", [["organs", "ANATOMY", 96, 102], ["organs", "ORGAN", 96, 102], ["broiler and 14 breeder flocks", "TREATMENT", 31, 60], ["the analysis", "TEST", 158, 170]]], ["Available analysis results from the remaining flocks were mostly obtained from the respiratory system (131 broiler, 200 breeder), followed by the digestive (62 broiler, 82 breeder) and urinary/reproductive (37 broiler, 109 breeder) systems (Table 3).IBV in Different Avian Physiological Systems ::: RESULTSInfectious bronchitis virus-positive samples were mostly found in samples of the digestive (59/144, 40.9%), followed by respiratory (82/331, 24.7%) and urinary/reproductive (24/146, 16.4%) systems, these last 2 without a significant difference (P < 0.05).", [["digestive", "ANATOMY", 146, 155], ["urinary", "ANATOMY", 185, 192], ["samples", "ANATOMY", 343, 350], ["samples", "ANATOMY", 372, 379], ["digestive", "ANATOMY", 387, 396], ["respiratory", "ANATOMY", 426, 437], ["urinary", "ANATOMY", 458, 465], ["bronchitis", "DISEASE", 317, 327], ["digestive", "ORGAN", 146, 155], ["urinary", "ORGANISM_SUBDIVISION", 185, 192], ["IBV", "ORGANISM", 250, 253], ["RESULTSInfectious bronchitis virus", "ORGANISM", 299, 333], ["digestive", "ORGAN", 387, 396], ["urinary", "ORGANISM_SUBDIVISION", 458, 465], ["IBV", "SPECIES", 250, 253], ["Available analysis", "TEST", 0, 18], ["urinary/reproductive", "PROBLEM", 185, 205], ["RESULTSInfectious bronchitis virus", "PROBLEM", 299, 333], ["positive samples", "PROBLEM", 334, 350], ["respiratory", "TEST", 426, 437], ["urinary/reproductive", "TEST", 458, 478], ["respiratory system", "ANATOMY", 83, 101], ["urinary", "ANATOMY", 185, 192], ["digestive", "ANATOMY", 387, 396], ["urinary", "ANATOMY", 458, 465], ["significant", "OBSERVATION_MODIFIER", 527, 538]]], ["In the separate analysis of broiler and breeder flocks results, this finding was confirmed only for breeders, because 32 of 82 (39%) were IBV positive in the digestive system, in comparison with 33 of 200 (16.5%) in the respiratory and 18 of 109 (16.5%) in the urinary/reproductive systems (P < 0.05).", [["digestive system", "ANATOMY", 158, 174], ["respiratory", "ANATOMY", 220, 231], ["urinary", "ANATOMY", 261, 268], ["IBV", "ORGANISM", 138, 141], ["digestive", "ORGAN", 158, 167], ["system", "ANATOMICAL_SYSTEM", 168, 174], ["urinary", "ORGANISM_SUBDIVISION", 261, 268], ["IBV", "SPECIES", 138, 141], ["IBV positive in the digestive system", "PROBLEM", 138, 174], ["the respiratory", "TEST", 216, 231], ["the urinary/reproductive systems", "TEST", 257, 289], ["digestive system", "ANATOMY", 158, 174], ["respiratory", "ANATOMY", 220, 231], ["urinary", "ANATOMY", 261, 268]]], ["In broilers, the frequency of IBV detection was similar in the digestive (27 of 62, 43.5%) and respiratory (49 of 131, 37.4%) systems, which were significantly higher than in samples of the urinary/reproductive systems (6 of 37, 16.2%;P < 0.05;Table 3).IBV in Different Avian Physiological Systems ::: RESULTSThese results were confirmed in the comparative analysis of 87 flocks (27 broiler and 60 breeder), which had PCR results for the 3 organ groups (digestive, respiratory, and urinary/reproductive).", [["digestive", "ANATOMY", 63, 72], ["respiratory", "ANATOMY", 95, 106], ["samples", "ANATOMY", 175, 182], ["urinary", "ANATOMY", 190, 197], ["organ", "ANATOMY", 440, 445], ["digestive", "ANATOMY", 454, 463], ["respiratory", "ANATOMY", 465, 476], ["urinary", "ANATOMY", 482, 489], ["broilers", "ORGANISM", 3, 11], ["IBV", "ORGANISM", 30, 33], ["digestive", "ORGAN", 63, 72], ["urinary", "ORGANISM_SUBDIVISION", 190, 197], ["IBV", "ORGANISM", 253, 256], ["organ", "ORGAN", 440, 445], ["digestive", "ORGAN", 454, 463], ["urinary", "ORGANISM_SUBDIVISION", 482, 489], ["broilers", "SPECIES", 3, 11], ["IBV", "SPECIES", 30, 33], ["IBV", "SPECIES", 253, 256], ["IBV detection", "TEST", 30, 43], ["respiratory", "TEST", 95, 106], ["the urinary/reproductive systems", "TEST", 186, 218], ["P", "TEST", 235, 236], ["the comparative analysis", "TEST", 341, 365], ["PCR", "TEST", 418, 421], ["respiratory", "ANATOMY", 95, 106], ["significantly", "OBSERVATION_MODIFIER", 146, 159], ["higher", "OBSERVATION_MODIFIER", 160, 166], ["urinary", "ANATOMY", 190, 197], ["respiratory", "ANATOMY", 465, 476], ["urinary", "ANATOMY", 482, 489]]], ["In broilers, IBV was commonly detected in the samples of the digestive and respiratory tracts (9 out of 12, 75% for both groups), but rarely in samples of the urinary/reproductive systems (2 out of 12, 16.7%;P < 0.01).", [["samples", "ANATOMY", 46, 53], ["digestive", "ANATOMY", 61, 70], ["respiratory tracts", "ANATOMY", 75, 93], ["samples", "ANATOMY", 144, 151], ["urinary", "ANATOMY", 159, 166], ["broilers", "ORGANISM", 3, 11], ["IBV", "ORGANISM", 13, 16], ["digestive", "ORGAN", 61, 70], ["respiratory tracts", "ORGANISM_SUBDIVISION", 75, 93], ["urinary", "ORGANISM_SUBDIVISION", 159, 166], ["broilers", "SPECIES", 3, 11], ["broilers", "SPECIES", 3, 11], ["IBV", "SPECIES", 13, 16], ["IBV", "TREATMENT", 13, 16], ["the urinary/reproductive systems", "TEST", 155, 187], ["P", "TEST", 208, 209], ["IBV", "OBSERVATION", 13, 16], ["digestive", "ANATOMY", 61, 70], ["respiratory tracts", "ANATOMY", 75, 93], ["urinary", "ANATOMY", 159, 166]]], ["In breeders, IBV was detected mainly in the samples of the digestive system (22 out of 26, 84.6%), whereas virus frequency detection was significantly lower in the samples of the respiratory (6 out of 26, 23.1%) and urinary/reproductive (11 out of 26, 42.3%) systems (P < 0.01;Table 4).IBV in Different Avian Physiological Systems ::: RESULTSGenotypes Mass and BR were found in the different physiological systems investigated.", [["samples", "ANATOMY", 44, 51], ["digestive system", "ANATOMY", 59, 75], ["samples", "ANATOMY", 164, 171], ["respiratory", "ANATOMY", 179, 190], ["urinary", "ANATOMY", 216, 223], ["IBV", "ORGANISM", 13, 16], ["digestive", "ORGAN", 59, 68], ["system", "ANATOMICAL_SYSTEM", 69, 75], ["IBV", "ORGANISM", 286, 289], ["IBV", "SPECIES", 13, 16], ["IBV", "SPECIES", 286, 289], ["IBV", "PROBLEM", 13, 16], ["virus frequency detection", "TEST", 107, 132], ["the respiratory", "TEST", 175, 190], ["urinary/reproductive", "TEST", 216, 236], ["P", "TEST", 268, 269], ["IBV", "TREATMENT", 286, 289], ["RESULTSGenotypes Mass", "PROBLEM", 335, 356], ["BR", "PROBLEM", 361, 363], ["IBV", "OBSERVATION", 13, 16], ["digestive system", "ANATOMY", 59, 75], ["lower", "OBSERVATION_MODIFIER", 151, 156], ["respiratory", "ANATOMY", 179, 190], ["urinary", "ANATOMY", 216, 223], ["Mass", "OBSERVATION", 352, 356]]], ["The BR genotypes were found in similar frequency in the 3 systems, whereas the Mass genotype was significantly more frequent in the respiratory system than in the 2 other systems (P < 0.01;Table 5).DISCUSSIONIn a total of 432 flocks (broilers and breeders) with suggestive signs of infectious bronchitis, IBV was detected in 41.4% of them in 3 important poultry-producing regions of Brazil.", [["respiratory system", "ANATOMY", 132, 150], ["infectious bronchitis", "DISEASE", 282, 303], ["BR", "GENE_OR_GENE_PRODUCT", 4, 6], ["broilers", "ORGANISM_SUBDIVISION", 234, 242], ["IBV", "ORGANISM", 305, 308], ["broilers", "SPECIES", 234, 242], ["IBV", "SPECIES", 305, 308], ["The BR genotypes", "TEST", 0, 16], ["the Mass genotype", "PROBLEM", 75, 92], ["432 flocks (broilers and breeders", "TREATMENT", 222, 255], ["infectious bronchitis", "PROBLEM", 282, 303], ["IBV", "PROBLEM", 305, 308], ["Mass", "OBSERVATION", 79, 83], ["respiratory system", "ANATOMY", 132, 150], ["suggestive signs of", "UNCERTAINTY", 262, 281], ["infectious", "OBSERVATION_MODIFIER", 282, 292], ["bronchitis", "OBSERVATION", 293, 303]]], ["There was no difference in IBV frequency in these regions, even between the south, traditional poultry-producing zone, and the other 2 regions (midwest and northeast) that started commercial poultry production more recently.", [["IBV", "ORGANISM", 27, 30], ["IBV", "SPECIES", 27, 30], ["difference in IBV frequency", "PROBLEM", 13, 40], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["IBV", "OBSERVATION", 27, 30], ["frequency", "OBSERVATION_MODIFIER", 31, 40]]], ["Other previous studies have also reported IBV prevalence in different regions of the country, showing that infectious bronchitis is a disseminated disease in Brazilian poultry flocks (Villarreal et al., 2010;Chac\u00f3n et al., 2011).", [["infectious bronchitis", "DISEASE", 107, 128], ["IBV", "ORGANISM", 42, 45], ["IBV", "SPECIES", 42, 45], ["Other previous studies", "TEST", 0, 22], ["IBV prevalence", "PROBLEM", 42, 56], ["infectious bronchitis", "PROBLEM", 107, 128], ["a disseminated disease", "PROBLEM", 132, 154], ["infectious", "OBSERVATION_MODIFIER", 107, 117], ["bronchitis", "OBSERVATION", 118, 128], ["disseminated", "OBSERVATION_MODIFIER", 134, 146], ["Brazilian poultry flocks", "OBSERVATION", 158, 182]]], ["The present study reinforces the high frequency of this disease in the country, even in the 2 more recent and growing producing regions.", [["The present study", "TEST", 0, 17], ["this disease", "PROBLEM", 51, 63], ["high", "OBSERVATION_MODIFIER", 33, 37], ["disease", "OBSERVATION", 56, 63]]], ["It was also further demonstrated that IBV is detected in a significantly higher proportion of broiler (average 54.8%) than in breeder flocks (28.8%), probably because the biosecurity programs applied to breeders are more rigorous than to broilers.DISCUSSIONThis study also observed the occurrence of local field variant genotypes (BR-I and-II) and Mass vaccine strains in Brazilian broiler and breeder commercial poultry flocks.", [["IBV", "ORGANISM", 38, 41], ["broilers", "ORGANISM_SUBDIVISION", 238, 246], ["BR-I", "GENE_OR_GENE_PRODUCT", 331, 335], ["broilers", "SPECIES", 238, 246], ["breeder", "SPECIES", 394, 401], ["IBV", "SPECIES", 38, 41], ["breeder", "SPECIES", 126, 133], ["broilers", "SPECIES", 238, 246], ["IBV", "PROBLEM", 38, 41], ["breeder flocks", "TEST", 126, 140], ["the biosecurity programs", "TREATMENT", 167, 191], ["local field variant genotypes", "PROBLEM", 300, 329], ["Mass vaccine strains", "PROBLEM", 348, 368], ["Brazilian broiler", "TREATMENT", 372, 389], ["IBV", "OBSERVATION", 38, 41], ["Mass", "OBSERVATION", 348, 352], ["poultry flocks", "OBSERVATION", 413, 427]]], ["The BR genotype was found in a higher frequency than Mass genotype in all the 3 regions.", [["BR", "GENE_OR_GENE_PRODUCT", 4, 6], ["The BR genotype", "TEST", 0, 15], ["a higher frequency than Mass genotype", "PROBLEM", 29, 66], ["higher", "OBSERVATION_MODIFIER", 31, 37], ["Mass", "OBSERVATION", 53, 57]]], ["Further, BR genotype sequences had a higher identity with other Brazilian field variants previously described (Villarreal et al., 2007;Felippe et al., 2010;Chac\u00f3n et al., 2011;Fraga et al., 2013).", [["BR", "GENE_OR_GENE_PRODUCT", 9, 11], ["BR genotype sequences", "DNA", 9, 30], ["Further, BR genotype sequences", "TEST", 0, 30]]], ["These data reaffirm the high prevalence of BR genotypes in Brazilian commercial poultry flocks in 2 recent years (2010 to 2011), a similar scenario for the period between 2003 and 2009 (Felippe et al., 2010;Villarreal et al., 2010;Chac\u00f3n et al., 2011).", [["BR", "GENE_OR_GENE_PRODUCT", 43, 45], ["BR genotypes", "PROBLEM", 43, 55], ["poultry flocks", "OBSERVATION", 80, 94]]], ["An important new finding is the high frequency (90%) of BR genotypes in breeder flocks in all ages (Table 1).DISCUSSIONOn the other hand, the Mass genotype was found in a significant number of poultry flocks from the 3 geographic regions, mainly in broiler flocks.", [["BR", "GENE_OR_GENE_PRODUCT", 56, 58], ["BR genotypes", "PROBLEM", 56, 68], ["the Mass genotype", "PROBLEM", 138, 155], ["new", "OBSERVATION_MODIFIER", 13, 16], ["high", "OBSERVATION_MODIFIER", 32, 36], ["breeder flocks", "OBSERVATION", 72, 86], ["Mass", "OBSERVATION", 142, 146], ["significant", "OBSERVATION_MODIFIER", 171, 182], ["number", "OBSERVATION_MODIFIER", 183, 189], ["poultry flocks", "OBSERVATION", 193, 207], ["broiler flocks", "OBSERVATION", 249, 263]]], ["The samples identified as Mass displayed a high identity with Massachusetts reference sequences (H120, M41), demonstrating these flocks were probably infected with vaccine-derived strains.", [["samples", "ANATOMY", 4, 11], ["Massachusetts reference sequences", "DNA", 62, 95], ["The samples", "TEST", 0, 11], ["Mass", "PROBLEM", 26, 30], ["these flocks", "PROBLEM", 123, 135], ["vaccine", "TREATMENT", 164, 171], ["Mass", "OBSERVATION", 26, 30], ["probably", "UNCERTAINTY", 141, 149], ["infected", "OBSERVATION_MODIFIER", 150, 158]]], ["Although there was no information about the IBV immunization status of the flocks, the higher frequency of Mass genotype in young broiler flocks is probably related to the use of commercial Mass vaccines (usually held in the hatchery in the first day of life;Cavanagh and Gelb, 2008;Maclachlan and Dubovi, 2011).DISCUSSIONThe comparative analysis of samples from different physiological systems demonstrated a higher frequency of IBV-positive samples (mostly BR genotype, but even Mass vaccine strains) in the digestive tract than in the other physiological systems.", [["samples", "ANATOMY", 350, 357], ["samples", "ANATOMY", 443, 450], ["digestive tract", "ANATOMY", 510, 525], ["IBV", "ORGANISM", 44, 47], ["samples", "CANCER", 350, 357], ["IBV", "ORGANISM", 430, 433], ["digestive tract", "ORGANISM_SUBDIVISION", 510, 525], ["IBV", "SPECIES", 44, 47], ["IBV", "SPECIES", 430, 433], ["the IBV immunization", "TREATMENT", 40, 60], ["the flocks", "PROBLEM", 71, 81], ["Mass genotype", "PROBLEM", 107, 120], ["young broiler flocks", "PROBLEM", 124, 144], ["commercial Mass vaccines", "TREATMENT", 179, 203], ["The comparative analysis of samples", "TEST", 322, 357], ["different physiological systems", "TEST", 363, 394], ["IBV", "PROBLEM", 430, 433], ["positive samples", "PROBLEM", 434, 450], ["mostly BR genotype", "PROBLEM", 452, 470], ["Mass vaccine strains", "PROBLEM", 481, 501], ["Mass", "OBSERVATION", 107, 111], ["broiler flocks", "OBSERVATION", 130, 144], ["probably related to", "UNCERTAINTY", 148, 167], ["Mass", "OBSERVATION", 190, 194], ["digestive tract", "ANATOMY", 510, 525]]], ["Coronaviruses support the harsh conditions of the gastrointestinal tract (Flint et al., 2000).", [["gastrointestinal tract", "ANATOMY", 50, 72], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 50, 72], ["Coronaviruses", "PROBLEM", 0, 13], ["harsh", "OBSERVATION_MODIFIER", 26, 31], ["gastrointestinal tract", "ANATOMY", 50, 72]]], ["Further IBV strains have tropism and grow in cells of the digestive system (esophagus, proventriculus, duodenum, jejunum, cloacal bursa, cecal tonsils, rectum, and cloaca) and may establish persistent infections in birds of different ages without any pathobiological clinical effect (Cavanagh, 2003).", [["cells", "ANATOMY", 45, 50], ["digestive system", "ANATOMY", 58, 74], ["esophagus", "ANATOMY", 76, 85], ["proventriculus", "ANATOMY", 87, 101], ["duodenum", "ANATOMY", 103, 111], ["jejunum", "ANATOMY", 113, 120], ["cloacal bursa", "ANATOMY", 122, 135], ["cecal tonsils", "ANATOMY", 137, 150], ["rectum", "ANATOMY", 152, 158], ["cloaca", "ANATOMY", 164, 170], ["infections", "DISEASE", 201, 211], ["IBV", "ORGANISM", 8, 11], ["cells", "CELL", 45, 50], ["digestive system", "ANATOMICAL_SYSTEM", 58, 74], ["esophagus", "ORGAN", 76, 85], ["proventriculus", "ORGAN", 87, 101], ["duodenum", "MULTI-TISSUE_STRUCTURE", 103, 111], ["jejunum", "MULTI-TISSUE_STRUCTURE", 113, 120], ["cloacal bursa", "MULTI-TISSUE_STRUCTURE", 122, 135], ["cecal tonsils", "MULTI-TISSUE_STRUCTURE", 137, 150], ["rectum", "ORGAN", 152, 158], ["cloaca", "ORGAN", 164, 170], ["birds", "ORGANISM", 215, 220], ["IBV", "SPECIES", 8, 11], ["Further IBV strains", "PROBLEM", 0, 19], ["tropism", "PROBLEM", 25, 32], ["esophagus, proventriculus, duodenum, jejunum, cloacal bursa, cecal tonsils, rectum", "PROBLEM", 76, 158], ["cloaca", "PROBLEM", 164, 170], ["persistent infections", "PROBLEM", 190, 211], ["tropism", "OBSERVATION_MODIFIER", 25, 32], ["digestive system", "ANATOMY", 58, 74], ["esophagus", "ANATOMY", 76, 85], ["proventriculus", "ANATOMY_MODIFIER", 87, 101], ["duodenum", "ANATOMY", 103, 111], ["jejunum", "ANATOMY", 113, 120], ["cloacal bursa", "ANATOMY", 122, 135], ["cecal tonsils", "ANATOMY", 137, 150], ["rectum", "ANATOMY", 152, 158], ["cloaca", "ANATOMY", 164, 170], ["persistent", "OBSERVATION_MODIFIER", 190, 200], ["infections", "OBSERVATION", 201, 211]]], ["Different strains have been isolated from cecal tonsils, cloacal swabs, and feces, many of them persisting for long periods (Raj and Jones, 1997;Cook et al., 2012).", [["cecal tonsils", "ANATOMY", 42, 55], ["cloacal swabs", "ANATOMY", 57, 70], ["feces", "ANATOMY", 76, 81], ["cecal tonsils", "MULTI-TISSUE_STRUCTURE", 42, 55], ["cloacal swabs", "MULTI-TISSUE_STRUCTURE", 57, 70], ["feces", "ORGANISM_SUBDIVISION", 76, 81], ["Different strains", "PROBLEM", 0, 17], ["cecal tonsils", "PROBLEM", 42, 55], ["cloacal swabs", "TEST", 57, 70], ["strains", "OBSERVATION", 10, 17], ["cecal tonsils", "ANATOMY", 42, 55]]], ["Other studies have already shown that intensive virus replication occurs in the cecal tonsils, ileum, and rectum, but not in the duodenum or proventriculus (Raj and Jones, 1996;Dolz et al., 2012).", [["cecal tonsils", "ANATOMY", 80, 93], ["ileum", "ANATOMY", 95, 100], ["rectum", "ANATOMY", 106, 112], ["duodenum", "ANATOMY", 129, 137], ["proventriculus", "ANATOMY", 141, 155], ["cecal tonsils", "MULTI-TISSUE_STRUCTURE", 80, 93], ["ileum", "MULTI-TISSUE_STRUCTURE", 95, 100], ["rectum", "ORGAN", 106, 112], ["duodenum", "ORGAN", 129, 137], ["proventriculus", "ORGAN", 141, 155], ["Other studies", "TEST", 0, 13], ["intensive virus replication", "PROBLEM", 38, 65], ["cecal tonsils", "ANATOMY", 80, 93], ["ileum", "ANATOMY", 95, 100], ["rectum", "ANATOMY", 106, 112], ["duodenum", "ANATOMY", 129, 137], ["proventriculus", "ANATOMY", 141, 155]]], ["These viruses are probably being excreted in the feces, where they can still remain for a long period and be a potential source of infection (Cavanagh and Gelb, 2008;Cook et al., 2012).", [["feces", "ANATOMY", 49, 54], ["infection", "DISEASE", 131, 140], ["feces", "ORGANISM_SUBDIVISION", 49, 54], ["These viruses", "PROBLEM", 0, 13], ["infection", "PROBLEM", 131, 140], ["viruses", "OBSERVATION", 6, 13], ["excreted", "OBSERVATION_MODIFIER", 33, 41], ["infection", "OBSERVATION", 131, 140]]], ["This is a likely explanation for the IBV persistence in the commercial flocks (mainly BR genotypes) and consequently the high prevalence of these field variants in studies performed previously in Brazil (Villarreal et al., 2010;Chac\u00f3n et al., 2011;Fraga et al., 2013).", [["IBV", "ORGANISM", 37, 40], ["IBV", "SPECIES", 37, 40], ["the IBV persistence", "PROBLEM", 33, 52], ["likely explanation for", "UNCERTAINTY", 10, 32], ["IBV", "OBSERVATION", 37, 40], ["persistence", "OBSERVATION_MODIFIER", 41, 52]]], ["Further studies should be conducted to assess the occurrence and viability of the different genotypes (BR-I, BR-II, and Mass) in feces under field conditions.DISCUSSIONAlthough less frequent, IBV was also detected in respiratory samples.", [["feces", "ANATOMY", 129, 134], ["respiratory samples", "ANATOMY", 217, 236], ["BR-I", "GENE_OR_GENE_PRODUCT", 103, 107], ["BR-II", "GENE_OR_GENE_PRODUCT", 109, 114], ["feces", "ORGANISM_SUBSTANCE", 129, 134], ["IBV", "ORGANISM", 192, 195], ["IBV", "SPECIES", 192, 195], ["Further studies", "TEST", 0, 15], ["the different genotypes", "PROBLEM", 78, 101], ["BR", "TEST", 103, 105], ["Mass) in feces under field conditions", "PROBLEM", 120, 157], ["IBV", "PROBLEM", 192, 195], ["Mass", "OBSERVATION", 120, 124], ["respiratory", "ANATOMY", 217, 228]]], ["The respiratory tract is the main site for the multiplication of the IBV strains, especially during the first 3 to 5 d after infection (De Wit, 2000).", [["respiratory tract", "ANATOMY", 4, 21], ["infection", "DISEASE", 125, 134], ["respiratory tract", "ORGANISM_SUBDIVISION", 4, 21], ["IBV", "ORGANISM", 69, 72], ["IBV", "SPECIES", 69, 72], ["the IBV strains", "PROBLEM", 65, 80], ["infection", "PROBLEM", 125, 134], ["respiratory tract", "ANATOMY", 4, 21], ["main", "OBSERVATION_MODIFIER", 29, 33], ["IBV strains", "OBSERVATION", 69, 80], ["infection", "OBSERVATION", 125, 134]]], ["The viral titer decreases rapidly in the second week after infection; however, IBV can persist for a period up to 77 d in the trachea in some special situations (Naqi et al., 2003).", [["trachea", "ANATOMY", 126, 133], ["infection", "DISEASE", 59, 68], ["IBV", "ORGANISM", 79, 82], ["trachea", "ORGAN", 126, 133], ["IBV", "SPECIES", 79, 82], ["The viral titer", "TEST", 0, 15], ["infection", "PROBLEM", 59, 68], ["IBV", "PROBLEM", 79, 82], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["titer", "OBSERVATION_MODIFIER", 10, 15], ["decreases", "OBSERVATION_MODIFIER", 16, 25], ["rapidly", "OBSERVATION_MODIFIER", 26, 33], ["infection", "OBSERVATION", 59, 68], ["trachea", "ANATOMY", 126, 133]]], ["In the present study, Mass and field variant genotypes were detected in the trachea of birds with different ages.", [["trachea", "ANATOMY", 76, 83], ["trachea", "ORGAN", 76, 83], ["birds", "ORGANISM", 87, 92], ["the present study", "TEST", 3, 20], ["Mass and field variant genotypes", "PROBLEM", 22, 54], ["Mass", "OBSERVATION", 22, 26], ["field variant", "OBSERVATION", 31, 44], ["trachea", "ANATOMY", 76, 83]]], ["Mass genotypes were detected primarily in younger broilers (between 0 and 4.5 wk of age, corresponding to the probable multiplication period after vaccination), although they were also observed in 3 additional breeder flocks with older ages (24, 28, and 49 wk).", [["broilers", "ORGANISM_SUBDIVISION", 50, 58], ["broilers", "SPECIES", 50, 58], ["Mass genotypes", "PROBLEM", 0, 14], ["vaccination", "TREATMENT", 147, 158]]], ["However, strains from the BR genotype were detected in a different number of ages in breeder and broiler flocks.", [["BR", "GENE_OR_GENE_PRODUCT", 26, 28], ["breeder", "SPECIES", 85, 92], ["strains", "PROBLEM", 9, 16], ["the BR genotype", "TEST", 22, 37], ["broiler flocks", "OBSERVATION", 97, 111]]], ["Infectious bronchitis virus-positive breeder flocks had a minimum of 13 wk and a maximum of 61 wk of age, whereas positive broiler flocks had a minimum of 1.4 and a maximum of 6.5 wk (data not shown).", [["Infectious bronchitis virus", "DISEASE", 0, 27], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["breeder", "ORGANISM", 37, 44], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["Infectious bronchitis virus", "PROBLEM", 0, 27], ["positive breeder flocks", "PROBLEM", 28, 51], ["positive broiler flocks", "PROBLEM", 114, 137], ["positive", "OBSERVATION_MODIFIER", 28, 36], ["breeder flocks", "OBSERVATION", 37, 51]]], ["This wide age variation is probably related to the different episodes of initial infection with BR strains that are circulating in the flocks (Cavanagh and Gelb, 2008).", [["infection", "DISEASE", 81, 90], ["initial infection", "PROBLEM", 73, 90], ["BR strains", "PROBLEM", 96, 106], ["probably related to", "UNCERTAINTY", 27, 46], ["initial", "OBSERVATION_MODIFIER", 73, 80], ["infection", "OBSERVATION", 81, 90], ["BR strains", "OBSERVATION", 96, 106], ["circulating", "OBSERVATION_MODIFIER", 116, 127], ["flocks", "OBSERVATION_MODIFIER", 135, 141]]], ["However, the possibility should not be ruled out that strains from the BR genotype have a longer persistence in the trachea, as found with the Arkansas strain (Cavanagh and Gelb, 2008;Jackwood et al., 2009).DISCUSSIONInfectious bronchitis virus was rarely detected in samples (such as kidneys and oviducts) of the urinary and reproductive system of broilers and breeders.", [["trachea", "ANATOMY", 116, 123], ["samples", "ANATOMY", 268, 275], ["kidneys", "ANATOMY", 285, 292], ["oviducts", "ANATOMY", 297, 305], ["urinary", "ANATOMY", 314, 321], ["bronchitis", "DISEASE", 228, 238], ["BR", "GENE_OR_GENE_PRODUCT", 71, 73], ["trachea", "ORGAN", 116, 123], ["samples", "TISSUE", 268, 275], ["kidneys", "ORGAN", 285, 292], ["oviducts", "ORGAN", 297, 305], ["urinary", "ORGANISM_SUBDIVISION", 314, 321], ["reproductive system", "ANATOMICAL_SYSTEM", 326, 345], ["broilers", "ORGANISM_SUBDIVISION", 349, 357], ["broilers", "SPECIES", 349, 357], ["DISCUSSIONInfectious bronchitis virus", "SPECIES", 207, 244], ["broilers", "SPECIES", 349, 357], ["strains", "PROBLEM", 54, 61], ["the BR genotype", "PROBLEM", 67, 82], ["a longer persistence in the trachea", "PROBLEM", 88, 123], ["DISCUSSIONInfectious bronchitis virus", "PROBLEM", 207, 244], ["trachea", "ANATOMY", 116, 123], ["kidneys", "ANATOMY", 285, 292], ["urinary", "ANATOMY", 314, 321], ["broilers", "OBSERVATION", 349, 357]]], ["The only positive sample of these system in broilers belonged to the Mass genotype, whereas all the positive samples found in the oviducts (n = 3) and kidney (n = 9) of breeders belonged to the BR genotype.", [["samples", "ANATOMY", 109, 116], ["oviducts", "ANATOMY", 130, 138], ["kidney", "ANATOMY", 151, 157], ["broilers", "ORGANISM", 44, 52], ["oviducts", "ORGAN", 130, 138], ["kidney", "ORGAN", 151, 157], ["BR", "GENE_OR_GENE_PRODUCT", 194, 196], ["the Mass genotype", "PROBLEM", 65, 82], ["the positive samples", "TEST", 96, 116], ["breeders", "PROBLEM", 169, 177], ["positive", "OBSERVATION_MODIFIER", 9, 17], ["Mass", "OBSERVATION", 69, 73], ["oviducts", "ANATOMY", 130, 138], ["kidney", "ANATOMY", 151, 157]]], ["The Mass genotype was detected in a sample of broilers at 4.1 wk of age (probably related to the dissemination of the Mass vaccine strain in immunized flock), whereas the BR genotype was found in breeder flocks with different ages (13 to 30 wk).", [["broilers", "ORGANISM_SUBDIVISION", 46, 54], ["BR", "GENE_OR_GENE_PRODUCT", 171, 173], ["broilers", "SPECIES", 46, 54], ["breeder", "SPECIES", 196, 203], ["The Mass genotype", "PROBLEM", 0, 17], ["the Mass vaccine strain", "TREATMENT", 114, 137], ["the BR genotype", "TEST", 167, 182], ["Mass", "OBSERVATION", 4, 8], ["probably related to", "UNCERTAINTY", 73, 92], ["Mass", "OBSERVATION", 118, 122], ["breeder flocks", "OBSERVATION", 196, 210]]], ["Infectious bronchitis virus replication in the kidney or oviduct is not directly correlated with evident renal disease, but some IBV strains are intrinsically nephropathogenic (Cavanagh, 2007).", [["kidney", "ANATOMY", 47, 53], ["oviduct", "ANATOMY", 57, 64], ["renal", "ANATOMY", 105, 110], ["Infectious bronchitis virus", "DISEASE", 0, 27], ["renal disease", "DISEASE", 105, 118], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["kidney", "ORGAN", 47, 53], ["oviduct", "ORGAN", 57, 64], ["renal", "ORGAN", 105, 110], ["IBV", "ORGANISM", 129, 132], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["IBV", "SPECIES", 129, 132], ["Infectious bronchitis virus replication in the kidney", "PROBLEM", 0, 53], ["renal disease", "PROBLEM", 105, 118], ["some IBV strains", "PROBLEM", 124, 140], ["kidney", "ANATOMY", 47, 53], ["oviduct", "ANATOMY", 57, 64], ["renal", "ANATOMY", 105, 110], ["disease", "OBSERVATION", 111, 118], ["IBV strains", "OBSERVATION", 129, 140], ["nephropathogenic", "OBSERVATION_MODIFIER", 159, 175]]], ["Specifically, strains from the BR genotype have already been detected in poultry flocks with nephritis and reproductive disorders (Villarreal et al., 2010;Chac\u00f3n et al., 2011).", [["nephritis", "DISEASE", 93, 102], ["reproductive disorders", "DISEASE", 107, 129], ["BR", "GENE_OR_GENE_PRODUCT", 31, 33], ["strains", "PROBLEM", 14, 21], ["the BR genotype", "PROBLEM", 27, 42], ["nephritis", "PROBLEM", 93, 102], ["reproductive disorders", "PROBLEM", 107, 129], ["poultry flocks", "OBSERVATION", 73, 87], ["nephritis", "OBSERVATION", 93, 102]]], ["Furthermore,Dolz et al. (2012) detected IBV in epithelial cells of the ureters by immunohistochemistry, suggesting that retrograde tubular peristalsis, a physiological characteristic of poultry (Laverty et al., 2006), can contribute to the successful replication of IBV in this system.DISCUSSIONIn Brazil, veterinary laboratories usually recommend collecting and analyzing samples of the respiratory system for IBV detection.", [["epithelial cells", "ANATOMY", 47, 63], ["ureters", "ANATOMY", 71, 78], ["tubular", "ANATOMY", 131, 138], ["IBV", "ORGANISM", 40, 43], ["epithelial cells", "CELL", 47, 63], ["ureters", "ORGAN", 71, 78], ["IBV", "ORGANISM", 266, 269], ["IBV", "ORGANISM", 411, 414], ["epithelial cells", "CELL_TYPE", 47, 63], ["IBV", "SPECIES", 40, 43], ["IBV", "SPECIES", 266, 269], ["IBV", "SPECIES", 411, 414], ["IBV", "PROBLEM", 40, 43], ["immunohistochemistry", "TEST", 82, 102], ["retrograde tubular peristalsis", "PROBLEM", 120, 150], ["IBV in this system", "TREATMENT", 266, 284], ["the respiratory system", "TEST", 384, 406], ["IBV detection", "TEST", 411, 424], ["epithelial cells", "OBSERVATION", 47, 63], ["ureters", "ANATOMY", 71, 78], ["retrograde", "OBSERVATION_MODIFIER", 120, 130], ["tubular peristalsis", "OBSERVATION", 131, 150], ["IBV", "OBSERVATION", 266, 269], ["respiratory system", "ANATOMY", 388, 406]]], ["In the present study, trachea and tracheal swabs were the only samples collected and evaluated by RT-qPCR in approximately half of the commercial poultry flocks (45.5% breeders and 48.2% broilers;Table 2).", [["trachea", "ANATOMY", 22, 29], ["tracheal swabs", "ANATOMY", 34, 48], ["samples", "ANATOMY", 63, 70], ["trachea", "MULTI-TISSUE_STRUCTURE", 22, 29], ["tracheal swabs", "MULTI-TISSUE_STRUCTURE", 34, 48], ["broilers", "SPECIES", 187, 195], ["the present study", "TEST", 3, 20], ["trachea and tracheal swabs", "TREATMENT", 22, 48], ["RT-qPCR", "TEST", 98, 105], ["trachea", "ANATOMY", 22, 29], ["tracheal", "ANATOMY", 34, 42]]], ["Although infectious bronchitis is initially a respiratory disease, viral titers are often lower in the trachea than in the enteric organs (Cavanagh and Gelb, 2008).", [["respiratory", "ANATOMY", 46, 57], ["trachea", "ANATOMY", 103, 110], ["enteric organs", "ANATOMY", 123, 137], ["infectious bronchitis", "DISEASE", 9, 30], ["respiratory disease", "DISEASE", 46, 65], ["trachea", "ORGAN", 103, 110], ["organs", "ORGAN", 131, 137], ["infectious bronchitis", "PROBLEM", 9, 30], ["a respiratory disease", "PROBLEM", 44, 65], ["viral titers", "TEST", 67, 79], ["infectious", "OBSERVATION_MODIFIER", 9, 19], ["bronchitis", "OBSERVATION", 20, 30], ["respiratory disease", "OBSERVATION", 46, 65], ["viral titers", "OBSERVATION", 67, 79], ["trachea", "ANATOMY", 103, 110], ["enteric organs", "ANATOMY", 123, 137]]], ["Previous studies also reported a higher probability to detect IBV with the use of digestive tract samples than with respiratory samples (El-Houadfi et al., 1986;Almeida et al., 2012;Boroomand et al., 2012;Dolz et al., 2012).", [["digestive tract samples", "ANATOMY", 82, 105], ["respiratory samples", "ANATOMY", 116, 135], ["IBV", "ORGANISM", 62, 65], ["digestive tract samples", "CANCER", 82, 105], ["IBV", "SPECIES", 62, 65], ["Previous studies", "TEST", 0, 16], ["IBV", "PROBLEM", 62, 65], ["digestive tract samples", "TEST", 82, 105], ["respiratory samples", "TEST", 116, 135], ["IBV", "OBSERVATION", 62, 65], ["digestive tract", "ANATOMY", 82, 97]]], ["Therefore, an important recommendation would be to collect samples of at least these 2 systems (respiratory and digestive) to a more conclusive diagnosis of the IBV status in the flocks.DISCUSSIONIn conclusion, this study demonstrates IBV detection in broiler and breeder flocks from different geographic regions of Brazil.", [["respiratory", "ANATOMY", 96, 107], ["digestive", "ANATOMY", 112, 121], ["digestive", "ORGAN", 112, 121], ["IBV", "ORGANISM", 161, 164], ["IBV", "ORGANISM", 235, 238], ["IBV", "SPECIES", 161, 164], ["IBV", "SPECIES", 235, 238], ["the IBV status", "PROBLEM", 157, 171], ["this study", "TEST", 211, 221], ["IBV detection in broiler", "PROBLEM", 235, 259], ["breeder flocks", "TREATMENT", 264, 278], ["IBV", "OBSERVATION", 161, 164], ["IBV", "OBSERVATION", 235, 238], ["breeder flocks", "OBSERVATION", 264, 278]]], ["The BR variant genotype was more prevalent than Mass vaccine strains, mostly in breeders.", [["BR", "GENE_OR_GENE_PRODUCT", 4, 6], ["Mass vaccine strains", "PROBLEM", 48, 68], ["more prevalent", "OBSERVATION_MODIFIER", 28, 42]]], ["Moreover, it was possible to detect strains from the BR and Mass genotype in different physiological systems, mainly in the organs of the digestive system.", [["organs", "ANATOMY", 124, 130], ["digestive system", "ANATOMY", 138, 154], ["BR", "GENE_OR_GENE_PRODUCT", 53, 55], ["organs", "ORGAN", 124, 130], ["digestive", "ORGAN", 138, 147], ["system", "ANATOMICAL_SYSTEM", 148, 154], ["strains", "PROBLEM", 36, 43], ["the BR", "PROBLEM", 49, 55], ["Mass genotype in different physiological systems", "PROBLEM", 60, 108], ["Mass", "OBSERVATION", 60, 64], ["organs", "ANATOMY", 124, 130], ["digestive system", "ANATOMY", 138, 154]]]], "0a9ed84b2d6679a8348ec48b48d493b2931998d5": [["IntroductionIn the modern world, large numbers of patients initially turn to various online sources for self-diagnoses before seeking diagnoses from a trained medical professional.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["large", "OBSERVATION_MODIFIER", 33, 38], ["numbers", "OBSERVATION_MODIFIER", 39, 46]]], ["But web sources have inherent problems such as misinformation, misunderstandings, misleading advertisements and varying quality [1] .", [["inherent problems", "PROBLEM", 21, 38]]], ["Interactive examples of web sources developed to meet the need of online diagnoses are sometimes referred to as symptom checkers or chatbots [2] [3] .", [["symptom checkers", "TEST", 112, 128]]], ["Based on a list of entered symptoms and other factors, symptom checkers return a list of potential diseases.IntroductionOnline symptom checkers have become popular in the context of the novel coronavirus disease 2019 (COVID-19) pandemic as access to doctors is reduced, worry in the population is high, and lots of misinformation is circulating the web [1] .", [["coronavirus disease", "DISEASE", 192, 211], ["COVID-19", "CHEMICAL", 218, 226], ["coronavirus", "ORGANISM", 192, 203], ["entered symptoms", "PROBLEM", 19, 35], ["other factors", "PROBLEM", 40, 53], ["symptom", "PROBLEM", 55, 62], ["potential diseases", "PROBLEM", 89, 107], ["IntroductionOnline symptom checkers", "PROBLEM", 108, 143], ["the novel coronavirus disease", "PROBLEM", 182, 211], ["coronavirus", "OBSERVATION", 192, 203], ["reduced", "OBSERVATION_MODIFIER", 261, 268], ["high", "OBSERVATION_MODIFIER", 297, 301]]], ["On COVID-19 symptom checker web pages users are asked a series of COVID-19 specific questions and, upon completion, an association between the answers and COVID-19 is given alongside behavioural recommendations, e.g., self-isolate.IntroductionCOVID-19 symptom checkers are valuable tools for pre-assessment and screening during this pandemic, both taking pressure off from clinicians and reducing footfall within hospitals.", [["COVID", "TEST", 3, 8], ["COVID", "TEST", 155, 160], ["IntroductionCOVID", "TEST", 231, 248], ["pre-assessment", "TEST", 292, 306], ["screening", "TEST", 311, 320]]], ["A large number of symptom checkers specific to COVID-19 have been developed.", [["COVID-19", "CHEMICAL", 47, 55], ["COVID-19", "CHEMICAL", 47, 55], ["COVID-19", "DNA", 47, 55], ["symptom", "PROBLEM", 18, 25], ["COVID", "TEST", 47, 52], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["Anecdotal evidence (e.g. a newspaper article [4] ) suggests that their conclusions differ with possible implications on the quality of the symptom assessment.", [["the symptom assessment", "TEST", 135, 157]]], ["To our knowledge, there exist no studies comparing and evaluating COVID-19 symptom checkers.IntroductionIn the following, we present a study evaluating 10 different COVID-19 online symptom checkers using 50 COVID-19 cases extracted from the literature and 410 non-COVID-19 control cases of patients with other diseases.", [["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 290, 298], ["studies", "TEST", 33, 40], ["COVID", "TEST", 66, 71], ["symptom checkers", "TEST", 75, 91], ["a study evaluating", "TEST", 133, 151], ["different COVID", "TEST", 155, 170], ["non-COVID", "TEST", 260, 269], ["other diseases", "PROBLEM", 304, 318], ["diseases", "OBSERVATION", 310, 318]]], ["We find that the COVID-19 symptom checkers' classification of many patient cases differ as well as their accuracies.", [["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74], ["the COVID", "TEST", 13, 22], ["symptom", "PROBLEM", 26, 33]]], ["Symptoma (F1=0.92, MCC=0.85) shows the overall best performance followed by Infermedica (F1=0.80, MCC=0.61).COVID-19 symptom checkersTen COVID-19 symptom checkers that were freely available online between 3rd and 9th of April 2020 were selected for this study ( Table 1 ).", [["Symptoma", "TEST", 0, 8], ["F1", "TEST", 10, 12], ["MCC", "TEST", 19, 22], ["Infermedica", "TEST", 76, 87], ["MCC", "TEST", 98, 101], ["COVID", "TEST", 108, 113], ["symptom checkers", "TEST", 117, 133], ["Ten COVID", "TEST", 133, 142], ["symptom checkers", "TEST", 146, 162], ["this study", "TEST", 249, 259]]], ["These symptom checkers were used in the versions available in this date range and updates after this date were not considered for analysis.COVID-19 symptom checkersAs a baseline for the performance evaluation of the 10 online COVID-19 symptom checkers, we developed two additional simplistic symptom checkers.", [["These symptom checkers", "PROBLEM", 0, 22], ["analysis", "TEST", 130, 138], ["COVID", "TEST", 139, 144], ["symptom checkers", "TEST", 148, 164], ["the performance evaluation", "TEST", 182, 208], ["symptom checkers", "TEST", 235, 251], ["two additional simplistic symptom checkers", "PROBLEM", 266, 308]]], ["These two checkers evaluate and weigh the presence of WHO [5] provided COVID-19 symptom frequencies (see S1 Table ) based on vector distance (SF-DIST) and cosine similarity (SF-COS).", [["COVID", "TEST", 71, 76], ["symptom frequencies", "TEST", 80, 99], ["cosine similarity", "TEST", 155, 172]]], ["List of online COVID-19 symptom checkers included in this study.Name URL Control cases COVID-19 cases allow us to evaluate the sensitivity of symptom checkers.", [["online COVID", "TEST", 8, 20], ["symptom checkers", "TEST", 24, 40], ["this study", "TEST", 53, 63], ["symptom checkers", "PROBLEM", 142, 158]]], ["To allow a fair assessment, we only used cases containing at least one of the COVID-19 symptoms (see S4 Table ) reported by the WHO [5] .", [["a fair assessment", "TEST", 9, 26], ["symptoms", "PROBLEM", 87, 95]]], ["Classifying non-relevant cases (e.g., a fracture) would overestimate the symptom checkers' specificity.", [["fracture", "DISEASE", 40, 48], ["a fracture", "PROBLEM", 38, 48], ["the symptom", "PROBLEM", 69, 80], ["fracture", "OBSERVATION", 40, 48]]], ["Furthermore, these patients would not consult an online COVID-19 symptom checker.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["an online COVID", "TEST", 46, 61]]], ["None of these 410 BMJ cases has COVID-19 listed as the diagnosis as the cases where collected before the COVID-19 outbreak. .", [["BMJ", "CANCER", 18, 21], ["COVID-19", "DNA", 32, 40], ["COVID", "TEST", 32, 37], ["the COVID", "TEST", 101, 110]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020.Classification of symptom checkers' outputsMost COVID-19 symptom checkers return a human-readable text which contains an association between entered symptoms and COVID-19.", [["CC", "CHEMICAL", 0, 2], ["human", "ORGANISM", 356, 361], ["COVID-19 symptom checkers", "DNA", 321, 346], ["human", "SPECIES", 356, 361], ["human", "SPECIES", 356, 361], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["symptom", "PROBLEM", 291, 298], ["' outputs", "TEST", 307, 316], ["Most COVID", "TEST", 316, 326], ["symptom", "PROBLEM", 330, 337], ["entered symptoms", "PROBLEM", 414, 430], ["COVID", "TEST", 435, 440], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We classified these associations into three different categories: high risk, medium risk and low risk.", [["high risk", "OBSERVATION_MODIFIER", 66, 75], ["medium risk", "OBSERVATION_MODIFIER", 77, 88], ["low risk", "OBSERVATION_MODIFIER", 93, 101]]], ["Examples of a high, medium and low risk classifications are \"There is a high risk that COVID-19 is causing your symptoms\", \"Your symptoms are worrisome and may be related to COVID-19\" and \"There's nothing at present to suggest that you have coronavirus (COVID-19).", [["coronavirus", "DISEASE", 241, 252], ["coronavirus", "ORGANISM", 241, 252], ["a high, medium and low risk classifications", "PROBLEM", 12, 55], ["COVID", "TEST", 87, 92], ["your symptoms", "PROBLEM", 107, 120], ["Your symptoms", "PROBLEM", 124, 137], ["coronavirus", "PROBLEM", 241, 252], ["high", "OBSERVATION_MODIFIER", 14, 18], ["low risk", "OBSERVATION_MODIFIER", 31, 39]]], ["Our full text-output to risk mapping for all symptom checkers and all text outputs is given in S5 Table .", [["risk mapping", "TEST", 24, 36], ["all symptom checkers", "TEST", 41, 61], ["all text outputs", "TEST", 66, 82]]], ["Some symptom checkers only have two possible outputs: COVID-19 risk or no COVID-19 risk.Classification of symptom checkers' outputsIn order to make symptom checkers with three and two risk levels comparable we performed .", [["Some symptom checkers", "PROBLEM", 0, 21], ["COVID", "TEST", 54, 59], ["COVID", "TEST", 74, 79], ["symptom", "PROBLEM", 106, 113], ["' outputs", "TEST", 122, 131], ["symptom checkers", "TEST", 148, 164]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) two analysis versions: (a) medium risk and high risk is treated as COVID-19 positive (and low risk as COVID-19 as negative) and (b) high risk is treated as COVID-19 positive (and low risk and medium risk as COVID-19 negative).BootstrappingTo evaluate the robustness of our statistical measures and account for the unbalanced dataset, we performed bootstrapping across our cases.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["COVID", "TEST", 270, 275], ["COVID", "TEST", 305, 310], ["COVID", "TEST", 359, 364], ["low risk", "PROBLEM", 382, 390], ["COVID", "TEST", 410, 415], ["BootstrappingTo", "TREATMENT", 429, 444], ["the unbalanced dataset", "PROBLEM", 513, 535], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["A total of 3000 random samples consisting of 50 COVID-19 cases and 50 control cases were created by sampling with replacement from the original set of 50 COVID-19 cases and the 410 control cases.Sensitivity and specificityIn order to analyse the performance of the 10 online symptom checkers, we calculated the sensitivity and the specificity of each symptom checker based on the cases described in the method section.", [["samples", "ANATOMY", 23, 30], ["random samples", "TEST", 16, 30], ["replacement", "TREATMENT", 114, 125], ["Sensitivity", "TEST", 195, 206], ["specificity", "TEST", 211, 222], ["the sensitivity", "TEST", 307, 322], ["each symptom", "PROBLEM", 346, 358]]], ["A scatterplot between sensitivity and specificity to COVID-19 of the different symptom checkers is given in Fig 1 and Further analysis of true and false case classifications of these groups shows that the group in the upper left corner is composed of symptom checkers that require one (or few) highly specific symptoms to be present in order to classify a case as COVID-19 positive (e.g. \"intensive contact with a COVID-19 positive person\").", [["left corner", "ANATOMY", 224, 235], ["person", "SPECIES", 432, 438], ["A scatterplot between sensitivity", "PROBLEM", 0, 33], ["COVID", "TEST", 53, 58], ["the different symptom checkers", "PROBLEM", 65, 95], ["Further analysis", "TEST", 118, 134], ["symptom checkers", "PROBLEM", 251, 267], ["highly specific symptoms", "PROBLEM", 294, 318], ["COVID", "TEST", 364, 369], ["upper", "ANATOMY_MODIFIER", 218, 223], ["left", "ANATOMY_MODIFIER", 224, 228]]], ["By this way, these symptom checkers miss many COVID-19 positive patients that did not report exactly this highly specific symptom.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["these symptom checkers", "TEST", 13, 35], ["many COVID", "TEST", 41, 51]]], ["Vice versa such highly specific symptoms are hardly present in non-COVID-19 cases.", [["highly specific symptoms", "PROBLEM", 16, 40]]], ["This results in low sensitivity and high specificity.Sensitivity and specificityThe group in the lower right corner is composed of symptom checkers which predict a case as COVID-19 positive based on the presence of one or few COVID-19 associated symptoms, e.g. the presence of fever or cough is enough to predict a patient as COVID-19 positive.", [["lower right corner", "ANATOMY", 97, 115], ["fever", "DISEASE", 277, 282], ["cough", "DISEASE", 286, 291], ["patient", "ORGANISM", 315, 322], ["patient", "SPECIES", 315, 322], ["low sensitivity", "PROBLEM", 16, 31], ["Sensitivity", "TEST", 53, 64], ["specificity", "TEST", 69, 80], ["symptom checkers", "PROBLEM", 131, 147], ["COVID", "TEST", 172, 177], ["few COVID-19 associated symptoms", "PROBLEM", 222, 254], ["fever", "PROBLEM", 277, 282], ["cough", "PROBLEM", 286, 291], ["COVID", "TEST", 326, 331], ["low sensitivity", "OBSERVATION_MODIFIER", 16, 31], ["lower", "ANATOMY_MODIFIER", 97, 102], ["right", "ANATOMY_MODIFIER", 103, 108], ["fever", "OBSERVATION", 277, 282], ["cough", "OBSERVATION", 286, 291]]], ["These checkers classify nearly every patient that has a respiratory disorder or viral infection as COVID-19 positive.", [["respiratory", "ANATOMY", 56, 67], ["respiratory disorder", "DISEASE", 56, 76], ["viral infection", "DISEASE", 80, 95], ["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["a respiratory disorder", "PROBLEM", 54, 76], ["viral infection", "PROBLEM", 80, 95], ["COVID", "TEST", 99, 104], ["respiratory disorder", "OBSERVATION", 56, 76], ["viral", "OBSERVATION_MODIFIER", 80, 85], ["infection", "OBSERVATION", 86, 95]]], ["As such, they do not miss many COVID-19 patients but wrongly predict many non-COVID-19 patients as COVID-19 positive.", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 87, 95], ["COVID-19", "GENE_OR_GENE_PRODUCT", 99, 107], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 87, 95], ["non-COVID", "TEST", 74, 83], ["COVID", "TEST", 99, 104]]], ["This results in low specificity and high sensitivity.Sensitivity and specificityThe group in the more central region is composed of symptom checkers which use a more balanced prediction but exhibit limited success correctly classifying COVID-19 and non-COVID-19 patients.Sensitivity and specificityThe group in the upper right corner is composed of symptom checkers which also use a more balanced \"symptoms to COVID-19 association model\" but in this case, the classification between COVID-19 and non-COVID-19 patients is more successful.Sensitivity and specificity.", [["right corner", "ANATOMY", 321, 333], ["COVID-19", "CANCER", 236, 244], ["patients", "ORGANISM", 262, 270], ["patients", "ORGANISM", 509, 517], ["patients", "SPECIES", 262, 270], ["patients", "SPECIES", 509, 517], ["low specificity", "PROBLEM", 16, 31], ["high sensitivity", "PROBLEM", 36, 52], ["Sensitivity", "TEST", 53, 64], ["specificity", "TEST", 69, 80], ["symptom checkers", "PROBLEM", 132, 148], ["COVID", "TEST", 236, 241], ["non-COVID", "TEST", 249, 258], ["Sensitivity", "TEST", 271, 282], ["specificity", "TEST", 287, 298], ["symptom checkers", "PROBLEM", 349, 365], ["a more balanced \"symptoms", "PROBLEM", 381, 406], ["COVID", "TEST", 483, 488], ["non-COVID", "TEST", 496, 505], ["Sensitivity", "TEST", 537, 548], ["specificity", "TEST", 553, 564], ["low specificity", "OBSERVATION_MODIFIER", 16, 31], ["central", "ANATOMY_MODIFIER", 102, 109], ["region", "ANATOMY_MODIFIER", 110, 116], ["upper", "ANATOMY_MODIFIER", 315, 320], ["right", "ANATOMY_MODIFIER", 321, 326]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Sensitivity and specificityThe copyright holder for this preprint this version posted May 26, 2020. . is defined by either a medium risk or high risk returned by a symptom checker.Constraining symptoms for SymptomaAs Symptoma exhibits the best combination of sensitivity and specificity, we focused our analysis on Symptoma's performance.", [["CC", "CHEMICAL", 0, 2], ["Symptoma", "DISEASE", 419, 427], ["ND", "PROBLEM", 9, 11], ["Sensitivity", "TEST", 202, 213], ["specificity", "TEST", 218, 229], ["The copyright holder", "TREATMENT", 229, 249], ["a symptom checker", "PROBLEM", 364, 381], ["Constraining symptoms", "PROBLEM", 382, 403], ["SymptomaAs Symptoma", "PROBLEM", 408, 427], ["sensitivity", "PROBLEM", 461, 472], ["our analysis", "TEST", 501, 513], ["med", "ANATOMY", 105, 108]]], ["Symptoma allows free-text input of one's symptoms and thereby a more precise representation of the clinical test cases.", [["one's symptoms", "PROBLEM", 35, 49], ["the clinical test cases", "TEST", 95, 118]]], ["The other symptom checkers do not allow free text input which limits the number of possible symptoms considerably ( Fig 2A ) .", [["The other symptom", "PROBLEM", 0, 17], ["symptoms", "PROBLEM", 92, 100]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Constraining symptoms for SymptomaThe copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20109777 doi: medRxiv preprint comparisons where Symptoma is only allowed to use the symptoms of another symptom checker.", [["CC", "CHEMICAL", 0, 2], ["Symptoma", "DISEASE", 228, 236], ["ND", "PROBLEM", 9, 11], ["Constraining symptoms", "PROBLEM", 202, 223], ["Symptoma", "PROBLEM", 228, 236], ["The copyright holder", "TREATMENT", 236, 256], ["the symptoms", "PROBLEM", 427, 439], ["another symptom checker", "PROBLEM", 443, 466], ["med", "ANATOMY", 105, 108]]], ["In this setup, Symptoma is massively disadvantaged as it can not use its full abilities.Constraining symptoms for SymptomaFor example, in the pairwise comparison with \"Your.MD\", Symptoma considers only \"fever\", \"dry cough\", \"shortness of breath\", and \"contact with a confirmed COVID-19 case\" for the classification of cases.", [["Symptoma", "DISEASE", 15, 23], ["Symptoma", "DISEASE", 178, 186], ["fever", "DISEASE", 203, 208], ["dry cough", "DISEASE", 212, 221], ["shortness of breath", "DISEASE", 225, 244], ["Constraining symptoms", "PROBLEM", 88, 109], ["fever", "PROBLEM", 203, 208], ["dry cough", "PROBLEM", 212, 221], ["shortness of breath", "PROBLEM", 225, 244]]], ["The results of this analysis are summarised in Fig 2B , Table and S10 Table .", [["this analysis", "TEST", 15, 28]]], ["Under these constraints and when COVID-19 positive is defined by high risk only, Symptoma still significantly outperforms Apple and Cleveland Clinic, while performing statistically similar to six of the remaining symptom checkers (upper panel of Fig 2B ) .", [["COVID-19", "DNA", 33, 41], ["COVID", "TEST", 33, 38]]], ["When COVID-19-positive is defined by high and medium risk (lower panel of Fig 2B ) , Symptoma's constrained performance is similar to seven of the other checkers, while outperforming Ada and Docyet.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 5, 13], ["COVID-19", "DNA", 5, 13], ["Ada", "PROTEIN", 183, 186], ["COVID", "TEST", 5, 10], ["Symptoma's constrained performance", "PROBLEM", 85, 119], ["high", "OBSERVATION_MODIFIER", 37, 41], ["medium risk", "OBSERVATION_MODIFIER", 46, 57]]], ["For Apple, Babylon, CDC, Cleveland Clinic, Providence and \"Your.MD\" the performance is about the same.Constraining symptoms for SymptomaWhen Symptoma is allowed to use all symptoms of the case descriptions, it clearly outperforms all other checkers (dashed blue line in Fig 2B ) .", [["Constraining symptoms", "PROBLEM", 102, 123], ["SymptomaWhen Symptoma", "PROBLEM", 128, 149], ["all symptoms", "PROBLEM", 168, 180]]], ["This suggests that performance is directly related to the number of symptom's any given checker considers as input, and as such, free-text input (non-constrained) will normally lead to a higher likelihood of correct diagnosis.Constraining symptoms for Symptoma.", [["Symptoma", "DISEASE", 252, 260], ["symptom", "PROBLEM", 68, 75], ["Constraining symptoms", "PROBLEM", 226, 247], ["Symptoma", "PROBLEM", 252, 260]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Constraining symptoms for SymptomaThe copyright holder for this preprint this version posted May 26, 2020. . .", [["CC", "CHEMICAL", 0, 2], ["Symptoma", "DISEASE", 228, 236], ["ND", "PROBLEM", 9, 11], ["Constraining symptoms", "PROBLEM", 202, 223], ["Symptoma", "PROBLEM", 228, 236], ["The copyright holder", "TREATMENT", 236, 256], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Constraining symptoms for SymptomaThe copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20109777 doi: medRxiv preprintDiscussionWe classified 50 COVID-19 case descriptions from the recent literature as well as 410 non-COVID-19 control cases with ten different online COVID-19 symptom checkers.", [["CC", "CHEMICAL", 0, 2], ["Symptoma", "DISEASE", 228, 236], ["ND", "PROBLEM", 9, 11], ["Constraining symptoms", "PROBLEM", 202, 223], ["Symptoma", "PROBLEM", 228, 236], ["The copyright holder", "TREATMENT", 236, 256], ["medRxiv", "TREATMENT", 360, 367], ["med", "ANATOMY", 105, 108]]], ["Only two out of ten symptom checkers showed a reasonably good balance between sensitivity and specificity: namely Infermedica (F 1 =0.80) and Symptoma (F 1 =0.92).", [["ten symptom checkers", "TEST", 16, 36], ["specificity", "TEST", 94, 105]]], ["Most other checkers are either too sensitive, classifying almost all patients as COVID-19 positive, or too specific, classifying many COVID-19 patients as COVID-19 negative (see Fig 1 ) .", [["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 143, 151], ["COVID", "TEST", 81, 86], ["COVID", "TEST", 155, 160]]], ["For example, our BMJ control cases contain a patient suffering from a pulmonary disease who presents with various symptoms, including fever, cough and shortness of breath, the three most frequent symptoms associated with COVID-19.", [["pulmonary", "ANATOMY", 70, 79], ["pulmonary disease", "DISEASE", 70, 87], ["fever", "DISEASE", 134, 139], ["cough", "DISEASE", 141, 146], ["shortness of breath", "DISEASE", 151, 170], ["COVID-19", "CHEMICAL", 221, 229], ["COVID-19", "CHEMICAL", 221, 229], ["patient", "ORGANISM", 45, 52], ["pulmonary", "ORGAN", 70, 79], ["patient", "SPECIES", 45, 52], ["a pulmonary disease", "PROBLEM", 68, 87], ["various symptoms", "PROBLEM", 106, 122], ["fever", "PROBLEM", 134, 139], ["cough", "PROBLEM", 141, 146], ["shortness of breath", "PROBLEM", 151, 170], ["the three most frequent symptoms", "PROBLEM", 172, 204], ["COVID", "TEST", 221, 226], ["pulmonary", "ANATOMY", 70, 79], ["disease", "OBSERVATION", 80, 87]]], ["Symptoma uses the additional symptoms and risk factors not considered by the other checkers, namely loss of appetite, green sputum, and a history of smoking, to discern the correct diagnosis of COVID-19 negative.", [["Symptoma", "DISEASE", 0, 8], ["loss of appetite", "DISEASE", 100, 116], ["the additional symptoms", "PROBLEM", 14, 37], ["risk factors", "PROBLEM", 42, 54], ["loss of appetite", "PROBLEM", 100, 116], ["green sputum", "PROBLEM", 118, 130], ["COVID", "TEST", 194, 199]]], ["Five of the other checkers consider this case as high risk.DiscussionFurthermore, most of the symptom checkers are even out-performed by our simplistic symptom frequency vector approaches (SF-DIST (F 1 =0.57) and SF-COS (F 1 =0.79)).", [["the symptom checkers", "TEST", 90, 110], ["SF", "TEST", 213, 215]]], ["Notably, the cosine version shows surprisingly good results outperforming 8 out of 10 symptom checkers based on the F 1 score.DiscussionTo our knowledge this is the first scientific evaluation of online COVID-19 symptom checkers, however, there are a number of related studies evaluating symptom checkers.", [["the cosine version", "TEST", 9, 27], ["symptom checkers", "TEST", 86, 102], ["online COVID", "TEST", 196, 208], ["symptom checkers", "PROBLEM", 288, 304]]], ["These include a study that evaluated 23 general-purpose symptom checkers based on 45 clinical case descriptions across a wide range of medical conditions and found that the correct diagnosis was on average listed among the top 20 results of the checkers in 58% of all cases [2] .", [["a study", "TEST", 14, 21], ["the checkers", "TEST", 241, 253]]], ["This study design was extended for five additional symptom checkers using ear, nose and throat (ENT)Discussion.", [["ear", "ANATOMY", 74, 77], ["ear", "ORGAN", 74, 77], ["nose", "ORGANISM_SUBDIVISION", 79, 83], ["This study", "TEST", 0, 10], ["five additional symptom checkers", "TEST", 35, 67], ["ear", "ANATOMY", 74, 77], ["nose", "ANATOMY", 79, 83], ["throat", "ANATOMY", 88, 94]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .(which was not certified by peer review)cases showing similar results [8] .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Other evaluations include symptom checkers used for knee pain cases that found, based on 527 patients and 26 knee problems, that the physician's diagnosis was present within the prediction list in 89% of the cases while the specificity was only 27% [9] .", [["knee", "ANATOMY", 52, 56], ["pain", "DISEASE", 57, 61], ["knee", "ORGANISM_SUBDIVISION", 52, 56], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["Other evaluations", "TEST", 0, 17], ["symptom checkers", "TEST", 26, 42], ["knee pain", "PROBLEM", 52, 61], ["26 knee problems", "PROBLEM", 106, 122], ["the specificity", "TEST", 220, 235], ["knee", "ANATOMY", 52, 56], ["knee", "ANATOMY", 109, 113]]], ["In another study, an analysis of a university students' automated self-assessment triage system prior to an in-person consultation with a medical doctor found that the system's urgency rating agreed perfectly in only 39% of cases while for the remaining cases the system tended to be more risk averse than the doctor [10] .", [["another study", "TEST", 3, 16], ["the system's urgency", "PROBLEM", 164, 184]]], ["Also, the applicability of online symptom checkers for 79 persons aged \u226550 years based on \"think-aloud\" protocols [11] , deep learning algorithms for medical imaging [12] , and services for urgent care [3] were evaluated.(which was not certified by peer review)If the performance of any (COVID-19) online symptom checker is acceptable depends on the perspective and use of the results.", [["persons", "ORGANISM", 58, 65], ["persons", "SPECIES", 58, 65], ["medical imaging", "TEST", 150, 165], ["COVID", "TEST", 288, 293], ["online symptom checker", "TEST", 298, 320]]], ["In the case of COVID-19, an online assessment can not fully replace a PCR-test as some people are asymptomatic, while others presenting with very specific COVID-19 symptoms might, in fact, have a very similar but different disease.(which was not certified by peer review)Regardless, online COVID-19 symptom checkers can act as a first triage shield to take pressure off from in-person physician visits or hospitals.", [["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93], ["COVID", "TEST", 15, 20], ["an online assessment", "TEST", 25, 45], ["a PCR-test", "TEST", 68, 78], ["asymptomatic", "PROBLEM", 98, 110], ["very specific COVID-19 symptoms", "PROBLEM", 141, 172], ["different disease", "PROBLEM", 213, 230], ["online COVID", "TEST", 283, 295], ["different", "OBSERVATION_MODIFIER", 213, 222], ["disease", "OBSERVATION", 223, 230]]], ["Symptom checkers could even replace telephone triage lines in which non-medically trained personnel read a predefined sequence of questions.", [["Symptom", "PROBLEM", 0, 7]]], ["Even though this was not part of this study, the authors believe that COVID-19 symptom checkers (if appropriately maintained and tested) might also be more reliable than the direct use of search engines such as Google or information via social media.(which was not certified by peer review)The strength of this study lies in the fact that it is based on a large number (n=460) of real patients' case descriptions from the literature and a detailed evaluation on the best performing symptom checker ( Fig 2 ) .", [["patients", "ORGANISM", 385, 393], ["patients", "SPECIES", 385, 393], ["this study", "TEST", 33, 43], ["COVID", "TEST", 70, 75], ["symptom checkers", "TEST", 79, 95], ["this study", "TEST", 306, 316], ["a detailed evaluation", "TEST", 437, 458], ["symptom checker", "TEST", 482, 497]]], ["Vice versa, a potential weakness of this study lies in using real literature-based cases, which might have biased the test set to rather severe cases of COVID-19, as mild and uninteresting cases are usually not found in the literature.", [["a potential weakness", "PROBLEM", 12, 32], ["this study", "TEST", 36, 46], ["the test", "TEST", 114, 122], ["COVID", "TEST", 153, 158], ["mild and uninteresting cases", "PROBLEM", 166, 194], ["mild", "OBSERVATION_MODIFIER", 166, 170]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . this bias by not including extreme edge cases from the literature into our 50 COVID-19 cases.(which was not certified by peer review)Another bias might be that our control case descriptions do not report a \"COVID-19 contact\", even though a person with, for example a cold, might have had a COVID-19 contact (and did not get infected).", [["CC", "CHEMICAL", 0, 2], ["person", "SPECIES", 516, 522], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["med", "ANATOMY", 105, 108]]], ["Another limit of this study is the non-straight forward mapping of the symptom checker outputs to risk levels ( S5 Table ) .", [["this study", "TEST", 17, 27]]], ["The interpretation of the textual output is debatable in some cases.", [["the textual output", "TEST", 22, 40]]], ["We also classified every symptom checker output by multiple persons until consensus was reached.ConclusionSymptom checkers are being widely used in response to the COVID-19 global pandemic.", [["persons", "ORGANISM", 60, 67], ["persons", "SPECIES", 60, 67], ["the COVID", "TEST", 160, 169]]], ["As such, quality assessment of these tools is critical.", [["quality assessment", "TEST", 9, 27]]], ["We show that various online COVID-19 symptom checkers vary widely in their predictive capabilities, with some performing equivalently to randomly guessing, while others, namely Symptoma (F 1 = 0.92) and Infermedica (F 1 = 0.80), exhibiting high accuracy.Declaration of interestsAll authors are employees of Symptoma GmbH.", [["various online COVID", "TEST", 13, 33], ["symptom checkers", "TEST", 37, 53]]], ["JN holds shares of Symptoma.AcknowledgmentsThis study has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 830017.Acknowledgments.", [["Symptoma", "DISEASE", 19, 27], ["This study", "TEST", 43, 53], ["Symptoma", "OBSERVATION", 19, 27]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20109777 doi: medRxiv preprint Supporting information S1 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Output : return disease with maximum similarity .", [["return disease", "PROBLEM", 9, 23], ["return disease", "OBSERVATION", 9, 23], ["maximum similarity", "OBSERVATION", 29, 47]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20109777 doi: medRxiv preprint(which was not certified by peer review)Call an ambulance immediately.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Please tell them you have symptoms that may be caused by coronavirus (COVID-19) .(which was not certified by peer review)High .", [["symptoms", "PROBLEM", 26, 34], ["coronavirus", "PROBLEM", 57, 68]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["The copyright holder", "TREATMENT", 490, 510], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 353, 356]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.22.20109777 doi: medRxiv preprint S10 Table.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Full table of sensitivity, specificity, accuracy, F1 score and MCC for Symptoma constrained by each symptom checker (COVID-19 positive defined by \"medium risk\" or \"high risk\" for non binary symptom checkers)", [["Symptoma", "DISEASE", 71, 79], ["sensitivity", "TEST", 14, 25], ["specificity", "TEST", 27, 38], ["accuracy", "TEST", 40, 48], ["Symptoma", "PROBLEM", 71, 79], ["each symptom checker", "TEST", 95, 115], ["COVID", "TEST", 117, 122], ["non binary symptom checkers", "PROBLEM", 179, 206]]]], "01fc023299bde5f92bf4c5cd485c57f59f0417b9": [["1 ABSTRACT 117 Background 118 COVID-19 patients can develop a cytokine release syndrome that eventually leads to acute 119 respiratory distress syndrome (ARDS) requiring invasive mechanical ventilation (IMV).", [["respiratory", "ANATOMY", 123, 134], ["respiratory distress syndrome", "DISEASE", 123, 152], ["ARDS", "DISEASE", 154, 158], ["patients", "ORGANISM", 39, 47], ["cytokine", "PROTEIN", 62, 70], ["patients", "SPECIES", 39, 47], ["ABSTRACT", "TEST", 2, 10], ["Background", "TEST", 15, 25], ["COVID", "TEST", 30, 35], ["a cytokine release syndrome", "PROBLEM", 60, 87], ["acute 119 respiratory distress syndrome", "PROBLEM", 113, 152], ["ARDS", "PROBLEM", 154, 158], ["invasive mechanical ventilation", "TREATMENT", 170, 201], ["IMV", "TREATMENT", 203, 206], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["respiratory distress", "OBSERVATION", 123, 143], ["mechanical ventilation", "OBSERVATION", 179, 201]]], ["Since 120 interleukin-6 (IL-6) is a relevant cytokine in ARDS, the blockade of its receptor with 121 Tocilizumab (TCZ) could reduce mortality and/or morbidity in severe Objective 123 To determine whether baseline IL-6 serum levels can predict the need for IMV and the 124 response to TCZ.", [["serum", "ANATOMY", 218, 223], ["ARDS", "DISEASE", 57, 61], ["Tocilizumab", "CHEMICAL", 101, 112], ["TCZ", "CHEMICAL", 114, 117], ["TCZ", "CHEMICAL", 284, 287], ["Tocilizumab", "CHEMICAL", 101, 112], ["TCZ", "CHEMICAL", 114, 117], ["TCZ", "CHEMICAL", 284, 287], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 10, 23], ["IL-6", "GENE_OR_GENE_PRODUCT", 25, 29], ["Tocilizumab", "SIMPLE_CHEMICAL", 101, 112], ["TCZ", "SIMPLE_CHEMICAL", 114, 117], ["IL-6", "GENE_OR_GENE_PRODUCT", 213, 217], ["serum", "ORGANISM_SUBSTANCE", 218, 223], ["TCZ", "SIMPLE_CHEMICAL", 284, 287], ["interleukin-6 (IL-6", "PROTEIN", 10, 29], ["cytokine", "PROTEIN", 45, 53], ["IL-6", "PROTEIN", 213, 217], ["interleukin", "TEST", 10, 21], ["a relevant cytokine in ARDS", "PROBLEM", 34, 61], ["the blockade of its receptor", "TREATMENT", 63, 91], ["Tocilizumab (TCZ", "TREATMENT", 101, 117], ["morbidity", "PROBLEM", 149, 158], ["baseline IL", "TEST", 204, 215], ["serum levels", "TEST", 218, 230], ["IMV", "TREATMENT", 256, 259], ["TCZ", "TREATMENT", 284, 287], ["ARDS", "OBSERVATION", 57, 61]]], ["125126Retrospective observational study performed in hospitalized patients diagnosed of Clinical information and laboratory findings, including IL-6 levels, were collected 128 approximately 3 and 9 days after admission to be matched with pre-and post-administration The recent exponential increase in cases of severe acute respiratory syndrome caused by 181 coronavirus 2 (SARS-CoV-2) has led the World Health Organization to declare a pandemic.", [["acute respiratory syndrome", "DISEASE", 317, 343], ["patients", "ORGANISM", 66, 74], ["IL-6", "GENE_OR_GENE_PRODUCT", 144, 148], ["181 coronavirus 2", "ORGANISM", 354, 371], ["SARS-CoV-2", "ORGANISM", 373, 383], ["IL", "PROTEIN", 144, 146], ["patients", "SPECIES", 66, 74], ["SARS-CoV-2", "SPECIES", 373, 383], ["Retrospective observational study", "TEST", 6, 39], ["laboratory findings", "TEST", 113, 132], ["IL", "TEST", 144, 146], ["severe acute respiratory syndrome", "PROBLEM", 310, 343], ["coronavirus", "PROBLEM", 358, 369], ["a pandemic", "PROBLEM", 434, 444], ["exponential", "OBSERVATION_MODIFIER", 277, 288], ["increase", "OBSERVATION_MODIFIER", 289, 297], ["severe", "OBSERVATION_MODIFIER", 310, 316], ["acute", "OBSERVATION_MODIFIER", 317, 322], ["respiratory syndrome", "OBSERVATION", 323, 343]]], ["The 182 disease, known as coronavirus disease 2019 , has pushed national health systems 183 to the brink of collapse, prompting national governments to impose complete population 184 lockdowns in an attempt to slow down the dynamics of infection (1, 2) 185 The spectrum of COVID-19 clinical manifestations varies widely, from mild to severe cases of 186 atypical pneumonia, some of them developing acute respiratory distress syndrome (ARDS), 187 which often requires invasive mechanical ventilation (IMV) and is the leading cause of death.", [["respiratory", "ANATOMY", 404, 415], ["coronavirus disease", "DISEASE", 26, 45], ["infection", "DISEASE", 236, 245], ["pneumonia", "DISEASE", 363, 372], ["acute respiratory distress syndrome", "DISEASE", 398, 433], ["ARDS", "DISEASE", 435, 439], ["death", "DISEASE", 533, 538], ["The 182 disease", "PROBLEM", 0, 15], ["coronavirus disease", "PROBLEM", 26, 45], ["collapse", "PROBLEM", 108, 116], ["infection", "PROBLEM", 236, 245], ["COVID", "TEST", 273, 278], ["clinical manifestations", "PROBLEM", 282, 305], ["mild to severe cases of 186 atypical pneumonia", "PROBLEM", 326, 372], ["acute respiratory distress syndrome", "PROBLEM", 398, 433], ["ARDS", "PROBLEM", 435, 439], ["invasive mechanical ventilation", "TREATMENT", 467, 498], ["IMV", "TREATMENT", 500, 503], ["death", "PROBLEM", 533, 538], ["182 disease", "OBSERVATION", 4, 15], ["coronavirus disease", "OBSERVATION", 26, 45], ["collapse", "OBSERVATION", 108, 116], ["infection", "OBSERVATION", 236, 245], ["mild", "OBSERVATION_MODIFIER", 326, 330], ["severe", "OBSERVATION_MODIFIER", 334, 340], ["atypical", "OBSERVATION_MODIFIER", 354, 362], ["pneumonia", "OBSERVATION", 363, 372], ["acute", "OBSERVATION_MODIFIER", 398, 403], ["respiratory distress syndrome", "OBSERVATION", 404, 433], ["invasive", "OBSERVATION_MODIFIER", 467, 475], ["mechanical ventilation", "OBSERVATION", 476, 498]]], ["188 It is suggested that the severity of the respiratory disease caused by SARS-CoV-2 is largely due 189 to an exacerbated immune response against the virus (3, 4).", [["respiratory", "ANATOMY", 45, 56], ["respiratory disease", "DISEASE", 45, 64], ["SARS", "DISEASE", 75, 79], ["SARS-CoV-2", "ORGANISM", 75, 85], ["SARS-CoV", "SPECIES", 75, 83], ["the respiratory disease", "PROBLEM", 41, 64], ["SARS", "PROBLEM", 75, 79], ["CoV", "TEST", 80, 83], ["an exacerbated immune response", "PROBLEM", 108, 138], ["the virus", "PROBLEM", 147, 156], ["respiratory disease", "OBSERVATION", 45, 64], ["virus", "OBSERVATION", 151, 156]]], ["This response has been observed 190 in previous respiratory virus outbreaks and can be also seen in patients treated with chimeric 191 antigen receptor (CAR) T cell therapy (5-7).", [["T cell", "ANATOMY", 158, 164], ["respiratory virus outbreaks", "DISEASE", 48, 75], ["patients", "ORGANISM", 100, 108], ["chimeric 191 antigen receptor", "GENE_OR_GENE_PRODUCT", 122, 151], ["chimeric 191 antigen receptor", "PROTEIN", 122, 151], ["CAR", "PROTEIN", 153, 156], ["patients", "SPECIES", 100, 108], ["previous respiratory virus outbreaks", "PROBLEM", 39, 75], ["chimeric 191 antigen receptor (CAR) T cell therapy", "TREATMENT", 122, 172], ["respiratory virus", "OBSERVATION", 48, 65]]], ["Pro-inflammatory cytokines such as interleukin (IL) 192 1 and IL-6 are crucial mediators of this process (3, 6).", [["interleukin (IL) 192 1", "GENE_OR_GENE_PRODUCT", 35, 57], ["IL-6", "GENE_OR_GENE_PRODUCT", 62, 66], ["Pro-inflammatory cytokines", "PROTEIN", 0, 26], ["interleukin (IL) 192 1 and IL-6", "PROTEIN", 35, 66], ["Pro-inflammatory cytokines", "TEST", 0, 26], ["interleukin (IL)", "TREATMENT", 35, 51]]], ["In this regard, recent studies have 193 indicated the usefulness of IL-6 serum levels, lymphocyte count, fibrinogen or D-dimer to 194 evaluate the development of ARDS and its mortality (8-11).", [["serum", "ANATOMY", 73, 78], ["lymphocyte", "ANATOMY", 87, 97], ["ARDS", "DISEASE", 162, 166], ["IL-6", "GENE_OR_GENE_PRODUCT", 68, 72], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["lymphocyte", "CELL", 87, 97], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 105, 115], ["D-dimer", "GENE_OR_GENE_PRODUCT", 119, 126], ["IL-6", "PROTEIN", 68, 72], ["fibrinogen", "PROTEIN", 105, 115], ["recent studies", "TEST", 16, 30], ["IL", "TEST", 68, 70], ["serum levels", "TEST", 73, 85], ["lymphocyte count", "TEST", 87, 103], ["fibrinogen", "TEST", 105, 115], ["D-dimer", "TEST", 119, 126], ["ARDS", "PROBLEM", 162, 166], ["ARDS", "OBSERVATION", 162, 166]]], ["196 Tocilizumab (TCZ), an anti-IL-6 receptor (IL-6R) antibody, is the only drug currently licensed for 197 the treatment of the cytokine release syndrome (CRS) associated with CAR-T cell therapy (13).", [["CAR-T cell", "ANATOMY", 176, 186], ["Tocilizumab", "CHEMICAL", 4, 15], ["TCZ", "CHEMICAL", 17, 20], ["CRS", "DISEASE", 155, 158], ["Tocilizumab", "CHEMICAL", 4, 15], ["Tocilizumab", "SIMPLE_CHEMICAL", 4, 15], ["TCZ", "SIMPLE_CHEMICAL", 17, 20], ["anti-IL-6 receptor", "GENE_OR_GENE_PRODUCT", 26, 44], ["IL-6R", "GENE_OR_GENE_PRODUCT", 46, 51], ["anti-IL-6 receptor (IL-6R) antibody", "PROTEIN", 26, 61], ["cytokine", "PROTEIN", 128, 136], ["CAR", "PROTEIN", 176, 179], ["Tocilizumab (TCZ", "TREATMENT", 4, 20], ["an anti-IL-6 receptor (IL", "TREATMENT", 23, 48], ["the cytokine release syndrome", "PROBLEM", 124, 153], ["CRS", "PROBLEM", 155, 158], ["CAR-T cell therapy", "TREATMENT", 176, 194]]], ["The rationale is to curb the deleterious effects of inflammation, thereby 205 This is a retrospective observational study including 146 consecutive patients with confirmed 206 detection of SARS-CoV-2 RNA, baseline IL-6 serum level measurement and admitted to the 207 Hospital Universitario La Princesa (HUP) with severe to critical COVID-19 (18), from February 208 24 th to March 23 rd 2020 (Flow chart in Suppl.", [["serum", "ANATOMY", 219, 224], ["inflammation", "DISEASE", 52, 64], ["SARS", "DISEASE", 189, 193], ["patients", "ORGANISM", 148, 156], ["IL-6", "GENE_OR_GENE_PRODUCT", 214, 218], ["serum", "ORGANISM_SUBSTANCE", 219, 224], ["IL", "PROTEIN", 214, 216], ["patients", "SPECIES", 148, 156], ["inflammation", "PROBLEM", 52, 64], ["a retrospective observational study", "TEST", 86, 121], ["SARS", "PROBLEM", 189, 193], ["CoV", "TEST", 194, 197], ["baseline IL", "TEST", 205, 216], ["serum level measurement", "TEST", 219, 242], ["critical COVID", "TEST", 323, 337], ["inflammation", "OBSERVATION", 52, 64]]], ["Fig. 1 240 Surplus sera from laboratory routine determinations were used to assess IL-6 levels, which 241 were retrospectively quantified in duplicate with the Human IL-6 Quantikine high sensitivity 242 enzyme-immune assay from R&D Systems Europe Ltd.", [["sera", "ANATOMY", 19, 23], ["sera", "ORGANISM_SUBSTANCE", 19, 23], ["IL-6", "GENE_OR_GENE_PRODUCT", 83, 87], ["Human", "ORGANISM", 160, 165], ["IL-6", "GENE_OR_GENE_PRODUCT", 166, 170], ["IL", "PROTEIN", 83, 85], ["Human", "SPECIES", 160, 165], ["laboratory routine determinations", "TEST", 29, 62], ["IL", "TEST", 83, 85], ["the Human IL", "TEST", 156, 168], ["enzyme", "TEST", 203, 209]]], ["The intra-assay and 243 inter-assay variability were 3% and 5%, respectively.", [["The intra-assay", "TEST", 0, 15], ["inter-assay variability", "TEST", 24, 47]]], ["Therefore, the decision to treat with TCZ was based on the AEMPS criteria, excluding IL-6>40 261 pg/ml, since no information about IL-6 results was available to physicians during the study 262 period.", [["TCZ", "CHEMICAL", 38, 41], ["TCZ", "CHEMICAL", 38, 41], ["TCZ", "SIMPLE_CHEMICAL", 38, 41], ["IL-6>40", "GENE_OR_GENE_PRODUCT", 85, 92], ["IL-6", "GENE_OR_GENE_PRODUCT", 131, 135], ["IL", "PROTEIN", 85, 87], ["IL", "PROTEIN", 131, 133], ["TCZ", "TREATMENT", 38, 41], ["IL", "TEST", 85, 87], ["the study", "TEST", 179, 188]]], ["After a preliminary analysis of data by the end of March, IL-6 measurement was 263 included in the baseline assessment of COVID-19 patients.", [["IL-6", "GENE_OR_GENE_PRODUCT", 58, 62], ["patients", "ORGANISM", 131, 139], ["IL", "PROTEIN", 58, 60], ["patients", "SPECIES", 131, 139], ["a preliminary analysis", "TEST", 6, 28], ["the baseline assessment", "TEST", 95, 118], ["COVID", "TEST", 122, 127]]], ["264 The administration schedule of TCZ at the time of the study was a first intravenous infusion of 265 8 mg/kg (maximum 800 mg) followed by a second one after 12 hours.", [["intravenous", "ANATOMY", 76, 87], ["TCZ", "CHEMICAL", 35, 38], ["TCZ", "SIMPLE_CHEMICAL", 35, 38], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 76, 87], ["TCZ", "TREATMENT", 35, 38], ["the study", "TEST", 54, 63], ["a first intravenous infusion", "TREATMENT", 68, 96]]], ["To analyze whether IL-6 levels can predict disease severity, two main outcomes were 269 considered: need for IMV and all-cause mortality.", [["IL-6", "GENE_OR_GENE_PRODUCT", 19, 23], ["IL-6", "PROTEIN", 19, 23], ["IL", "TEST", 19, 21], ["disease severity", "PROBLEM", 43, 59], ["IMV", "TREATMENT", 109, 112], ["mortality", "PROBLEM", 127, 136]]], ["270 To determine the effect of TCZ we analyzed the evolution of PaO 2 /FiO 2 between both 271 evaluation times.", [["TCZ", "CHEMICAL", 31, 34], ["TCZ", "CHEMICAL", 31, 34], ["TCZ", "SIMPLE_CHEMICAL", 31, 34], ["TCZ", "TREATMENT", 31, 34], ["PaO", "TEST", 64, 67], ["FiO", "TEST", 71, 74]]], ["In 160 out of 267 evaluations arterial oxygen tension (PaO 2 ) was 272 J o u r n a l P r e -p r o o f unavailable.", [["arterial", "ANATOMY", 30, 38], ["oxygen", "CHEMICAL", 39, 45], ["oxygen", "CHEMICAL", 39, 45], ["arterial", "MULTI-TISSUE_STRUCTURE", 30, 38], ["oxygen", "SIMPLE_CHEMICAL", 39, 45], ["arterial oxygen tension", "TEST", 30, 53], ["PaO", "TEST", 55, 58], ["arterial", "ANATOMY", 30, 38], ["oxygen tension", "OBSERVATION", 39, 53]]], ["So, in order to avoid missing data in these relevant outcomes, this parameter was 273 estimated from mean oxygen saturation (SatO 2 ) as proposed elsewhere (22).", [["oxygen", "CHEMICAL", 106, 112], ["oxygen", "CHEMICAL", 106, 112], ["oxygen", "SIMPLE_CHEMICAL", 106, 112], ["this parameter", "TEST", 63, 77], ["mean oxygen saturation", "TEST", 101, 123]]], ["274 IL-6 serum levels showed a heterogeneous distribution in patients and in healthy donors 275 (Suppl.", [["serum", "ANATOMY", 9, 14], ["IL-6", "GENE_OR_GENE_PRODUCT", 4, 8], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["patients", "ORGANISM", 61, 69], ["IL", "PROTEIN", 4, 6], ["patients", "SPECIES", 61, 69], ["IL", "TEST", 4, 6], ["serum levels", "TEST", 9, 21], ["heterogeneous", "OBSERVATION_MODIFIER", 31, 44], ["distribution", "OBSERVATION_MODIFIER", 45, 57]]], ["The procedure to determine the cut-off for 277 high baseline IL-6 is described below. represented as median and IQR and the Mann Whitney test was used to assess significant 283 differences.", [["IL-6", "GENE_OR_GENE_PRODUCT", 61, 65], ["IL-6", "PROTEIN", 61, 65], ["The procedure", "TREATMENT", 0, 13], ["the Mann Whitney test", "TEST", 120, 141]]], ["Variables with a normal distribution were described by mean\u00b1standard deviation 284 (SD) and differences between groups were assessed with Student's t-test.", [["Student's t-test", "TEST", 138, 154], ["normal", "OBSERVATION", 17, 23], ["distribution", "OBSERVATION_MODIFIER", 24, 36]]], ["Qualitative 285 variables were described as counts and proportions and 2 or Fisher\u00b4s exact test was used for 286 comparisons.", [["Fisher\u00b4s exact test", "TEST", 76, 95]]], ["Correlation between quantitative variables was analyzed using the Pearson 287 correlation test.", [["correlation test", "TEST", 78, 94]]], ["To estimate the 95% confidence interval of correlation coefficients we used 288 the ci2 command of Stata.", [["correlation coefficients", "TEST", 43, 67]]], ["289 To determine whether IL-6 serum levels were able to discriminate between: i) COVID-19 290 patients vs. healthy donors; ii) patients requiring IMV vs. those that did not; or iii) patients 291 treated with TCZ vs. not treated, receiver operating characteristic (ROC) analysis was 292 performed using the roctab command.", [["serum", "ANATOMY", 30, 35], ["TCZ", "CHEMICAL", 208, 211], ["TCZ", "CHEMICAL", 208, 211], ["IL-6", "GENE_OR_GENE_PRODUCT", 25, 29], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["patients", "ORGANISM", 94, 102], ["donors", "ORGANISM", 115, 121], ["patients", "ORGANISM", 127, 135], ["patients", "ORGANISM", 182, 190], ["TCZ", "SIMPLE_CHEMICAL", 208, 211], ["IL", "PROTEIN", 25, 27], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 182, 190], ["IL", "TEST", 25, 27], ["serum levels", "TEST", 30, 42], ["COVID", "TEST", 81, 86], ["IMV", "TREATMENT", 146, 149], ["TCZ vs", "TREATMENT", 208, 214], ["ROC) analysis", "TEST", 264, 277], ["the roctab command", "TEST", 302, 320]]], ["Each cut-off point was selected based on the best 293 trade-off values between sensitivity, specificity and the percentage of patients correctly 294 classified.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["sensitivity", "TEST", 79, 90], ["specificity", "TEST", 92, 103]]], ["Positive and negative likelihood ratios and ROC curves were also obtained.J o u r n a l P r e -p r o o fTo determine the variables associated with the need for IMV, we performed a multivariable 296 logistic regression analysis that was first modeled by adding all the variables with a p value 297 lower than 0.15 in the bivariable analysis, namely total lymphocyte count, D-dimer, LDH, 298 PaO 2 /FiO 2 , COPD, obesity, hypertension, C-reactive protein, and IL-6 (high vs low).", [["lymphocyte", "ANATOMY", 354, 364], ["COPD", "DISEASE", 405, 409], ["obesity", "DISEASE", 411, 418], ["hypertension", "DISEASE", 420, 432], ["lymphocyte", "CELL", 354, 364], ["D-dimer", "SIMPLE_CHEMICAL", 372, 379], ["LDH", "SIMPLE_CHEMICAL", 381, 384], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 434, 452], ["IL-6", "GENE_OR_GENE_PRODUCT", 458, 462], ["D-dimer", "PROTEIN", 372, 379], ["LDH", "PROTEIN", 381, 384], ["C-reactive protein", "PROTEIN", 434, 452], ["IL-6", "PROTEIN", 458, 462], ["ROC curves", "TEST", 44, 54], ["IMV", "TREATMENT", 160, 163], ["a p value", "TEST", 283, 292], ["the bivariable analysis", "TEST", 316, 339], ["total lymphocyte count", "TEST", 348, 370], ["D", "TEST", 372, 373], ["LDH", "TEST", 381, 384], ["PaO", "TEST", 390, 393], ["FiO", "TEST", 397, 400], ["COPD", "PROBLEM", 405, 409], ["obesity", "PROBLEM", 411, 418], ["hypertension", "PROBLEM", 420, 432], ["C-reactive protein", "PROBLEM", 434, 452], ["IL", "TEST", 458, 460], ["negative", "OBSERVATION_MODIFIER", 13, 21], ["lymphocyte count", "OBSERVATION", 354, 370], ["COPD", "OBSERVATION", 405, 409], ["obesity", "OBSERVATION", 411, 418], ["hypertension", "OBSERVATION", 420, 432], ["reactive protein", "OBSERVATION", 436, 452]]], ["The final 299 model was reached with backward stepwise removal of variables with p-value higher than 300 0.15, and using Wald tests to demonstrate that each model was better than its previous 301 iteration.", [["backward stepwise removal", "TREATMENT", 37, 62], ["p-value", "TEST", 81, 88], ["Wald tests", "TEST", 121, 131]]], ["302 Next, we performed a multivariable analysis using generalized linear models nested by patient 303 and visit (xtgee command) in which the dependent variable was PaO 2 /FiO 2 .", [["PaO 2", "CHEMICAL", 164, 169], ["FiO 2", "CHEMICAL", 171, 176], ["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97], ["a multivariable analysis", "TEST", 23, 47], ["generalized linear models", "TREATMENT", 54, 79]]], ["This approach 304 allowed us to identify which variables influenced the evolution of PaO 2 /FiO 2 .", [["PaO 2", "CHEMICAL", 85, 90], ["FiO 2", "CHEMICAL", 92, 97], ["PaO 2", "GENE_OR_GENE_PRODUCT", 85, 90], ["FiO 2", "GENE_OR_GENE_PRODUCT", 92, 97], ["PaO 2", "PROTEIN", 85, 90], ["FiO 2", "PROTEIN", 92, 97], ["PaO", "TEST", 85, 88]]], ["The first model 305 included all variables with a p value <0.15 in the bivariable analysis, namely hypertension, 306 baseline radiological pattern, LDH, total lymphocyte count, baseline C-reactive protein, IMV.", [["lymphocyte", "ANATOMY", 159, 169], ["hypertension", "DISEASE", 99, 111], ["LDH", "SIMPLE_CHEMICAL", 148, 151], ["lymphocyte", "CELL", 159, 169], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 186, 204], ["LDH", "PROTEIN", 148, 151], ["baseline C-reactive protein", "PROTEIN", 177, 204], ["IMV", "PROTEIN", 206, 209], ["a p value", "TEST", 48, 57], ["the bivariable analysis", "TEST", 67, 90], ["hypertension", "PROBLEM", 99, 111], ["baseline radiological pattern", "TEST", 117, 146], ["LDH", "TEST", 148, 151], ["total lymphocyte count", "TEST", 153, 175], ["baseline C", "TEST", 177, 187], ["IMV", "TREATMENT", 206, 209], ["hypertension", "OBSERVATION", 99, 111], ["LDH", "ANATOMY", 148, 151], ["total lymphocyte count", "OBSERVATION", 153, 175], ["reactive protein", "OBSERVATION", 188, 204]]], ["Then, to assess the role of IL-6 as predictor of TCZ effect on PaO 2 /FiO 2, the composite 309 variable IL-6/TCZ (low IL-6/no TCZ, low IL-6/Early TCZ, low IL-6/Late TCZ, high IL-6/no TCZ, high 310 IL-6/Early TCZ and high IL-6/Late TCZ) was forced in the model.", [["TCZ", "CHEMICAL", 49, 52], ["TCZ", "CHEMICAL", 109, 112], ["IL-6", "GENE_OR_GENE_PRODUCT", 28, 32], ["TCZ", "SIMPLE_CHEMICAL", 49, 52], ["PaO 2", "GENE_OR_GENE_PRODUCT", 63, 68], ["FiO 2", "GENE_OR_GENE_PRODUCT", 70, 75], ["IL-6", "GENE_OR_GENE_PRODUCT", 104, 108], ["TCZ", "SIMPLE_CHEMICAL", 109, 112], ["IL-6", "GENE_OR_GENE_PRODUCT", 118, 122], ["TCZ", "SIMPLE_CHEMICAL", 126, 129], ["IL-6", "GENE_OR_GENE_PRODUCT", 135, 139], ["TCZ", "SIMPLE_CHEMICAL", 146, 149], ["IL-6", "GENE_OR_GENE_PRODUCT", 155, 159], ["TCZ", "SIMPLE_CHEMICAL", 165, 168], ["IL-6", "GENE_OR_GENE_PRODUCT", 175, 179], ["TCZ", "SIMPLE_CHEMICAL", 183, 186], ["IL-6", "GENE_OR_GENE_PRODUCT", 197, 201], ["TCZ", "SIMPLE_CHEMICAL", 208, 211], ["IL-6", "GENE_OR_GENE_PRODUCT", 221, 225], ["TCZ", "SIMPLE_CHEMICAL", 231, 234], ["IL-6", "PROTEIN", 28, 32], ["IL", "PROTEIN", 155, 157], ["IL", "PROTEIN", 175, 177], ["IL", "PROTEIN", 221, 223], ["TCZ effect", "TREATMENT", 49, 59], ["PaO", "TEST", 63, 66], ["FiO", "TEST", 70, 73], ["variable IL", "TEST", 95, 106], ["TCZ", "TEST", 109, 112], ["IL", "TEST", 118, 120], ["TCZ", "TREATMENT", 126, 129], ["low IL", "TEST", 151, 157], ["Late TCZ", "TREATMENT", 160, 168], ["high IL", "TEST", 170, 177], ["TCZ", "TEST", 183, 186], ["IL", "TEST", 197, 199], ["Early TCZ", "TEST", 202, 211], ["high IL", "TREATMENT", 216, 223], ["Late TCZ", "TREATMENT", 226, 234]]], ["329 One hundred and forty-six patients were included; their main demographic and clinical 330 characteristics are shown in Table 1 Fig. 3A and B).", [["patients", "ORGANISM", 30, 38], ["B", "GENE_OR_GENE_PRODUCT", 143, 144], ["patients", "SPECIES", 30, 38]]], ["346 No significant correlation was found between PaO 2 and IL-6 serum levels at baseline (r= -0.09 347 [95% CI: -0.270 to 0.085]; p=0.299; Figure 1A) , likely due to a higher oxygen supply in the most 348 severe cases; in fact, serum IL-6 levels showed a significant negative correlation with PaO 2 /FiO 2 ( Figure 1B ; r= -0.38 [95% CI: -0.526 to -0.218]; p<0.001), meaning that higher levels 350 of IL-6 at baseline were associated with lower PaO 2 /FiO 2 .", [["serum", "ANATOMY", 64, 69], ["serum", "ANATOMY", 228, 233], ["oxygen", "CHEMICAL", 175, 181], ["oxygen", "CHEMICAL", 175, 181], ["PaO 2", "CHEMICAL", 445, 450], ["FiO 2", "CHEMICAL", 452, 457], ["PaO 2", "GENE_OR_GENE_PRODUCT", 49, 54], ["IL-6", "GENE_OR_GENE_PRODUCT", 59, 63], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["oxygen", "SIMPLE_CHEMICAL", 175, 181], ["serum", "ORGANISM_SUBSTANCE", 228, 233], ["IL-6", "GENE_OR_GENE_PRODUCT", 234, 238], ["FiO 2", "GENE_OR_GENE_PRODUCT", 300, 305], ["IL-6", "GENE_OR_GENE_PRODUCT", 401, 405], ["FiO 2", "GENE_OR_GENE_PRODUCT", 452, 457], ["PaO 2", "PROTEIN", 49, 54], ["IL-6", "PROTEIN", 59, 63], ["serum IL-6", "PROTEIN", 228, 238], ["IL-6", "PROTEIN", 401, 405], ["PaO", "TEST", 49, 52], ["IL", "TEST", 59, 61], ["serum levels", "TEST", 64, 76], ["CI", "TEST", 108, 110], ["p", "TEST", 130, 131], ["a higher oxygen supply", "PROBLEM", 166, 188], ["serum IL", "TEST", 228, 236], ["PaO", "TEST", 293, 296], ["FiO", "TEST", 300, 303], ["Figure", "TEST", 308, 314], ["r=", "TEST", 320, 322], ["CI", "TEST", 334, 336], ["IL", "TEST", 401, 403], ["lower PaO", "TREATMENT", 439, 448]]], ["351 In this regard, forty-four patients (30%) required IMV at some point during their 352 hospitalization.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["IMV", "TREATMENT", 55, 58]]], ["As expected, these patients showed significantly worse PaO 2 /FiO 2 levels than 353 those not requiring IMV (p<0.001; Table 2 ).", [["patients", "ORGANISM", 19, 27], ["FiO 2", "GENE_OR_GENE_PRODUCT", 62, 67], ["patients", "SPECIES", 19, 27], ["PaO", "TEST", 55, 58], ["FiO 2 levels", "TEST", 62, 74], ["IMV", "TREATMENT", 104, 107]]], ["In addition, they showed increased leukocytes, 354 total lymphocytes, IL-6, C-reactive protein (CRP), and procalcitonin (PCT) showing a higher 355 inflammatory status than those not requiring IMV (p\u22640.001 except p=0.003 for CRP and 356 p=0.029 for lymphocyte count; Table 2 ).", [["leukocytes", "ANATOMY", 35, 45], ["lymphocytes", "ANATOMY", 57, 68], ["lymphocyte", "ANATOMY", 248, 258], ["leukocytes", "CELL", 35, 45], ["lymphocytes", "CELL", 57, 68], ["IL-6", "GENE_OR_GENE_PRODUCT", 70, 74], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 76, 94], ["CRP", "GENE_OR_GENE_PRODUCT", 96, 99], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 106, 119], ["PCT", "GENE_OR_GENE_PRODUCT", 121, 124], ["CRP", "GENE_OR_GENE_PRODUCT", 224, 227], ["lymphocyte", "CELL", 248, 258], ["leukocytes", "CELL_TYPE", 35, 45], ["IL-6", "PROTEIN", 70, 74], ["C-reactive protein", "PROTEIN", 76, 94], ["CRP", "PROTEIN", 96, 99], ["procalcitonin", "PROTEIN", 106, 119], ["PCT", "PROTEIN", 121, 124], ["CRP", "PROTEIN", 224, 227], ["IMV", "SPECIES", 192, 195], ["increased leukocytes", "PROBLEM", 25, 45], ["total lymphocytes", "TEST", 51, 68], ["IL", "TEST", 70, 72], ["C-reactive protein", "TEST", 76, 94], ["CRP", "TEST", 96, 99], ["procalcitonin", "TEST", 106, 119], ["PCT", "TEST", 121, 124], ["a higher 355 inflammatory status", "PROBLEM", 134, 166], ["IMV", "TREATMENT", 192, 195], ["CRP", "TEST", 224, 227], ["lymphocyte count", "TEST", 248, 264], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["leukocytes", "OBSERVATION", 35, 45], ["inflammatory", "OBSERVATION_MODIFIER", 147, 159]]], ["357 Furthermore, a baseline IL-6 above 30 pg/ml (henceforth high IL-6) discriminated patients 358 requiring IMV with 68% Se and 73% Sp.", [["Se", "CHEMICAL", 121, 123], ["Se", "CHEMICAL", 121, 123], ["IL-6", "GENE_OR_GENE_PRODUCT", 28, 32], ["IL-6", "GENE_OR_GENE_PRODUCT", 65, 69], ["patients", "ORGANISM", 85, 93], ["IL-6", "PROTEIN", 28, 32], ["patients", "SPECIES", 85, 93], ["IMV", "SPECIES", 108, 111], ["a baseline IL", "TEST", 17, 30], ["IMV", "TREATMENT", 108, 111]]], ["AUC was 0.725 ( Figure 1C ; LR+ 2.5, LR-0.4).", [["AUC", "TEST", 0, 3], ["Figure", "TEST", 16, 22], ["LR", "TEST", 28, 30], ["LR", "TEST", 37, 39]]], ["A logistic 359 regression model, adjusted for COPD and baseline white blood cell count, also showed that 360 high baseline IL-6 was a predictive biomarker for IMV (OR:7.1; 95% CI: 3.0 to 16.6; Supp Table 361 2).J o u r n a l P r e -p r o o fEven before physicians were aware of the potential value of IL-6 serum levels as a predictor of 375 severe disease, those patients with high IL-6 were more frequently treated with TCZ ( Figure 376 1D; AUC 0.634; 30 pg/ml as cut-off showed Se 57%, Sp 69%, LR+ 1.9, LR-0.7), although with 377 less accuracy than for IMV.", [["white blood cell", "ANATOMY", 64, 80], ["serum", "ANATOMY", 306, 311], ["COPD", "DISEASE", 46, 50], ["TCZ", "CHEMICAL", 421, 424], ["TCZ", "CHEMICAL", 421, 424], ["blood cell", "CELL", 70, 80], ["IL-6", "GENE_OR_GENE_PRODUCT", 123, 127], ["IL-6", "GENE_OR_GENE_PRODUCT", 301, 305], ["serum", "ORGANISM_SUBSTANCE", 306, 311], ["patients", "ORGANISM", 363, 371], ["IL-6", "GENE_OR_GENE_PRODUCT", 382, 386], ["TCZ", "SIMPLE_CHEMICAL", 421, 424], ["IL-6", "PROTEIN", 123, 127], ["IL", "PROTEIN", 301, 303], ["IL-6", "PROTEIN", 382, 386], ["patients", "SPECIES", 363, 371], ["IMV", "SPECIES", 555, 558], ["COPD", "PROBLEM", 46, 50], ["baseline white blood cell count", "TEST", 55, 86], ["a predictive biomarker", "TEST", 132, 154], ["IMV", "TEST", 159, 162], ["CI", "TEST", 176, 178], ["Supp Table", "TEST", 193, 203], ["IL", "TEST", 301, 303], ["serum levels", "TEST", 306, 318], ["severe disease", "PROBLEM", 341, 355], ["TCZ", "TREATMENT", 421, 424], ["AUC", "TEST", 442, 445], ["cut", "TEST", 465, 468], ["Se", "TEST", 480, 482], ["Sp", "TEST", 488, 490], ["LR", "TEST", 496, 498], ["LR", "TEST", 505, 507], ["IMV", "TREATMENT", 555, 558]]], ["The median time from the beginning of symptoms to TCZ 378 treatment was 11 days (IQR: 8-12.5).", [["TCZ", "CHEMICAL", 50, 53], ["symptoms", "PROBLEM", 38, 46], ["TCZ", "TREATMENT", 50, 53], ["treatment", "TREATMENT", 58, 67], ["IQR", "TEST", 81, 84]]], ["Therefore, we considered early TCZ when the treatment 379 was applied before 11 days of disease duration and late TCZ after this cut-off.", [["TCZ", "CHEMICAL", 31, 34], ["TCZ", "CHEMICAL", 114, 117], ["TCZ", "SIMPLE_CHEMICAL", 31, 34], ["early TCZ", "TREATMENT", 25, 34], ["the treatment", "TREATMENT", 40, 53], ["disease duration", "PROBLEM", 88, 104], ["late TCZ", "TREATMENT", 109, 117]]], ["380 As a consequence of IL-6R blockade with TCZ, a significant trend toward higher IL-6 serum 381 levels after administration of the drug was observed ( Since relevant differences were observed between patients treated and not treated with TCZ, 393 we used a multivariable analysis to determine which variables influenced the evolution of 394 PaO 2 /FiO 2 at the short-term.", [["serum", "ANATOMY", 88, 93], ["TCZ", "CHEMICAL", 44, 47], ["TCZ", "CHEMICAL", 240, 243], ["TCZ", "CHEMICAL", 44, 47], ["PaO 2", "CHEMICAL", 343, 348], ["FiO 2", "CHEMICAL", 350, 355], ["IL-6R", "GENE_OR_GENE_PRODUCT", 24, 29], ["TCZ", "SIMPLE_CHEMICAL", 44, 47], ["IL-6", "GENE_OR_GENE_PRODUCT", 83, 87], ["serum", "ORGANISM_SUBSTANCE", 88, 93], ["patients", "ORGANISM", 202, 210], ["IL", "PROTEIN", 24, 26], ["6R", "PROTEIN", 27, 29], ["IL", "PROTEIN", 83, 85], ["patients", "SPECIES", 202, 210], ["IL-6R blockade", "TREATMENT", 24, 38], ["TCZ", "TREATMENT", 44, 47], ["higher IL", "TEST", 76, 85], ["the drug", "TREATMENT", 129, 137], ["TCZ", "TREATMENT", 240, 243], ["a multivariable analysis", "TEST", 257, 281], ["PaO", "TEST", 343, 346], ["FiO", "TEST", 350, 353], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["trend", "OBSERVATION_MODIFIER", 63, 68]]], ["Baseline PaO 2 /FiO 2 and radiological pattern, HTA, LDH and CRP 395 levels and total lymphocyte blood count significantly explained variation in PaO 2 /FiO 2 (Suppl 396 Table 4 ).", [["lymphocyte blood", "ANATOMY", 86, 102], ["FiO 2", "CHEMICAL", 153, 158], ["PaO 2", "GENE_OR_GENE_PRODUCT", 9, 14], ["FiO 2", "GENE_OR_GENE_PRODUCT", 16, 21], ["LDH", "SIMPLE_CHEMICAL", 53, 56], ["CRP 395", "GENE_OR_GENE_PRODUCT", 61, 68], ["lymphocyte", "CELL", 86, 96], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["LDH", "PROTEIN", 53, 56], ["CRP", "PROTEIN", 61, 64], ["Baseline PaO", "TEST", 0, 12], ["FiO", "TEST", 16, 19], ["radiological pattern", "TEST", 26, 46], ["HTA", "TEST", 48, 51], ["LDH", "TEST", 53, 56], ["CRP", "TEST", 61, 64], ["levels", "TEST", 69, 75], ["total lymphocyte blood count", "TEST", 80, 108], ["PaO", "TEST", 146, 149], ["FiO", "TEST", 153, 156], ["LDH", "ANATOMY", 53, 56]]], ["Adjusted by these confounders, the best PaO 2 /FiO 2 evolution was achieved in 397 J o u r n a l P r e -p r o o f patients with low IL-6 not requiring TCZ treatment ( Figure 3C first dot on the left; reference 398 group in analysis showed in Suppl Table 4 ), likely because they were the less severe patients.", [["TCZ", "CHEMICAL", 151, 154], ["TCZ", "CHEMICAL", 151, 154], ["patients", "ORGANISM", 114, 122], ["IL-6", "GENE_OR_GENE_PRODUCT", 132, 136], ["TCZ", "SIMPLE_CHEMICAL", 151, 154], ["patients", "ORGANISM", 300, 308], ["IL", "PROTEIN", 132, 134], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 300, 308], ["the best PaO", "TEST", 31, 43], ["low IL", "TREATMENT", 128, 134], ["TCZ treatment", "TREATMENT", 151, 164], ["left", "ANATOMY_MODIFIER", 194, 198]]], ["399 Patients with low IL-6 that due to their bad evolution were prescribed with TCZ showed a 400 significant worsening of PaO 2 /FiO 2 ( Figure 3C , 2nd and 3rd dots; Suppl Table 4 ).", [["TCZ", "CHEMICAL", 80, 83], ["FiO 2", "CHEMICAL", 129, 134], ["Patients", "ORGANISM", 4, 12], ["IL-6", "GENE_OR_GENE_PRODUCT", 22, 26], ["TCZ", "SIMPLE_CHEMICAL", 80, 83], ["IL", "PROTEIN", 22, 24], ["Patients", "SPECIES", 4, 12], ["TCZ", "TEST", 80, 83], ["PaO", "TEST", 122, 125], ["FiO", "TEST", 129, 132], ["2nd and 3rd dots", "TREATMENT", 149, 165], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["worsening", "OBSERVATION_MODIFIER", 109, 118]]], ["A similar 401 evolution was observed in patients with high IL-6 and late TCZ treatment, whereas those with 402 high IL-6 not treated or treated early with TCZ showed no significant differences compared 403 with the reference group ( Figure 3C ; Suppl Table 4 ). role in the regulation of D-dimer production; or ii) more likely, D-dimer production has a 471 slower kinetics than CRP or other acute phase reactants, since in patients not treated with TCZ 472 a similar rise in D-dimer levels was observed (data not shown ).", [["TCZ", "CHEMICAL", 73, 76], ["TCZ", "CHEMICAL", 155, 158], ["TCZ", "CHEMICAL", 449, 452], ["D-dimer", "CHEMICAL", 288, 295], ["D-dimer", "CHEMICAL", 328, 335], ["patients", "ORGANISM", 40, 48], ["IL-6", "GENE_OR_GENE_PRODUCT", 59, 63], ["TCZ", "SIMPLE_CHEMICAL", 73, 76], ["IL-6", "GENE_OR_GENE_PRODUCT", 116, 120], ["TCZ", "SIMPLE_CHEMICAL", 155, 158], ["D-dimer", "SIMPLE_CHEMICAL", 288, 295], ["D-dimer", "SIMPLE_CHEMICAL", 328, 335], ["CRP", "GENE_OR_GENE_PRODUCT", 378, 381], ["patients", "ORGANISM", 423, 431], ["D-dimer", "GENE_OR_GENE_PRODUCT", 475, 482], ["IL", "PROTEIN", 59, 61], ["IL", "PROTEIN", 116, 118], ["CRP", "PROTEIN", 378, 381], ["D-dimer", "PROTEIN", 475, 482], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 423, 431], ["high IL", "TREATMENT", 54, 61], ["late TCZ treatment", "TREATMENT", 68, 86], ["TCZ", "TEST", 155, 158], ["significant differences", "PROBLEM", 169, 192], ["D-dimer production", "TEST", 328, 346], ["CRP", "TEST", 378, 381], ["other acute phase reactants", "PROBLEM", 385, 412], ["TCZ", "TREATMENT", 449, 452], ["D-dimer levels", "TEST", 475, 489], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["401 evolution", "OBSERVATION_MODIFIER", 10, 23], ["no", "UNCERTAINTY", 166, 168], ["significant", "OBSERVATION_MODIFIER", 169, 180], ["acute", "OBSERVATION_MODIFIER", 391, 396], ["rise", "OBSERVATION_MODIFIER", 467, 471]]], ["473 Apart from the novelty and the immediate clinical utility of these findings, a drawback of our 474 study is its retrospective and observational nature involving mainly very severe cases in the 475 group of treatment with TCZ.", [["TCZ", "CHEMICAL", 225, 228], ["TCZ", "CHEMICAL", 225, 228], ["TCZ", "SIMPLE_CHEMICAL", 225, 228], ["our 474 study", "TEST", 95, 108], ["treatment", "TREATMENT", 210, 219], ["TCZ", "TREATMENT", 225, 228]]], ["A stricter selection of a control group through a propensity score 476 strategy was unfeasible, since once the physicians were aware of IL-6 measurement they 477 focused their efforts on treating with TCZ those patients with the highest IL-6 levels.", [["TCZ", "CHEMICAL", 201, 204], ["IL-6", "GENE_OR_GENE_PRODUCT", 136, 140], ["TCZ", "SIMPLE_CHEMICAL", 201, 204], ["patients", "ORGANISM", 211, 219], ["IL-6", "GENE_OR_GENE_PRODUCT", 237, 241], ["IL", "PROTEIN", 136, 138], ["IL-6", "PROTEIN", 237, 241], ["patients", "SPECIES", 211, 219], ["TCZ", "TREATMENT", 201, 204]]], ["478 Therefore, prospective studies should be carried out to confirm our observations.", [["prospective studies", "TEST", 15, 34]]], ["479 In addition, there is some controversy about the reliability of PaO 2 /FiO 2 as an outcome for 480 improvement of lung damage, especially in patients with IMV.", [["lung", "ANATOMY", 118, 122], ["lung damage", "DISEASE", 118, 129], ["PaO 2", "CHEMICAL", 68, 73], ["FiO 2", "CHEMICAL", 75, 80], ["FiO 2", "GENE_OR_GENE_PRODUCT", 75, 80], ["lung", "ORGAN", 118, 122], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["lung damage", "PROBLEM", 118, 129], ["IMV", "TREATMENT", 159, 162], ["lung", "ANATOMY", 118, 122], ["damage", "OBSERVATION", 123, 129]]], ["However, our population was a 481 mix of patients with IMV and non-IMV, so despite the many factors that could interfere with 482 PaO 2 /FiO 2 , we considered it the most objective outcome for patients' assessment. and p5 (line below the box) before (grey boxes) and after (white boxes) treatment with TCZ.", [["TCZ", "CHEMICAL", 302, 305], ["TCZ", "CHEMICAL", 302, 305], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 193, 201], ["TCZ", "SIMPLE_CHEMICAL", 302, 305], ["p5", "DNA", 219, 221], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 193, 201], ["IMV", "TREATMENT", 55, 58], ["non-IMV", "TREATMENT", 63, 70], ["PaO", "TEST", 130, 133], ["FiO", "TREATMENT", 137, 140], ["patients' assessment", "TEST", 193, 213], ["p5 (line below the box", "TREATMENT", 219, 241], ["white boxes) treatment", "TREATMENT", 274, 296], ["TCZ", "TREATMENT", 302, 305]]], ["In 694 non-treated patients PRE and POST mean first and second evaluation, respectively.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["second evaluation", "TEST", 56, 73]]]], "30e79769eebd559a314cd31b2a3d7cdf9729fe4a": [["Introduction SARS-CoV-2 infection has spread rapidly across the planet.", [["infection", "DISEASE", 24, 33], ["SARS-CoV-2", "ORGANISM", 13, 23], ["Introduction SARS", "PROBLEM", 0, 17], ["2 infection", "PROBLEM", 22, 33], ["infection", "OBSERVATION", 24, 33], ["spread", "OBSERVATION_MODIFIER", 38, 44], ["rapidly", "OBSERVATION_MODIFIER", 45, 52]]], ["It is thought to have originated in China's Wuhan province; however, it has spread to more than 140 countries on 6 continents, according to the WHO.", [["thought to have", "UNCERTAINTY", 6, 21]]], ["Over 80% of SARS-CoV-2 infection cases have flu-like symptoms; however, 20% require hospitalization and 5-15% intensive care [1] .", [["SARS", "DISEASE", 12, 16], ["infection", "DISEASE", 23, 32], ["flu-like symptoms", "DISEASE", 44, 61], ["SARS-CoV-2", "ORGANISM", 12, 22], ["CoV-", "SPECIES", 17, 21], ["SARS-CoV", "SPECIES", 12, 20], ["SARS", "PROBLEM", 12, 16], ["CoV", "TEST", 17, 20], ["2 infection cases", "PROBLEM", 21, 38], ["flu-like symptoms", "PROBLEM", 44, 61]]]], "PMC5028968": [["BackgroundEndotoxemia is defined as the presence of endotoxins in blood.", [["blood", "ANATOMY", 66, 71], ["Endotoxemia", "DISEASE", 10, 21], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["BackgroundEndotoxemia", "PROBLEM", 0, 21], ["endotoxins in blood", "PROBLEM", 52, 71], ["Endotoxemia", "OBSERVATION", 10, 21], ["endotoxins", "OBSERVATION", 52, 62]]], ["This situation can occur by Gram-negative bacterial infections which liberate endotoxin (lipopolysaccharides; LPS) during rapid growth.", [["infections", "DISEASE", 52, 62], ["endotoxin", "CHEMICAL", 78, 87], ["lipopolysaccharides", "CHEMICAL", 89, 108], ["LPS", "CHEMICAL", 110, 113], ["endotoxin", "SIMPLE_CHEMICAL", 78, 87], ["lipopolysaccharides", "SIMPLE_CHEMICAL", 89, 108], ["LPS", "SIMPLE_CHEMICAL", 110, 113], ["Gram", "TEST", 28, 32], ["negative bacterial infections", "PROBLEM", 33, 62], ["endotoxin (lipopolysaccharides", "TREATMENT", 78, 108], ["LPS", "PROBLEM", 110, 113], ["rapid growth", "PROBLEM", 122, 134], ["negative bacterial", "OBSERVATION_MODIFIER", 33, 51], ["infections", "OBSERVATION", 52, 62]]], ["This results in the fact that Gram-negative sepsis is associated with high mortality rates, despite comprehensive treatment in intensive care patients [1].", [["sepsis", "DISEASE", 44, 50], ["Gram-", "GENE_OR_GENE_PRODUCT", 30, 35], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["Gram-negative sepsis", "PROBLEM", 30, 50], ["high mortality rates", "PROBLEM", 70, 90], ["sepsis", "OBSERVATION", 44, 50]]], ["Studies are underway with regards to understanding the complex pathophysiological mechanism of endotoxemia, describing criteria for early diagnosis and developing new treatment approaches in order to decrease mortality [2, 3].BackgroundIntravenous choline administration show beneficial effects in the treatment of endotoxemia [4\u20137] in various species such as dogs and rats.", [["endotoxemia", "DISEASE", 95, 106], ["choline", "CHEMICAL", 248, 255], ["endotoxemia", "DISEASE", 315, 326], ["choline", "CHEMICAL", 248, 255], ["choline", "SIMPLE_CHEMICAL", 248, 255], ["dogs", "ORGANISM", 360, 364], ["rats", "ORGANISM", 369, 373], ["dogs", "SPECIES", 360, 364], ["rats", "SPECIES", 369, 373], ["endotoxemia", "PROBLEM", 95, 106], ["new treatment approaches", "TREATMENT", 163, 187], ["BackgroundIntravenous choline administration", "TREATMENT", 226, 270], ["endotoxemia", "PROBLEM", 315, 326], ["various species", "PROBLEM", 336, 351], ["endotoxemia", "OBSERVATION", 95, 106], ["endotoxemia", "OBSERVATION", 315, 326]]], ["Beneficial effects of intravenous choline treatment are reported in association with the activation of the efferent vagus nerve-based cholinergic anti-inflammatory pathway by the increase in nicotinic cholinergic neuro-transmission [5, 8] following enhanced acetylcholine release by choline [9].", [["intravenous", "ANATOMY", 22, 33], ["vagus nerve", "ANATOMY", 116, 127], ["choline", "CHEMICAL", 34, 41], ["acetylcholine", "CHEMICAL", 258, 271], ["choline", "CHEMICAL", 283, 290], ["choline", "CHEMICAL", 34, 41], ["acetylcholine", "CHEMICAL", 258, 271], ["choline", "CHEMICAL", 283, 290], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 33], ["choline", "SIMPLE_CHEMICAL", 34, 41], ["vagus nerve", "MULTI-TISSUE_STRUCTURE", 116, 127], ["nicotinic", "SIMPLE_CHEMICAL", 191, 200], ["acetylcholine", "SIMPLE_CHEMICAL", 258, 271], ["choline [9]", "SIMPLE_CHEMICAL", 283, 294], ["intravenous choline treatment", "TREATMENT", 22, 51], ["the efferent vagus nerve", "TREATMENT", 103, 127], ["cholinergic anti-inflammatory pathway", "TREATMENT", 134, 171], ["enhanced acetylcholine release", "TREATMENT", 249, 279], ["vagus nerve", "ANATOMY", 116, 127]]], ["However the possible changes in serum proteins that choline treatment can produce has not been studied.BackgroundProteomics analysis allows the simultaneous analysis of thousands of proteins in a sample.", [["serum", "ANATOMY", 32, 37], ["choline", "CHEMICAL", 52, 59], ["choline", "CHEMICAL", 52, 59], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["choline", "SIMPLE_CHEMICAL", 52, 59], ["serum proteins", "PROTEIN", 32, 46], ["changes in serum proteins", "PROBLEM", 21, 46], ["choline treatment", "TREATMENT", 52, 69], ["BackgroundProteomics analysis", "TEST", 103, 132], ["the simultaneous analysis", "TEST", 140, 165], ["possible", "UNCERTAINTY", 12, 20]]], ["This could facilitate the identification of new biomarkers of use for diagnosis and prognosis of sepsis/endotoxemia [10, 11].", [["sepsis", "DISEASE", 97, 103], ["endotoxemia", "DISEASE", 104, 115], ["sepsis", "PROBLEM", 97, 103], ["endotoxemia", "PROBLEM", 104, 115], ["sepsis", "OBSERVATION", 97, 103]]], ["Thus, proteomic analyses are a growing trend in human [12] and veterinary medicine [13].", [["human", "ORGANISM", 48, 53], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["proteomic analyses", "TEST", 6, 24]]], ["In particular proteomic studies allow identifying new proteins that change in endotoxemia, and by knowing the function of these new proteins, new mechanisms involved in endotoxemia could be elucidated and therefore increase the knowledge about its pathophysiology [14].BackgroundIn the light of our previous findings [4\u20137], we hypothesize that the beneficial effect of choline administration in endotoxemic patients could be mediated by changes in concentrations of selected serum proteins.", [["serum", "ANATOMY", 475, 480], ["endotoxemia", "DISEASE", 78, 89], ["endotoxemia", "DISEASE", 169, 180], ["choline", "CHEMICAL", 369, 376], ["choline", "CHEMICAL", 369, 376], ["choline", "SIMPLE_CHEMICAL", 369, 376], ["patients", "ORGANISM", 407, 415], ["serum", "ORGANISM_SUBSTANCE", 475, 480], ["serum proteins", "PROTEIN", 475, 489], ["patients", "SPECIES", 407, 415], ["proteomic studies", "TEST", 14, 31], ["new proteins", "PROBLEM", 50, 62], ["endotoxemia", "PROBLEM", 78, 89], ["these new proteins", "PROBLEM", 122, 140], ["endotoxemia", "PROBLEM", 169, 180], ["choline administration", "TREATMENT", 369, 391], ["endotoxemic patients", "TREATMENT", 395, 415], ["selected serum proteins", "TEST", 466, 489], ["endotoxemia", "OBSERVATION", 78, 89]]], ["Therefore the objective of this study was to evaluate the possible changes that can occur in serum proteins, by a proteomic analysis, after endotoxin administration in healthy and choline-treated calves.Experimental set up ::: MethodsHealthy Holstein calves (4 weeks of age; 40 kg mean weight; n = 20) were used in the present study.", [["serum", "ANATOMY", 93, 98], ["endotoxin", "CHEMICAL", 140, 149], ["choline", "CHEMICAL", 180, 187], ["choline", "CHEMICAL", 180, 187], ["serum", "ORGANISM_SUBSTANCE", 93, 98], ["endotoxin", "SIMPLE_CHEMICAL", 140, 149], ["choline", "SIMPLE_CHEMICAL", 180, 187], ["calves", "ORGANISM", 196, 202], ["calves", "ORGANISM", 251, 257], ["serum proteins", "PROTEIN", 93, 107], ["calves", "SPECIES", 196, 202], ["calves", "SPECIES", 251, 257], ["Holstein", "SPECIES", 242, 250], ["this study", "TEST", 27, 37], ["serum proteins", "TEST", 93, 107], ["a proteomic analysis", "TEST", 112, 132], ["endotoxin administration", "TREATMENT", 140, 164], ["MethodsHealthy Holstein calves", "TREATMENT", 227, 257], ["weight", "TEST", 286, 292], ["the present study", "TEST", 315, 332]]], ["Their health status was evaluated by clinical, haematological and serum biochemical analyses.", [["serum", "ANATOMY", 66, 71], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["serum biochemical analyses", "TEST", 66, 92]]], ["Calves were negative for bovine herpes virus, bovine leucosis virus, brucellosis, bovine viral diarrhea, foot and mouth disease, infectious bovine rhinotracheitis, paratuberculosis, and tuberculosis when tested by commercial ELISA kits (IDVet Diagnostics, Grabels, France).Experimental set up ::: MethodsCalves were randomized equally into 4 groups: Control, Choline treated (C), Lipopolysaccharide administered (LPS), and LPS + C. Calves in the Control group were injected with 0.9 % NaCl (saline; 5 ml, i.v.) twice at an interval of 5 min while those in C group received choline chloride (1 mg/kg, dissolved in 5 ml of saline, i.v., once), 5 min after 0.9 % NaCl administration (5 ml, i.v.).", [["foot", "ANATOMY", 105, 109], ["mouth", "ANATOMY", 114, 119], ["bovine herpes virus", "DISEASE", 25, 44], ["bovine leucosis virus", "DISEASE", 46, 67], ["brucellosis", "DISEASE", 69, 80], ["viral diarrhea", "DISEASE", 89, 103], ["foot and mouth disease", "DISEASE", 105, 127], ["infectious bovine rhinotracheitis, paratuberculosis", "DISEASE", 129, 180], ["tuberculosis", "DISEASE", 186, 198], ["Choline", "CHEMICAL", 359, 366], ["Lipopolysaccharide", "CHEMICAL", 380, 398], ["LPS", "CHEMICAL", 413, 416], ["LPS", "CHEMICAL", 423, 426], ["NaCl", "CHEMICAL", 485, 489], ["choline chloride", "CHEMICAL", 573, 589], ["NaCl", "CHEMICAL", 660, 664], ["Choline", "CHEMICAL", 359, 366], ["NaCl", "CHEMICAL", 485, 489], ["choline chloride", "CHEMICAL", 573, 589], ["NaCl", "CHEMICAL", 660, 664], ["Calves", "ORGANISM", 0, 6], ["bovine", "ORGANISM", 25, 31], ["herpes virus", "ORGANISM", 32, 44], ["bovine leucosis virus", "ORGANISM", 46, 67], ["bovine", "ORGANISM", 82, 88], ["foot", "ORGANISM_SUBDIVISION", 105, 109], ["mouth", "ORGANISM_SUBDIVISION", 114, 119], ["bovine", "ORGANISM", 140, 146], ["rhinotracheitis", "ORGANISM", 147, 162], ["paratuberculosis", "ORGANISM", 164, 180], ["Choline", "SIMPLE_CHEMICAL", 359, 366], ["Lipopolysaccharide", "SIMPLE_CHEMICAL", 380, 398], ["LPS", "SIMPLE_CHEMICAL", 413, 416], ["LPS", "SIMPLE_CHEMICAL", 423, 426], ["Calves", "ORGANISM", 432, 438], ["saline", "SIMPLE_CHEMICAL", 491, 497], ["choline chloride", "SIMPLE_CHEMICAL", 573, 589], ["saline", "SIMPLE_CHEMICAL", 621, 627], ["Calves", "SPECIES", 0, 6], ["bovine", "SPECIES", 25, 31], ["herpes virus", "SPECIES", 32, 44], ["bovine", "SPECIES", 46, 52], ["leucosis virus", "SPECIES", 53, 67], ["bovine", "SPECIES", 82, 88], ["bovine", "SPECIES", 140, 146], ["rhinotracheitis, paratuberculosis", "SPECIES", 147, 180], ["Calves", "SPECIES", 432, 438], ["bovine herpes virus", "SPECIES", 25, 44], ["bovine leucosis virus", "SPECIES", 46, 67], ["bovine", "SPECIES", 82, 88], ["bovine rhinotracheitis", "SPECIES", 140, 162], ["paratuberculosis", "SPECIES", 164, 180], ["Calves", "TEST", 0, 6], ["bovine herpes virus", "PROBLEM", 25, 44], ["bovine leucosis virus", "PROBLEM", 46, 67], ["brucellosis", "PROBLEM", 69, 80], ["bovine viral diarrhea", "PROBLEM", 82, 103], ["foot and mouth disease", "PROBLEM", 105, 127], ["infectious bovine rhinotracheitis", "PROBLEM", 129, 162], ["paratuberculosis", "PROBLEM", 164, 180], ["tuberculosis", "PROBLEM", 186, 198], ["MethodsCalves", "TREATMENT", 297, 310], ["Choline treated (C)", "TREATMENT", 359, 378], ["Lipopolysaccharide", "TREATMENT", 380, 398], ["LPS + C. Calves", "TREATMENT", 423, 438], ["0.9 % NaCl (saline", "TREATMENT", 479, 497], ["choline chloride", "TREATMENT", 573, 589], ["saline", "TREATMENT", 621, 627], ["0.9 % NaCl administration", "TREATMENT", 654, 679], ["negative for", "UNCERTAINTY", 12, 24], ["bovine herpes virus", "OBSERVATION", 25, 44], ["bovine leucosis virus", "OBSERVATION", 46, 67], ["brucellosis", "OBSERVATION", 69, 80], ["viral diarrhea", "OBSERVATION", 89, 103], ["foot", "ANATOMY", 105, 109], ["mouth", "ANATOMY", 114, 119], ["disease", "OBSERVATION", 120, 127], ["infectious", "OBSERVATION_MODIFIER", 129, 139], ["bovine", "OBSERVATION_MODIFIER", 140, 146], ["rhinotracheitis", "OBSERVATION", 147, 162], ["paratuberculosis", "OBSERVATION", 164, 180], ["tuberculosis", "OBSERVATION", 186, 198]]], ["In the LPS group, endotoxin (LPS) was injected (2 \u03bcg/kg, dissolved in 5 ml of normal saline, i.v., once) to the calves, followed 5 min later by intravenous injection of normal saline.", [["calves", "ANATOMY", 112, 118], ["intravenous", "ANATOMY", 144, 155], ["LPS", "CHEMICAL", 7, 10], ["endotoxin", "CHEMICAL", 18, 27], ["LPS", "CHEMICAL", 29, 32], ["LPS", "SIMPLE_CHEMICAL", 7, 10], ["endotoxin", "SIMPLE_CHEMICAL", 18, 27], ["LPS", "SIMPLE_CHEMICAL", 29, 32], ["saline", "SIMPLE_CHEMICAL", 85, 91], ["calves", "ORGANISM", 112, 118], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 144, 155], ["saline", "SIMPLE_CHEMICAL", 176, 182], ["calves", "SPECIES", 112, 118], ["endotoxin (LPS)", "TREATMENT", 18, 33], ["normal saline", "TREATMENT", 78, 91], ["normal saline", "TREATMENT", 169, 182], ["calves", "ANATOMY", 112, 118]]], ["In LPS + C group, endotoxin injection was followed 5 min later by choline chloride injection at the doses described in the LPS and C groups, respectively [15, 16].Clinical data ::: MethodsRoutine clinical examinations were performed before (baseline) and 0.5\u201348 h after the treatments.", [["LPS", "CHEMICAL", 3, 6], ["endotoxin", "CHEMICAL", 18, 27], ["choline chloride", "CHEMICAL", 66, 82], ["choline chloride", "CHEMICAL", 66, 82], ["LPS + C", "SIMPLE_CHEMICAL", 3, 10], ["endotoxin", "SIMPLE_CHEMICAL", 18, 27], ["choline chloride", "SIMPLE_CHEMICAL", 66, 82], ["LPS", "SIMPLE_CHEMICAL", 123, 126], ["C", "SIMPLE_CHEMICAL", 131, 132], ["endotoxin injection", "TREATMENT", 18, 37], ["choline chloride injection", "TREATMENT", 66, 92], ["MethodsRoutine clinical examinations", "TEST", 181, 217], ["the treatments", "TREATMENT", 270, 284]]], ["A scoring system adapted from a previous paper [17] was used to evaluate clinical status in the study.", [["the study", "TEST", 92, 101]]], ["Each parameter was scored by minimum 0 point (means normal) to maximum 6 points (means severely affected).Serum proteomic analysis ::: MethodsIn order to analyse differences in protein expression in the course of the study, three serum samples at each time point for each treatment were obtained and the protein profiles of the serum samples were analysed by LC-MS/MS method [18\u201320].", [["Serum", "ANATOMY", 106, 111], ["serum samples", "ANATOMY", 230, 243], ["serum samples", "ANATOMY", 328, 341], ["Serum", "ORGANISM_SUBSTANCE", 106, 111], ["serum samples", "ORGANISM_SUBSTANCE", 230, 243], ["serum samples", "ORGANISM_SUBSTANCE", 328, 341], ["Each parameter", "TEST", 0, 14], ["severely affected", "PROBLEM", 87, 104], ["Serum proteomic analysis", "TEST", 106, 130], ["Methods", "TREATMENT", 135, 142], ["the study", "TEST", 213, 222], ["three serum samples", "TEST", 224, 243], ["each treatment", "TREATMENT", 267, 281], ["the protein profiles", "TEST", 300, 320], ["the serum samples", "TEST", 324, 341], ["LC", "TEST", 359, 361], ["MS", "TEST", 362, 364], ["MS method", "TEST", 365, 374]]], ["Albumin depletion from serum samples was done with albumin depletion spin columns (Pierce, Thermo Scientific).", [["serum samples", "ANATOMY", 23, 36], ["Albumin", "CHEMICAL", 0, 7], ["Albumin", "GENE_OR_GENE_PRODUCT", 0, 7], ["serum samples", "ORGANISM_SUBSTANCE", 23, 36], ["albumin", "SIMPLE_CHEMICAL", 51, 58], ["Albumin depletion", "PROBLEM", 0, 17], ["serum samples", "TEST", 23, 36], ["albumin depletion spin columns", "TREATMENT", 51, 81], ["depletion", "OBSERVATION", 8, 17]]], ["IgGs from the albumin-depleted serum samples were also depleted with an Albumin/IgG Removal Kit (Pierce, Thermo scientific).", [["serum samples", "ANATOMY", 31, 44], ["IgGs", "GENE_OR_GENE_PRODUCT", 0, 4], ["albumin", "GENE_OR_GENE_PRODUCT", 14, 21], ["serum samples", "ORGANISM_SUBSTANCE", 31, 44], ["Albumin", "GENE_OR_GENE_PRODUCT", 72, 79], ["IgGs", "PROTEIN", 0, 4], ["albumin", "PROTEIN", 14, 21], ["Albumin", "PROTEIN", 72, 79], ["IgG", "PROTEIN", 80, 83], ["IgGs", "TEST", 0, 4], ["the albumin", "TEST", 10, 21], ["serum samples", "TEST", 31, 44], ["an Albumin/IgG Removal", "TREATMENT", 69, 91]]], ["The remaining serum proteins (at same concentration for all samples) were extracted and enzymatically digested into peptides, and the resulting peptides were subjected to the nanoUPLC-ESI-qTOF-MS system (nano-ultra-performance LC and ESI quadrupole TOF MS) (Waters) with the application of data independent acquisition method also known as the MSE as previously described in detail [20].", [["serum", "ANATOMY", 14, 19], ["samples", "ANATOMY", 60, 67], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["serum proteins", "PROTEIN", 14, 28], ["The remaining serum proteins", "TEST", 0, 28], ["all samples", "TEST", 56, 67], ["the resulting peptides", "PROBLEM", 130, 152], ["the nanoUPLC", "TEST", 171, 183], ["ESI", "TEST", 184, 187]]], ["Minimum 3 technical replicates for each sample were used for the analysis.", [["the analysis", "TEST", 61, 73]]], ["The proteomic data was searched against a reviewed database [including protein sequences of Bos taurus and an internal standard (enolase, Saccharomyces cerevisiae; #P00924), obtained from UniProt (htpp://www.uniprot.org)] with previously described in silico parameters [19].", [["Bos taurus", "ORGANISM", 92, 102], ["enolase", "GENE_OR_GENE_PRODUCT", 129, 136], ["Saccharomyces cerevisiae", "ORGANISM", 138, 162], ["enolase", "PROTEIN", 129, 136], ["Bos taurus", "SPECIES", 92, 102], ["Saccharomyces cerevisiae", "SPECIES", 138, 162], ["Bos taurus", "SPECIES", 92, 102], ["Saccharomyces cerevisiae", "SPECIES", 138, 162], ["a reviewed database", "TEST", 40, 59], ["protein sequences", "TEST", 71, 88], ["Bos taurus", "PROBLEM", 92, 102], ["Saccharomyces cerevisiae", "TEST", 138, 162]]], ["Quantitative differences of proteins at different time points were calculated using Progenesis LC-MS software V4.0 (Nonlinear Dynamics) [20].Chemicals ::: MethodsCholine chloride and endotoxin (E. coli lipopolysaccharide, LPS, serotype 055:B5) were purchased from Sigma Chemical Co. (St. Louis, Missouri, USA).Statistical analysis ::: MethodsResults were expressed as mean \u00b1 SEM.", [["Choline chloride", "CHEMICAL", 162, 178], ["endotoxin", "CHEMICAL", 183, 192], ["lipopolysaccharide", "CHEMICAL", 202, 220], ["LPS", "CHEMICAL", 222, 225], ["Choline chloride", "CHEMICAL", 162, 178], ["Choline chloride", "SIMPLE_CHEMICAL", 162, 178], ["endotoxin", "SIMPLE_CHEMICAL", 183, 192], ["E. coli", "ORGANISM", 194, 201], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 202, 220], ["LPS", "SIMPLE_CHEMICAL", 222, 225], ["St. Louis", "ORGANISM", 284, 293], ["E. coli", "SPECIES", 194, 201], ["E. coli", "SPECIES", 194, 201], ["Quantitative differences of proteins", "PROBLEM", 0, 36], ["Progenesis", "TEST", 84, 94], ["LC", "TEST", 95, 97], ["MS software", "TEST", 98, 109], ["MethodsCholine chloride", "TREATMENT", 155, 178], ["endotoxin (E. coli lipopolysaccharide", "TREATMENT", 183, 220]]], ["Data were evaluated by one-way analysis of variance by repeated measures, followed by Tukey test for pairwise comparisons.", [["Tukey test", "TEST", 86, 96], ["pairwise comparisons", "TEST", 101, 121]]], ["Clinical scores were compared by a non-parametric test (Friedman Repeated Measure ANOVA on Ranks).", [["Clinical scores", "TEST", 0, 15], ["a non-parametric test", "TEST", 33, 54]]], ["P values less than 0.05 were considered significant.Clinical data ::: ResultsClinical findings are presented as Additional file 1 (Fig. 1).", [["P values", "TEST", 0, 8]]], ["Briefly, choline induced a decrease in heart and respiratory rates compared with the control animals.", [["heart", "ANATOMY", 39, 44], ["respiratory", "ANATOMY", 49, 60], ["choline", "CHEMICAL", 9, 16], ["decrease in heart and respiratory rates", "DISEASE", 27, 66], ["choline", "CHEMICAL", 9, 16], ["choline", "SIMPLE_CHEMICAL", 9, 16], ["heart", "ORGAN", 39, 44], ["a decrease in heart and respiratory rates", "PROBLEM", 25, 66], ["decrease", "OBSERVATION_MODIFIER", 27, 35], ["heart", "ANATOMY", 39, 44], ["respiratory rates", "OBSERVATION", 49, 66]]], ["LPS administration increased body temperature and heart and respiratory rates as compared to their baselines.", [["body", "ANATOMY", 29, 33], ["heart", "ANATOMY", 50, 55], ["respiratory", "ANATOMY", 60, 71], ["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["body", "ORGANISM_SUBDIVISION", 29, 33], ["heart", "ORGAN", 50, 55], ["LPS administration", "TEST", 0, 18], ["increased body temperature and heart and respiratory rates", "PROBLEM", 19, 77], ["heart", "ANATOMY", 50, 55], ["respiratory rates", "OBSERVATION", 60, 77]]], ["The severities of these changes in LPS + C treatment were lower (p < 0.01) than those of calves treated with LPS.Clinical data ::: ResultsTwo calves died at 4 and 24 h after LPS and one at 48 h after LPS + C. Calves in control and choline groups survived until the end of the study.Serum proteins ::: ResultsProtein expression differences among experimental groups at different time points (30 min, 1, 4 and 48 h) are shown in Table 1.", [["Serum", "ANATOMY", 282, 287], ["LPS", "CHEMICAL", 35, 38], ["LPS", "CHEMICAL", 109, 112], ["LPS", "CHEMICAL", 174, 177], ["LPS", "CHEMICAL", 200, 203], ["choline", "CHEMICAL", 231, 238], ["choline", "CHEMICAL", 231, 238], ["LPS + C", "SIMPLE_CHEMICAL", 35, 42], ["calves", "ORGANISM", 89, 95], ["LPS", "SIMPLE_CHEMICAL", 109, 112], ["calves", "ORGANISM", 142, 148], ["LPS", "SIMPLE_CHEMICAL", 174, 177], ["LPS", "SIMPLE_CHEMICAL", 200, 203], ["Calves", "ORGANISM", 209, 215], ["choline", "SIMPLE_CHEMICAL", 231, 238], ["Serum", "ORGANISM_SUBSTANCE", 282, 287], ["Serum proteins", "PROTEIN", 282, 296], ["calves", "SPECIES", 89, 95], ["calves", "SPECIES", 142, 148], ["Calves", "SPECIES", 209, 215], ["these changes", "PROBLEM", 18, 31], ["LPS", "TEST", 35, 38], ["C treatment", "TREATMENT", 41, 52], ["LPS", "TREATMENT", 109, 112], ["LPS", "TEST", 174, 177], ["LPS", "TEST", 200, 203], ["choline groups", "TREATMENT", 231, 245], ["the study", "TEST", 272, 281], ["Serum proteins", "TEST", 282, 296], ["ResultsProtein expression differences", "PROBLEM", 301, 338], ["severities", "OBSERVATION_MODIFIER", 4, 14], ["calves", "ANATOMY", 89, 95]]], ["Details including numerical values for the quantitative analysis obtained from the Progenesis LC-MS software are shown in Additional file 1.Serum proteins ::: ResultsA total of 76 proteins were identified across the serum samples by the proteomic analysis.", [["Serum", "ANATOMY", 140, 145], ["serum samples", "ANATOMY", 216, 229], ["Serum", "ORGANISM_SUBSTANCE", 140, 145], ["serum samples", "ORGANISM_SUBSTANCE", 216, 229], ["Serum proteins", "PROTEIN", 140, 154], ["numerical values", "TEST", 18, 34], ["the quantitative analysis", "TEST", 39, 64], ["Serum proteins", "TEST", 140, 154], ["the serum samples", "TEST", 212, 229], ["the proteomic analysis", "TEST", 233, 255]]], ["After LPS administration, 14 proteins increased, whereas 13 proteins decreased within 48 h as compared to controls (Table 1).", [["LPS", "CHEMICAL", 6, 9], ["LPS", "SIMPLE_CHEMICAL", 6, 9], ["13 proteins", "PROTEIN", 57, 68], ["LPS administration", "TREATMENT", 6, 24], ["14 proteins", "TEST", 26, 37], ["increased", "OBSERVATION_MODIFIER", 38, 47]]], ["In LPS group, there was a dramatic increase (189 fold, at 24 h) in ragulator complex protein LAMTOR2 which was followed by other proteins showing changes ranging from 6 to 13 fold such as negative elongation factor E (at 4 h), galectin-3 binding protein (Gal-3BP), argininosuccinate lyase and membrane primary amine-oxidase (at 48 h).", [["membrane", "ANATOMY", 293, 301], ["LPS", "CHEMICAL", 3, 6], ["amine", "CHEMICAL", 310, 315], ["argininosuccinate", "CHEMICAL", 265, 282], ["primary amine", "CHEMICAL", 302, 315], ["LPS", "SIMPLE_CHEMICAL", 3, 6], ["ragulator complex", "GENE_OR_GENE_PRODUCT", 67, 84], ["LAMTOR2", "GENE_OR_GENE_PRODUCT", 93, 100], ["factor E", "GENE_OR_GENE_PRODUCT", 208, 216], ["galectin-3", "GENE_OR_GENE_PRODUCT", 227, 237], ["Gal-3BP", "GENE_OR_GENE_PRODUCT", 255, 262], ["argininosuccinate lyase", "GENE_OR_GENE_PRODUCT", 265, 288], ["membrane", "CELLULAR_COMPONENT", 293, 301], ["amine-oxidase", "GENE_OR_GENE_PRODUCT", 310, 323], ["ragulator complex protein", "PROTEIN", 67, 92], ["LAMTOR2", "PROTEIN", 93, 100], ["negative elongation factor E", "PROTEIN", 188, 216], ["galectin-3 binding protein", "PROTEIN", 227, 253], ["Gal", "PROTEIN", 255, 258], ["3BP", "PROTEIN", 259, 262], ["argininosuccinate lyase", "PROTEIN", 265, 288], ["membrane primary amine-oxidase", "PROTEIN", 293, 323], ["a dramatic increase (189 fold", "PROBLEM", 24, 53], ["other proteins", "TEST", 123, 137], ["galectin", "TEST", 227, 235], ["binding protein", "TEST", 238, 253], ["Gal", "TEST", 255, 258], ["argininosuccinate lyase", "TREATMENT", 265, 288], ["membrane primary amine-oxidase", "TREATMENT", 293, 323], ["LPS group", "OBSERVATION_MODIFIER", 3, 12], ["dramatic", "OBSERVATION_MODIFIER", 26, 34], ["increase", "OBSERVATION_MODIFIER", 35, 43]]], ["Following LPS administration, moderate decreases (< 5 fold changes) were observed in some proteins such as serpin A3-4 (at 30 min.), vitamin D binding protein (VDBP), inter alpha trypsin inhibitor heavy chain H3 (ITIH, at 4 h), apolipoprotein A IV (Apo-AIV), alpha-1B glycoprotein and serotransferrin (at 48 h).", [["LPS", "CHEMICAL", 10, 13], ["vitamin D", "CHEMICAL", 133, 142], ["vitamin D", "CHEMICAL", 133, 142], ["LPS", "SIMPLE_CHEMICAL", 10, 13], ["serpin A3-4", "GENE_OR_GENE_PRODUCT", 107, 118], ["vitamin D binding protein", "GENE_OR_GENE_PRODUCT", 133, 158], ["VDBP", "GENE_OR_GENE_PRODUCT", 160, 164], ["inter alpha trypsin inhibitor heavy chain H3", "GENE_OR_GENE_PRODUCT", 167, 211], ["ITIH", "GENE_OR_GENE_PRODUCT", 213, 217], ["apolipoprotein A IV", "GENE_OR_GENE_PRODUCT", 228, 247], ["Apo-AIV", "GENE_OR_GENE_PRODUCT", 249, 256], ["alpha-1B glycoprotein", "GENE_OR_GENE_PRODUCT", 259, 280], ["serotransferrin", "GENE_OR_GENE_PRODUCT", 285, 300], ["serpin A3-4", "PROTEIN", 107, 118], ["vitamin D binding protein", "PROTEIN", 133, 158], ["VDBP", "PROTEIN", 160, 164], ["inter alpha trypsin inhibitor heavy chain H3", "PROTEIN", 167, 211], ["ITIH", "PROTEIN", 213, 217], ["apolipoprotein A IV", "PROTEIN", 228, 247], ["Apo", "PROTEIN", 249, 252], ["AIV", "PROTEIN", 253, 256], ["alpha-1B glycoprotein", "PROTEIN", 259, 280], ["serotransferrin", "PROTEIN", 285, 300], ["LPS administration", "TREATMENT", 10, 28], ["moderate decreases (< 5 fold changes)", "PROBLEM", 30, 67], ["serpin A3", "TEST", 107, 116], ["vitamin D binding protein", "TEST", 133, 158], ["VDBP", "TEST", 160, 164], ["inter alpha trypsin inhibitor", "TREATMENT", 167, 196], ["apolipoprotein A IV (Apo-AIV", "TREATMENT", 228, 256], ["alpha-1B glycoprotein", "TREATMENT", 259, 280], ["serotransferrin", "TREATMENT", 285, 300], ["moderate", "OBSERVATION_MODIFIER", 30, 38], ["decreases", "OBSERVATION_MODIFIER", 39, 48]]], ["In addition more prominent decreases (\u2265 5 fold changes, at 48 h) were observed in transcription factor MafF and corticosteroid binding globulin (CBG).Serum proteins ::: ResultsWhen compared with LPS group, in LPS + C group, glucosamine-6-phosphate isomerase-2, membrane primary amine oxidase, fibrinogen gamma B chain, antithrombin and prothrombin were markedly up-regulated, while isoform 2 of membrane primary amine oxidase, hemopexin and histone-H4 were markedly down-regulated.", [["Serum", "ANATOMY", 150, 155], ["membrane", "ANATOMY", 261, 269], ["membrane", "ANATOMY", 395, 403], ["LPS", "CHEMICAL", 195, 198], ["LPS", "CHEMICAL", 209, 212], ["glucosamine-6-phosphate", "CHEMICAL", 224, 247], ["amine", "CHEMICAL", 278, 283], ["amine", "CHEMICAL", 412, 417], ["glucosamine-6-phosphate", "CHEMICAL", 224, 247], ["amine", "CHEMICAL", 278, 283], ["primary amine", "CHEMICAL", 404, 417], ["MafF", "GENE_OR_GENE_PRODUCT", 103, 107], ["corticosteroid binding globulin", "GENE_OR_GENE_PRODUCT", 112, 143], ["CBG", "GENE_OR_GENE_PRODUCT", 145, 148], ["Serum", "ORGANISM_SUBSTANCE", 150, 155], ["LPS", "SIMPLE_CHEMICAL", 195, 198], ["LPS + C", "SIMPLE_CHEMICAL", 209, 216], ["glucosamine-6-phosphate isomerase-2", "GENE_OR_GENE_PRODUCT", 224, 259], ["membrane", "CELLULAR_COMPONENT", 261, 269], ["amine oxidase", "GENE_OR_GENE_PRODUCT", 278, 291], ["fibrinogen gamma B chain", "GENE_OR_GENE_PRODUCT", 293, 317], ["antithrombin", "GENE_OR_GENE_PRODUCT", 319, 331], ["prothrombin", "GENE_OR_GENE_PRODUCT", 336, 347], ["membrane", "CELLULAR_COMPONENT", 395, 403], ["amine oxidase", "GENE_OR_GENE_PRODUCT", 412, 425], ["hemopexin", "GENE_OR_GENE_PRODUCT", 427, 436], ["histone-H4", "GENE_OR_GENE_PRODUCT", 441, 451], ["transcription factor", "PROTEIN", 82, 102], ["MafF", "PROTEIN", 103, 107], ["corticosteroid binding globulin", "PROTEIN", 112, 143], ["CBG", "PROTEIN", 145, 148], ["Serum proteins", "PROTEIN", 150, 164], ["glucosamine-6-phosphate isomerase-2", "PROTEIN", 224, 259], ["membrane primary amine oxidase", "PROTEIN", 261, 291], ["fibrinogen gamma B chain", "PROTEIN", 293, 317], ["antithrombin", "PROTEIN", 319, 331], ["prothrombin", "PROTEIN", 336, 347], ["isoform 2", "PROTEIN", 382, 391], ["membrane primary amine oxidase", "PROTEIN", 395, 425], ["hemopexin", "PROTEIN", 427, 436], ["histone", "PROTEIN", 441, 448], ["H4", "PROTEIN", 449, 451], ["more prominent decreases (\u2265 5 fold changes", "PROBLEM", 12, 54], ["transcription factor MafF", "TEST", 82, 107], ["corticosteroid binding globulin", "TEST", 112, 143], ["CBG", "TEST", 145, 148], ["Serum proteins", "TEST", 150, 164], ["LPS group", "TEST", 195, 204], ["LPS", "TEST", 209, 212], ["glucosamine", "TEST", 224, 235], ["phosphate isomerase", "TEST", 238, 257], ["membrane primary amine oxidase", "TEST", 261, 291], ["fibrinogen gamma B chain", "TEST", 293, 317], ["antithrombin", "TEST", 319, 331], ["prothrombin", "TEST", 336, 347], ["membrane primary amine oxidase", "TREATMENT", 395, 425], ["hemopexin", "TREATMENT", 427, 436], ["histone", "TEST", 441, 448], ["H4", "PROBLEM", 449, 451], ["more", "OBSERVATION_MODIFIER", 12, 16], ["prominent", "OBSERVATION_MODIFIER", 17, 26], ["decreases", "OBSERVATION_MODIFIER", 27, 36]]], ["Actin alpha cardiac muscle-1 expression increased at 1\u201348 h (15\u2013187 fold) in LPS and LPS + C groups, as compared to controls.", [["LPS", "CHEMICAL", 77, 80], ["LPS", "CHEMICAL", 85, 88], ["Actin alpha cardiac muscle-1", "GENE_OR_GENE_PRODUCT", 0, 28], ["LPS", "SIMPLE_CHEMICAL", 77, 80], ["LPS + C", "SIMPLE_CHEMICAL", 85, 92], ["Actin alpha", "PROTEIN", 0, 11], ["LPS", "TEST", 77, 80], ["LPS", "TEST", 85, 88], ["alpha", "ANATOMY_MODIFIER", 6, 11], ["cardiac muscle", "ANATOMY", 12, 26]]], ["The magnitude of increase in actin alpha cardiac muscle-1 was lower at 48 h in LPS + C group than that of LPS group.", [["cardiac muscle", "ANATOMY", 41, 55], ["LPS", "CHEMICAL", 79, 82], ["LPS", "CHEMICAL", 106, 109], ["actin alpha", "GENE_OR_GENE_PRODUCT", 29, 40], ["cardiac muscle-1", "GENE_OR_GENE_PRODUCT", 41, 57], ["LPS + C", "SIMPLE_CHEMICAL", 79, 86], ["LPS", "SIMPLE_CHEMICAL", 106, 109], ["actin alpha", "PROTEIN", 29, 40], ["actin alpha cardiac muscle", "TEST", 29, 55], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["actin alpha", "OBSERVATION", 29, 40], ["cardiac muscle", "ANATOMY", 41, 55]]], ["As compared to controls, following choline administration, a number of proteins (primary amine oxidase, serpin A3-7 and glucosamine-6-phosphate isomerase-2) were up-regulated while others (lysosome associated membrane glycoprotein-1 and glutaredoxin-1) were more down-regulated at different time points of the study.DiscussionIn this study, an experimental model consisting in the induction of endotoxemia by LPS administration in calves was chosen, because calves are very sensitive to LPS.", [["choline", "CHEMICAL", 35, 42], ["amine", "CHEMICAL", 89, 94], ["glucosamine-6-phosphate", "CHEMICAL", 120, 143], ["endotoxemia", "DISEASE", 394, 405], ["LPS", "CHEMICAL", 409, 412], ["LPS", "CHEMICAL", 487, 490], ["choline", "CHEMICAL", 35, 42], ["primary amine", "CHEMICAL", 81, 94], ["glucosamine-6-phosphate", "CHEMICAL", 120, 143], ["choline", "SIMPLE_CHEMICAL", 35, 42], ["primary amine oxidase", "GENE_OR_GENE_PRODUCT", 81, 102], ["serpin A3-7", "GENE_OR_GENE_PRODUCT", 104, 115], ["glucosamine-6-phosphate isomerase-2", "GENE_OR_GENE_PRODUCT", 120, 155], ["lysosome associated membrane glycoprotein-1", "GENE_OR_GENE_PRODUCT", 189, 232], ["glutaredoxin-1", "GENE_OR_GENE_PRODUCT", 237, 251], ["LPS", "SIMPLE_CHEMICAL", 409, 412], ["calves", "ORGANISM", 431, 437], ["calves", "ORGANISM", 458, 464], ["LPS", "SIMPLE_CHEMICAL", 487, 490], ["primary amine oxidase", "PROTEIN", 81, 102], ["serpin A3-7 and glucosamine-6-phosphate isomerase", "PROTEIN", 104, 153], ["lysosome associated membrane glycoprotein-1", "PROTEIN", 189, 232], ["glutaredoxin-1", "PROTEIN", 237, 251], ["calves", "SPECIES", 431, 437], ["calves", "SPECIES", 458, 464], ["calves", "SPECIES", 431, 437], ["calves", "SPECIES", 458, 464], ["choline administration", "TREATMENT", 35, 57], ["primary amine oxidase", "TEST", 81, 102], ["serpin A3", "TEST", 104, 113], ["glucosamine", "TEST", 120, 131], ["phosphate isomerase", "TEST", 134, 153], ["lysosome associated membrane glycoprotein", "TREATMENT", 189, 230], ["glutaredoxin", "TREATMENT", 237, 249], ["the study", "TEST", 306, 315], ["this study", "TEST", 329, 339], ["endotoxemia", "PROBLEM", 394, 405], ["LPS administration", "TREATMENT", 409, 427], ["endotoxemia", "OBSERVATION", 394, 405]]], ["Therefore is expected that the changes associated with LPS as well as its treatment will be easier to detect than with other animal models.", [["LPS", "CHEMICAL", 55, 58], ["LPS", "SIMPLE_CHEMICAL", 55, 58], ["LPS", "TREATMENT", 55, 58], ["its treatment", "TREATMENT", 70, 83]]], ["The clinical changes occurred after LPS treatment in our experimental model in calves showed similarities with the results of experimental human [21] and animal studies of sepsis/endotoxemia [4\u20137, 15\u201317].DiscussionTo our knowledge, our study describes for the first time 14 proteins that are up-regulated, and 13 proteins that are down-regulated in endotoxemia in calves.", [["LPS", "CHEMICAL", 36, 39], ["sepsis", "DISEASE", 172, 178], ["endotoxemia", "DISEASE", 179, 190], ["endotoxemia", "DISEASE", 349, 360], ["LPS", "SIMPLE_CHEMICAL", 36, 39], ["calves", "ORGANISM", 79, 85], ["human", "ORGANISM", 139, 144], ["calves", "ORGANISM", 364, 370], ["13 proteins", "PROTEIN", 310, 321], ["calves", "SPECIES", 79, 85], ["human", "SPECIES", 139, 144], ["calves", "SPECIES", 364, 370], ["human", "SPECIES", 139, 144], ["The clinical changes", "PROBLEM", 0, 20], ["LPS treatment", "TREATMENT", 36, 49], ["animal studies", "TEST", 154, 168], ["sepsis", "PROBLEM", 172, 178], ["endotoxemia", "PROBLEM", 179, 190], ["our study", "TEST", 232, 241], ["sepsis", "OBSERVATION", 172, 178], ["endotoxemia", "OBSERVATION", 179, 190], ["endotoxemia", "OBSERVATION", 349, 360], ["calves", "ANATOMY", 364, 370]]], ["The roles of some of these altered proteins are highlighted below.DiscussionOne of the proteins that were dramatically up-regulated was ragulator complex protein LAMTOR2.", [["LAMTOR2", "GENE_OR_GENE_PRODUCT", 162, 169], ["ragulator complex protein", "PROTEIN", 136, 161], ["LAMTOR2", "PROTEIN", 162, 169], ["these altered proteins", "PROBLEM", 21, 43], ["the proteins", "PROBLEM", 83, 95]]], ["This protein is known to be involved in amino acid sensing and activation of mTORC1 [22], a signalling complex promoting cell growth in response to growth factors, energy levels, and amino acids.", [["cell", "ANATOMY", 121, 125], ["amino acid", "CHEMICAL", 40, 50], ["amino acids", "CHEMICAL", 183, 194], ["amino acid", "CHEMICAL", 40, 50], ["amino acids", "CHEMICAL", 183, 194], ["amino acid", "AMINO_ACID", 40, 50], ["mTORC1 [22]", "GENE_OR_GENE_PRODUCT", 77, 88], ["cell", "CELL", 121, 125], ["amino acids", "AMINO_ACID", 183, 194], ["mTORC1 [22]", "PROTEIN", 77, 88], ["signalling complex", "PROTEIN", 92, 110], ["growth factors", "PROTEIN", 148, 162], ["amino acid sensing", "TREATMENT", 40, 58], ["mTORC1", "TEST", 77, 83], ["a signalling complex promoting cell growth", "PROBLEM", 90, 132], ["energy levels", "TEST", 164, 177], ["amino acids", "TREATMENT", 183, 194], ["complex", "OBSERVATION_MODIFIER", 103, 110], ["promoting cell growth", "OBSERVATION", 111, 132]]], ["A previous study reported that severe immunological defects affecting the immunity in human primary immunodeficiency syndrome was associated with reduced levels of LAMTOR2 [22].", [["primary immunodeficiency syndrome", "DISEASE", 92, 125], ["human", "ORGANISM", 86, 91], ["LAMTOR2", "GENE_OR_GENE_PRODUCT", 164, 171], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["A previous study", "TEST", 0, 16], ["severe immunological defects", "PROBLEM", 31, 59], ["the immunity in human primary immunodeficiency syndrome", "PROBLEM", 70, 125], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["immunological defects", "OBSERVATION", 38, 59], ["immunodeficiency syndrome", "OBSERVATION", 100, 125]]], ["Hence, the elevated serum levels of ragulator complex in our study may be associated with host\u2019s response by increasing macrophage activity and enhancing adaptive immunity in response to LPS.", [["serum", "ANATOMY", 20, 25], ["macrophage", "ANATOMY", 120, 130], ["LPS", "CHEMICAL", 187, 190], ["serum", "ORGANISM_SUBSTANCE", 20, 25], ["ragulator", "GENE_OR_GENE_PRODUCT", 36, 45], ["macrophage", "CELL", 120, 130], ["LPS", "SIMPLE_CHEMICAL", 187, 190], ["ragulator complex", "PROTEIN", 36, 53], ["the elevated serum levels of ragulator complex", "PROBLEM", 7, 53], ["our study", "TEST", 57, 66], ["increasing macrophage activity", "PROBLEM", 109, 139], ["LPS", "TREATMENT", 187, 190], ["macrophage activity", "OBSERVATION", 120, 139]]], ["Thus, ragulator complex may represent a new early diagnostic marker for the detection of inflammation in calves, due to its dramatic overexpression shortly after LPS treatment.DiscussionAnother protein, which significantly increased in calves after LPS administration, was Gal-3BP.", [["inflammation", "DISEASE", 89, 101], ["LPS", "CHEMICAL", 162, 165], ["LPS", "CHEMICAL", 249, 252], ["Gal-3BP", "CHEMICAL", 273, 280], ["ragulator complex", "GENE_OR_GENE_PRODUCT", 6, 23], ["calves", "ORGANISM", 105, 111], ["LPS", "SIMPLE_CHEMICAL", 162, 165], ["calves", "ORGANISM", 236, 242], ["LPS", "SIMPLE_CHEMICAL", 249, 252], ["Gal-3BP", "GENE_OR_GENE_PRODUCT", 273, 280], ["ragulator complex", "PROTEIN", 6, 23], ["Gal-3BP", "PROTEIN", 273, 280], ["calves", "SPECIES", 105, 111], ["calves", "SPECIES", 236, 242], ["inflammation in calves", "PROBLEM", 89, 111], ["its dramatic overexpression", "PROBLEM", 120, 147], ["LPS treatment", "TREATMENT", 162, 175], ["Another protein", "TEST", 186, 201], ["LPS administration", "TREATMENT", 249, 267], ["may represent", "UNCERTAINTY", 24, 37], ["new", "OBSERVATION_MODIFIER", 40, 43], ["early", "OBSERVATION_MODIFIER", 44, 49], ["inflammation", "OBSERVATION", 89, 101], ["calves", "ANATOMY", 105, 111], ["dramatic", "OBSERVATION_MODIFIER", 124, 132], ["overexpression", "OBSERVATION", 133, 147]]], ["This protein has stimulatory activity on lymphokine-activated and natural killer cells, and also stimulates the secretion of many cytokines and interleukins in peripheral blood mononuclear cells that all play a contributory role in inflammation [23].", [["natural killer cells", "ANATOMY", 66, 86], ["peripheral blood mononuclear cells", "ANATOMY", 160, 194], ["inflammation", "DISEASE", 232, 244], ["lymphokine", "GENE_OR_GENE_PRODUCT", 41, 51], ["natural killer cells", "CELL", 66, 86], ["interleukins", "GENE_OR_GENE_PRODUCT", 144, 156], ["peripheral blood mononuclear cells", "CELL", 160, 194], ["lymphokine", "PROTEIN", 41, 51], ["natural killer cells", "CELL_TYPE", 66, 86], ["cytokines", "PROTEIN", 130, 139], ["interleukins", "PROTEIN", 144, 156], ["peripheral blood mononuclear cells", "CELL_TYPE", 160, 194], ["stimulatory activity", "PROBLEM", 17, 37], ["lymphokine", "TREATMENT", 41, 51], ["activated and natural killer cells", "TREATMENT", 52, 86], ["many cytokines", "PROBLEM", 125, 139], ["interleukins in peripheral blood mononuclear cells", "PROBLEM", 144, 194], ["inflammation", "PROBLEM", 232, 244], ["stimulatory activity", "OBSERVATION", 17, 37], ["natural killer cells", "OBSERVATION", 66, 86], ["peripheral", "ANATOMY_MODIFIER", 160, 170], ["blood", "ANATOMY", 171, 176], ["mononuclear cells", "OBSERVATION", 177, 194]]], ["In this study, up-regulated expression of Gal-3BP may be associated with limiting an on-going inflammation in response to LPS, because of its immune modulatory activity [23].", [["inflammation", "DISEASE", 94, 106], ["LPS", "CHEMICAL", 122, 125], ["Gal-3BP", "GENE_OR_GENE_PRODUCT", 42, 49], ["LPS", "SIMPLE_CHEMICAL", 122, 125], ["Gal-3BP", "PROTEIN", 42, 49], ["this study", "TEST", 3, 13], ["Gal-3BP", "TREATMENT", 42, 49], ["an on-going inflammation", "PROBLEM", 82, 106], ["LPS", "TREATMENT", 122, 125], ["inflammation", "OBSERVATION", 94, 106]]], ["In addition, overexpressed Gal-3BP may be considered as a host response to neutralize harmful effects of Galectin-3 which is released from LPS-stimulated cells to produce heightened levels of inflammatory mediators, resulting in further tissue damage and, ultimately, organ failure, characteristics of sepsis.", [["cells", "ANATOMY", 154, 159], ["tissue", "ANATOMY", 237, 243], ["organ", "ANATOMY", 268, 273], ["Galectin-3", "CHEMICAL", 105, 115], ["LPS", "CHEMICAL", 139, 142], ["tissue damage", "DISEASE", 237, 250], ["organ failure", "DISEASE", 268, 281], ["sepsis", "DISEASE", 302, 308], ["Gal-3BP", "GENE_OR_GENE_PRODUCT", 27, 34], ["Galectin-3", "GENE_OR_GENE_PRODUCT", 105, 115], ["LPS", "SIMPLE_CHEMICAL", 139, 142], ["cells", "CELL", 154, 159], ["tissue", "TISSUE", 237, 243], ["organ", "ORGAN", 268, 273], ["Gal-3BP", "PROTEIN", 27, 34], ["LPS-stimulated cells", "CELL_LINE", 139, 159], ["inflammatory mediators", "PROTEIN", 192, 214], ["overexpressed Gal-3BP", "TEST", 13, 34], ["Galectin", "TEST", 105, 113], ["LPS-stimulated cells", "TREATMENT", 139, 159], ["heightened levels of inflammatory mediators", "PROBLEM", 171, 214], ["further tissue damage", "PROBLEM", 229, 250], ["organ failure", "PROBLEM", 268, 281], ["sepsis", "PROBLEM", 302, 308], ["inflammatory", "OBSERVATION_MODIFIER", 192, 204], ["tissue", "ANATOMY", 237, 243], ["damage", "OBSERVATION", 244, 250], ["failure", "OBSERVATION", 274, 281], ["sepsis", "OBSERVATION", 302, 308]]], ["On the other hand, Gal-3BP has a critical role in the development of venous thrombosis [24] and to increase the survival of cancer cells in the bloodstream [25], indicating that probably is involved in the pathophysiological responses of different pathological conditions.DiscussionTranscription factor MafF and CBG are associated with interleukin regulation [26], and have a protective effect in situations of cell stress, coagulation cascade activation and severe illness [27].", [["venous", "ANATOMY", 69, 75], ["cancer cells", "ANATOMY", 124, 136], ["bloodstream", "ANATOMY", 144, 155], ["cell", "ANATOMY", 411, 415], ["Gal-3BP", "CHEMICAL", 19, 26], ["venous thrombosis", "DISEASE", 69, 86], ["cancer", "DISEASE", 124, 130], ["illness", "DISEASE", 466, 473], ["Gal-3BP", "GENE_OR_GENE_PRODUCT", 19, 26], ["venous", "MULTI-TISSUE_STRUCTURE", 69, 75], ["cancer cells", "CELL", 124, 136], ["MafF", "GENE_OR_GENE_PRODUCT", 303, 307], ["CBG", "GENE_OR_GENE_PRODUCT", 312, 315], ["interleukin", "GENE_OR_GENE_PRODUCT", 336, 347], ["cell", "CELL", 411, 415], ["Gal-3BP", "PROTEIN", 19, 26], ["cancer cells", "CELL_TYPE", 124, 136], ["Transcription factor", "PROTEIN", 282, 302], ["MafF", "PROTEIN", 303, 307], ["CBG", "PROTEIN", 312, 315], ["interleukin", "PROTEIN", 336, 347], ["venous thrombosis", "PROBLEM", 69, 86], ["cancer cells", "PROBLEM", 124, 136], ["the bloodstream", "TEST", 140, 155], ["different pathological conditions", "PROBLEM", 238, 271], ["Transcription factor MafF", "TEST", 282, 307], ["CBG", "TEST", 312, 315], ["interleukin regulation", "TEST", 336, 358], ["cell stress", "PROBLEM", 411, 422], ["coagulation cascade activation", "PROBLEM", 424, 454], ["severe illness", "PROBLEM", 459, 473], ["venous", "ANATOMY", 69, 75], ["thrombosis", "OBSERVATION", 76, 86], ["cancer cells", "OBSERVATION", 124, 136], ["bloodstream", "ANATOMY", 144, 155], ["severe", "OBSERVATION_MODIFIER", 459, 465]]], ["A possible reason for the down regulations of these proteins found in our study may be excessive use of them to neutralize detrimental effects of LPS during acute phase reaction.DiscussionProteases from LPS-activated leukocytes can trigger tissue and organ damage and enhance the nonspecific proteolysis of plasma clotting factors in patients with severe sepsis.", [["leukocytes", "ANATOMY", 217, 227], ["tissue", "ANATOMY", 240, 246], ["organ", "ANATOMY", 251, 256], ["plasma", "ANATOMY", 307, 313], ["LPS", "CHEMICAL", 146, 149], ["LPS", "CHEMICAL", 203, 206], ["sepsis", "DISEASE", 355, 361], ["LPS", "SIMPLE_CHEMICAL", 146, 149], ["LPS", "SIMPLE_CHEMICAL", 203, 206], ["leukocytes", "CELL", 217, 227], ["tissue", "TISSUE", 240, 246], ["organ", "ORGAN", 251, 256], ["plasma", "ORGANISM_SUBSTANCE", 307, 313], ["clotting factors", "GENE_OR_GENE_PRODUCT", 314, 330], ["patients", "ORGANISM", 334, 342], ["activated leukocytes", "CELL_TYPE", 207, 227], ["plasma clotting factors", "PROTEIN", 307, 330], ["patients", "SPECIES", 334, 342], ["these proteins", "PROBLEM", 46, 60], ["our study", "TEST", 70, 79], ["LPS", "TREATMENT", 146, 149], ["acute phase reaction", "PROBLEM", 157, 177], ["LPS", "TEST", 203, 206], ["activated leukocytes", "PROBLEM", 207, 227], ["organ damage", "PROBLEM", 251, 263], ["the nonspecific proteolysis", "PROBLEM", 276, 303], ["plasma clotting factors", "PROBLEM", 307, 330], ["severe sepsis", "PROBLEM", 348, 361], ["possible", "UNCERTAINTY", 2, 10], ["nonspecific", "OBSERVATION_MODIFIER", 280, 291], ["severe", "OBSERVATION_MODIFIER", 348, 354], ["sepsis", "OBSERVATION", 355, 361]]], ["One example is the leukocyte elastase that is involved in the progress of complications in patients with sepsis [28].", [["leukocyte", "ANATOMY", 19, 28], ["sepsis", "DISEASE", 105, 111], ["leukocyte elastase", "GENE_OR_GENE_PRODUCT", 19, 37], ["patients", "ORGANISM", 91, 99], ["leukocyte elastase", "PROTEIN", 19, 37], ["patients", "SPECIES", 91, 99], ["the leukocyte elastase", "PROBLEM", 15, 37], ["complications", "PROBLEM", 74, 87], ["sepsis", "PROBLEM", 105, 111], ["leukocyte elastase", "OBSERVATION", 19, 37], ["complications", "OBSERVATION", 74, 87], ["sepsis", "OBSERVATION", 105, 111]]], ["In the present study, down regulation of ITIH-H3 in calves with LPS was most probably due to extended secretion of elastase [28], thereby this protein may be a part of the regulatory system that controls acute inflammation [29] in calves.", [["LPS", "CHEMICAL", 64, 67], ["inflammation", "DISEASE", 210, 222], ["ITIH-H3", "GENE_OR_GENE_PRODUCT", 41, 48], ["calves", "ORGANISM", 52, 58], ["LPS", "SIMPLE_CHEMICAL", 64, 67], ["elastase [28]", "GENE_OR_GENE_PRODUCT", 115, 128], ["calves", "ORGANISM", 231, 237], ["ITIH", "PROTEIN", 41, 45], ["H3", "PROTEIN", 46, 48], ["elastase", "PROTEIN", 115, 123], ["calves", "SPECIES", 52, 58], ["calves", "SPECIES", 231, 237], ["the present study", "TEST", 3, 20], ["ITIH", "PROBLEM", 41, 45], ["LPS", "TREATMENT", 64, 67], ["extended secretion of elastase", "PROBLEM", 93, 123], ["acute inflammation", "PROBLEM", 204, 222], ["most probably due to", "UNCERTAINTY", 72, 92], ["acute", "OBSERVATION_MODIFIER", 204, 209], ["inflammation", "OBSERVATION", 210, 222]]], ["Similar to our finding, circulating ITIH protein level was found lower in patients with severe sepsis than in healthy volunteers [28].DiscussionConfirming our previous findings in dogs and rats [4\u20137], we found in the present study that choline treatment improved the clinical signs associated to LPS.", [["sepsis", "DISEASE", 95, 101], ["choline", "CHEMICAL", 236, 243], ["LPS", "CHEMICAL", 296, 299], ["choline", "CHEMICAL", 236, 243], ["ITIH", "GENE_OR_GENE_PRODUCT", 36, 40], ["patients", "ORGANISM", 74, 82], ["dogs", "ORGANISM", 180, 184], ["rats", "ORGANISM", 189, 193], ["choline", "SIMPLE_CHEMICAL", 236, 243], ["LPS", "SIMPLE_CHEMICAL", 296, 299], ["ITIH", "PROTEIN", 36, 40], ["patients", "SPECIES", 74, 82], ["dogs", "SPECIES", 180, 184], ["rats", "SPECIES", 189, 193], ["circulating ITIH protein level", "TEST", 24, 54], ["severe sepsis", "PROBLEM", 88, 101], ["choline treatment", "TREATMENT", 236, 253], ["the clinical signs", "PROBLEM", 263, 281], ["LPS", "PROBLEM", 296, 299], ["lower", "OBSERVATION_MODIFIER", 65, 70], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["sepsis", "OBSERVATION", 95, 101]]], ["Further studies including larger number of calves are needed to evaluate if choline treatment could reduce mortality rate in this clinical condition.", [["choline", "CHEMICAL", 76, 83], ["choline", "CHEMICAL", 76, 83], ["calves", "ORGANISM", 43, 49], ["choline", "SIMPLE_CHEMICAL", 76, 83], ["Further studies", "TEST", 0, 15], ["choline treatment", "TREATMENT", 76, 93], ["mortality rate", "PROBLEM", 107, 121], ["larger", "OBSERVATION_MODIFIER", 26, 32]]], ["Endotoxemia studies in dogs showed that these beneficial effects of choline treatment might be related with inhibition of TNF-\u03b1 synthesis [4], prevention of hepato-renal injury [4], and attenuation of the changes of serum butrylcholinesterase and paraoxonase-1 activities [30].DiscussionMost of the down-regulated proteins after choline treatment such as kininogen-1, prothrombin, and ragulator complex are involved in coagulation and the development of DIC.", [["hepato", "ANATOMY", 157, 163], ["renal", "ANATOMY", 164, 169], ["serum", "ANATOMY", 216, 221], ["choline", "CHEMICAL", 68, 75], ["hepato-renal injury", "DISEASE", 157, 176], ["choline", "CHEMICAL", 329, 336], ["DIC", "DISEASE", 454, 457], ["choline", "CHEMICAL", 68, 75], ["choline", "CHEMICAL", 329, 336], ["dogs", "ORGANISM", 23, 27], ["choline", "SIMPLE_CHEMICAL", 68, 75], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 122, 127], ["renal", "ORGAN", 164, 169], ["serum", "ORGANISM_SUBSTANCE", 216, 221], ["butrylcholinesterase", "SIMPLE_CHEMICAL", 222, 242], ["paraoxonase-1", "GENE_OR_GENE_PRODUCT", 247, 260], ["choline", "SIMPLE_CHEMICAL", 329, 336], ["kininogen-1", "GENE_OR_GENE_PRODUCT", 355, 366], ["prothrombin", "GENE_OR_GENE_PRODUCT", 368, 379], ["ragulator complex", "GENE_OR_GENE_PRODUCT", 385, 402], ["TNF", "PROTEIN", 122, 125], ["serum butrylcholinesterase", "PROTEIN", 216, 242], ["paraoxonase", "PROTEIN", 247, 258], ["down-regulated proteins", "PROTEIN", 299, 322], ["kininogen-1", "PROTEIN", 355, 366], ["prothrombin", "PROTEIN", 368, 379], ["ragulator complex", "PROTEIN", 385, 402], ["dogs", "SPECIES", 23, 27], ["Endotoxemia studies", "TEST", 0, 19], ["choline treatment", "TREATMENT", 68, 85], ["inhibition of TNF", "TREATMENT", 108, 125], ["synthesis", "TREATMENT", 128, 137], ["hepato-renal injury", "PROBLEM", 157, 176], ["serum butrylcholinesterase", "TREATMENT", 216, 242], ["paraoxonase", "TREATMENT", 247, 258], ["choline treatment", "TREATMENT", 329, 346], ["kininogen", "TEST", 355, 364], ["prothrombin", "TEST", 368, 379], ["DIC", "PROBLEM", 454, 457], ["renal", "ANATOMY", 164, 169], ["injury", "OBSERVATION", 170, 176], ["DIC", "OBSERVATION", 454, 457]]], ["Therefore the decrease of these proteins could be associated with the preventive effects of choline treatment on the development of coagulopathy, as described previously in dogs [7].", [["choline", "CHEMICAL", 92, 99], ["coagulopathy", "DISEASE", 132, 144], ["choline", "CHEMICAL", 92, 99], ["choline", "SIMPLE_CHEMICAL", 92, 99], ["dogs", "SPECIES", 173, 177], ["the decrease of these proteins", "PROBLEM", 10, 40], ["choline treatment", "TREATMENT", 92, 109], ["coagulopathy", "PROBLEM", 132, 144], ["decrease", "OBSERVATION_MODIFIER", 14, 22], ["coagulopathy", "OBSERVATION", 132, 144]]], ["In addition the down-regulation of histones after choline treatment would be related with the protective effect of choline.", [["choline", "CHEMICAL", 50, 57], ["choline", "CHEMICAL", 115, 122], ["choline", "CHEMICAL", 50, 57], ["choline", "CHEMICAL", 115, 122], ["histones", "GENE_OR_GENE_PRODUCT", 35, 43], ["choline", "SIMPLE_CHEMICAL", 50, 57], ["choline", "SIMPLE_CHEMICAL", 115, 122], ["histones", "PROTEIN", 35, 43], ["choline treatment", "TREATMENT", 50, 67]]], ["Histone proteins, mainly the histones-H3 and H4, have been reported to exhibit cytotoxicity when released to the extracellular fluid in response to severe stress or inflammatory challenges like sepsis and to mediate excessive and overwhelming cell damage and death [31].", [["extracellular fluid", "ANATOMY", 113, 132], ["cell", "ANATOMY", 243, 247], ["sepsis", "DISEASE", 194, 200], ["death", "DISEASE", 259, 264], ["Histone", "GENE_OR_GENE_PRODUCT", 0, 7], ["histones-H3", "GENE_OR_GENE_PRODUCT", 29, 40], ["H4", "GENE_OR_GENE_PRODUCT", 45, 47], ["extracellular fluid", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 132], ["cell", "CELL", 243, 247], ["Histone proteins", "PROTEIN", 0, 16], ["histones", "PROTEIN", 29, 37], ["H3", "PROTEIN", 38, 40], ["H4", "PROTEIN", 45, 47], ["Histone proteins", "PROBLEM", 0, 16], ["the histones", "PROBLEM", 25, 37], ["H3", "PROBLEM", 38, 40], ["H4", "PROBLEM", 45, 47], ["cytotoxicity", "PROBLEM", 79, 91], ["the extracellular fluid", "TEST", 109, 132], ["severe stress", "PROBLEM", 148, 161], ["inflammatory challenges", "PROBLEM", 165, 188], ["sepsis", "PROBLEM", 194, 200], ["overwhelming cell damage", "PROBLEM", 230, 254], ["death", "PROBLEM", 259, 264], ["cytotoxicity", "OBSERVATION", 79, 91], ["fluid", "OBSERVATION", 127, 132], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["inflammatory", "OBSERVATION_MODIFIER", 165, 177], ["sepsis", "OBSERVATION", 194, 200], ["cell damage", "OBSERVATION", 243, 254]]], ["Hemopexin (Hx) is mainly expressed as an APP from liver after inflammation [32].", [["liver", "ANATOMY", 50, 55], ["Hemopexin", "CHEMICAL", 0, 9], ["Hx", "CHEMICAL", 11, 13], ["inflammation", "DISEASE", 62, 74], ["Hemopexin", "CHEMICAL", 0, 9], ["Hemopexin", "GENE_OR_GENE_PRODUCT", 0, 9], ["Hx", "GENE_OR_GENE_PRODUCT", 11, 13], ["APP", "GENE_OR_GENE_PRODUCT", 41, 44], ["liver", "ORGAN", 50, 55], ["APP", "PROTEIN", 41, 44], ["Hemopexin", "TREATMENT", 0, 9], ["inflammation", "PROBLEM", 62, 74], ["liver", "ANATOMY", 50, 55], ["inflammation", "OBSERVATION", 62, 74]]], ["In this study, Hx overexpression may be related with its antioxidant role [32] to facilitate tissue repair in response to LPS [33].", [["tissue", "ANATOMY", 93, 99], ["LPS", "CHEMICAL", 122, 125], ["Hx", "SIMPLE_CHEMICAL", 15, 17], ["tissue", "TISSUE", 93, 99], ["LPS", "SIMPLE_CHEMICAL", 122, 125], ["this study", "TEST", 3, 13], ["Hx overexpression", "PROBLEM", 15, 32], ["tissue repair", "TREATMENT", 93, 106], ["repair", "OBSERVATION", 100, 106]]], ["Choline treatment decreased Hx overexpression in calves with LPS, probably related with the reduction in body\u2019s antioxidant needs [32, 34] due to the reduction in tissue damage produced by choline [3].DiscussionThe increase found in SAA4 after choline administration could be related with the protective effect that has been described for SAA by inhibiting TNF and LPS as well as platelet aggregation [35].", [["body", "ANATOMY", 105, 109], ["tissue", "ANATOMY", 163, 169], ["platelet", "ANATOMY", 380, 388], ["Choline", "CHEMICAL", 0, 7], ["LPS", "CHEMICAL", 61, 64], ["choline", "CHEMICAL", 189, 196], ["choline", "CHEMICAL", 244, 251], ["LPS", "CHEMICAL", 365, 368], ["platelet aggregation", "DISEASE", 380, 400], ["Choline", "CHEMICAL", 0, 7], ["choline", "CHEMICAL", 189, 196], ["choline", "CHEMICAL", 244, 251], ["Choline", "SIMPLE_CHEMICAL", 0, 7], ["Hx", "SIMPLE_CHEMICAL", 28, 30], ["calves", "ORGANISM", 49, 55], ["LPS", "SIMPLE_CHEMICAL", 61, 64], ["body", "ORGANISM_SUBDIVISION", 105, 109], ["tissue", "TISSUE", 163, 169], ["choline", "SIMPLE_CHEMICAL", 189, 196], ["SAA4", "GENE_OR_GENE_PRODUCT", 233, 237], ["choline", "SIMPLE_CHEMICAL", 244, 251], ["SAA", "GENE_OR_GENE_PRODUCT", 339, 342], ["TNF", "GENE_OR_GENE_PRODUCT", 357, 360], ["LPS", "SIMPLE_CHEMICAL", 365, 368], ["platelet", "CELL", 380, 388], ["Hx", "PROTEIN", 28, 30], ["SAA", "PROTEIN", 339, 342], ["TNF", "PROTEIN", 357, 360], ["calves", "SPECIES", 49, 55], ["Choline treatment", "TREATMENT", 0, 17], ["overexpression in calves", "PROBLEM", 31, 55], ["LPS", "PROBLEM", 61, 64], ["the reduction in body\u2019s antioxidant needs", "TREATMENT", 88, 129], ["the reduction in tissue damage", "PROBLEM", 146, 176], ["choline administration", "TREATMENT", 244, 266], ["SAA", "PROBLEM", 339, 342], ["LPS", "TREATMENT", 365, 368], ["platelet aggregation", "TEST", 380, 400], ["probably related with", "UNCERTAINTY", 66, 87]]], ["In addition a correlation between SAA4 and cholinesterase has been found, therefore a link between SAA4 response and choline administration could be hypothesized [36].DiscussionCholine treatment attenuated overexpression of contractile protein actin alpha cardiac muscle-1 (ACTC1) at 48 h after LPS, indicating a protective effect of choline treatment on sepsis-induced myocardial dysfunction (SIMD).", [["myocardial", "ANATOMY", 370, 380], ["choline", "CHEMICAL", 117, 124], ["Choline", "CHEMICAL", 177, 184], ["LPS", "CHEMICAL", 295, 298], ["choline", "CHEMICAL", 334, 341], ["sepsis", "DISEASE", 355, 361], ["myocardial dysfunction", "DISEASE", 370, 392], ["SIMD", "DISEASE", 394, 398], ["choline", "CHEMICAL", 117, 124], ["Choline", "CHEMICAL", 177, 184], ["choline", "CHEMICAL", 334, 341], ["SAA4", "GENE_OR_GENE_PRODUCT", 34, 38], ["cholinesterase", "GENE_OR_GENE_PRODUCT", 43, 57], ["SAA4", "GENE_OR_GENE_PRODUCT", 99, 103], ["choline", "SIMPLE_CHEMICAL", 117, 124], ["Choline", "SIMPLE_CHEMICAL", 177, 184], ["actin alpha cardiac muscle-1", "GENE_OR_GENE_PRODUCT", 244, 272], ["ACTC1", "GENE_OR_GENE_PRODUCT", 274, 279], ["LPS", "SIMPLE_CHEMICAL", 295, 298], ["choline", "SIMPLE_CHEMICAL", 334, 341], ["myocardial", "MULTI-TISSUE_STRUCTURE", 370, 380], ["SAA4", "PROTEIN", 34, 38], ["cholinesterase", "PROTEIN", 43, 57], ["SAA4", "PROTEIN", 99, 103], ["contractile protein actin alpha cardiac muscle-1 (ACTC1)", "PROTEIN", 224, 280], ["SAA4", "TEST", 34, 38], ["choline administration", "TREATMENT", 117, 139], ["Choline treatment", "TREATMENT", 177, 194], ["contractile protein actin alpha cardiac muscle", "PROBLEM", 224, 270], ["LPS", "TEST", 295, 298], ["choline treatment", "TREATMENT", 334, 351], ["sepsis", "PROBLEM", 355, 361], ["myocardial dysfunction", "PROBLEM", 370, 392], ["contractile protein", "OBSERVATION", 224, 243], ["cardiac muscle", "ANATOMY", 256, 270], ["sepsis", "OBSERVATION", 355, 361], ["myocardial", "ANATOMY", 370, 380], ["dysfunction", "OBSERVATION", 381, 392]]], ["SIMD is a well-recognized manifestation of organ dysfunction in patient with sepsis [37] and calves with endotoxemia [38].", [["organ", "ANATOMY", 43, 48], ["SIMD", "DISEASE", 0, 4], ["organ dysfunction", "DISEASE", 43, 60], ["sepsis", "DISEASE", 77, 83], ["endotoxemia", "DISEASE", 105, 116], ["organ", "ORGAN", 43, 48], ["patient", "ORGANISM", 64, 71], ["calves", "ORGANISM", 93, 99], ["patient", "SPECIES", 64, 71], ["calves", "SPECIES", 93, 99], ["organ dysfunction", "PROBLEM", 43, 60], ["sepsis", "PROBLEM", 77, 83], ["endotoxemia", "PROBLEM", 105, 116], ["organ", "ANATOMY", 43, 48], ["dysfunction", "OBSERVATION", 49, 60], ["sepsis", "OBSERVATION", 77, 83], ["endotoxemia", "OBSERVATION", 105, 116]]], ["LPS-induced overexpression of ACTC1 may contribute to myocardial dysfunction during endotoxemia [39], most probably due to impaired sarcomere integrity [40].", [["myocardial", "ANATOMY", 54, 64], ["sarcomere", "ANATOMY", 132, 141], ["LPS", "CHEMICAL", 0, 3], ["myocardial dysfunction", "DISEASE", 54, 76], ["endotoxemia", "DISEASE", 84, 95], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["ACTC1", "GENE_OR_GENE_PRODUCT", 30, 35], ["myocardial", "MULTI-TISSUE_STRUCTURE", 54, 64], ["sarcomere", "CELLULAR_COMPONENT", 132, 141], ["ACTC1", "PROTEIN", 30, 35], ["LPS", "TEST", 0, 3], ["overexpression of ACTC1", "PROBLEM", 12, 35], ["myocardial dysfunction", "PROBLEM", 54, 76], ["endotoxemia", "PROBLEM", 84, 95], ["impaired sarcomere integrity", "PROBLEM", 123, 151], ["myocardial", "ANATOMY", 54, 64], ["dysfunction", "OBSERVATION", 65, 76], ["most probably due to", "UNCERTAINTY", 102, 122], ["impaired", "OBSERVATION", 123, 131]]], ["The observed overexpression of ACTC1 may be due to decreased thymosin beta-10 expression since thymosin beta-10 plays an important role in the organization of the cytoskeleton by binding to and sequestering actin monomers resulting with an inhibition in actin polymerization [41].ConclusionAlthough this is a pilot study made with a small sample size and therefore the results should be taken with caution.", [["cytoskeleton", "ANATOMY", 163, 175], ["thymosin beta-10", "CHEMICAL", 95, 111], ["ACTC1", "GENE_OR_GENE_PRODUCT", 31, 36], ["thymosin beta-10", "GENE_OR_GENE_PRODUCT", 61, 77], ["thymosin beta-10", "GENE_OR_GENE_PRODUCT", 95, 111], ["cytoskeleton", "CELLULAR_COMPONENT", 163, 175], ["actin", "GENE_OR_GENE_PRODUCT", 207, 212], ["actin", "GENE_OR_GENE_PRODUCT", 254, 259], ["ACTC1", "PROTEIN", 31, 36], ["thymosin beta-10", "PROTEIN", 61, 77], ["thymosin beta-10", "PROTEIN", 95, 111], ["actin monomers", "PROTEIN", 207, 221], ["actin", "PROTEIN", 254, 259], ["The observed overexpression of ACTC1", "PROBLEM", 0, 36], ["decreased thymosin beta", "PROBLEM", 51, 74], ["thymosin beta", "TREATMENT", 95, 108], ["an inhibition in actin polymerization", "TREATMENT", 237, 274], ["a pilot study", "TEST", 307, 320], ["a small sample size", "PROBLEM", 331, 350], ["may be due to", "UNCERTAINTY", 37, 50], ["decreased", "OBSERVATION_MODIFIER", 51, 60], ["thymosin", "OBSERVATION", 61, 69], ["size", "OBSERVATION_MODIFIER", 346, 350]]], ["It could be concluded that based on our experimental model, following LPS administration, there are changes in selected serum proteins which are associated with various biological processes such as lipid metabolism, immune and inflammatory response, protein binding and transport, cell adhesion, venous thrombosis, cardiac contraction and blood coagulation.", [["serum", "ANATOMY", 120, 125], ["cell", "ANATOMY", 281, 285], ["venous", "ANATOMY", 296, 302], ["cardiac", "ANATOMY", 315, 322], ["blood", "ANATOMY", 339, 344], ["LPS", "CHEMICAL", 70, 73], ["thrombosis", "DISEASE", 303, 313], ["blood coagulation", "DISEASE", 339, 356], ["LPS", "SIMPLE_CHEMICAL", 70, 73], ["serum", "ORGANISM_SUBSTANCE", 120, 125], ["lipid", "SIMPLE_CHEMICAL", 198, 203], ["cell", "CELL", 281, 285], ["venous", "MULTI-TISSUE_STRUCTURE", 296, 302], ["cardiac", "ORGAN", 315, 322], ["blood", "ORGANISM_SUBSTANCE", 339, 344], ["serum proteins", "PROTEIN", 120, 134], ["LPS administration", "TREATMENT", 70, 88], ["changes in selected serum proteins", "PROBLEM", 100, 134], ["various biological processes", "PROBLEM", 161, 189], ["lipid metabolism", "PROBLEM", 198, 214], ["immune and inflammatory response", "PROBLEM", 216, 248], ["protein binding", "PROBLEM", 250, 265], ["cell adhesion", "PROBLEM", 281, 294], ["venous thrombosis", "PROBLEM", 296, 313], ["cardiac contraction", "PROBLEM", 315, 334], ["blood coagulation", "TEST", 339, 356], ["lipid metabolism", "OBSERVATION", 198, 214], ["inflammatory", "OBSERVATION_MODIFIER", 227, 239], ["cell adhesion", "OBSERVATION", 281, 294], ["venous", "ANATOMY", 296, 302], ["thrombosis", "OBSERVATION", 303, 313], ["cardiac", "ANATOMY", 315, 322], ["contraction", "OBSERVATION", 323, 334]]], ["In addition choline administration is associated with changes in serum concentrations of selected serum proteins that would be related with its beneficial effect in this clinical situation.", [["serum", "ANATOMY", 65, 70], ["serum", "ANATOMY", 98, 103], ["choline", "CHEMICAL", 12, 19], ["choline", "CHEMICAL", 12, 19], ["choline", "SIMPLE_CHEMICAL", 12, 19], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["serum", "ORGANISM_SUBSTANCE", 98, 103], ["serum proteins", "PROTEIN", 98, 112], ["choline administration", "TREATMENT", 12, 34], ["changes in serum concentrations of selected serum proteins", "PROBLEM", 54, 112]]], ["These findings would reinforce the effectiveness of choline administration in the treatment of endotoxemia.", [["choline", "CHEMICAL", 52, 59], ["endotoxemia", "DISEASE", 95, 106], ["choline", "CHEMICAL", 52, 59], ["choline", "SIMPLE_CHEMICAL", 52, 59], ["choline administration", "TREATMENT", 52, 74], ["endotoxemia", "PROBLEM", 95, 106], ["endotoxemia", "OBSERVATION", 95, 106]]], ["However further studies are needed to confirm our results due to small sample size of this study, and in addition it would be interesting to evaluate the effectiveness of choline treatment in combination with other drugs such as steroidal or non-steroidal anti-inflammatory drugs.", [["non-steroidal", "ANATOMY", 242, 255], ["choline", "CHEMICAL", 171, 178], ["choline", "CHEMICAL", 171, 178], ["choline", "SIMPLE_CHEMICAL", 171, 178], ["non-steroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 242, 279], ["further studies", "TEST", 8, 23], ["this study", "TEST", 86, 96], ["choline treatment", "TREATMENT", 171, 188], ["other drugs", "TREATMENT", 209, 220], ["steroidal", "TREATMENT", 229, 238], ["non-steroidal anti-inflammatory drugs", "TREATMENT", 242, 279], ["size", "OBSERVATION_MODIFIER", 78, 82]]]], "PMC7129930": [["Reagents ::: Materials and methodsHigh fidelity Taq DNA polymerase was purchased from TaKaRa Biotech (Japan).", [["Taq", "GENE_OR_GENE_PRODUCT", 48, 51], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["Taq DNA polymerase", "PROTEIN", 48, 66], ["Materials", "TREATMENT", 13, 22], ["methods", "TEST", 27, 34], ["High fidelity Taq DNA polymerase", "PROBLEM", 34, 66]]], ["Restriction enzymes and T4 ligase were from Invitrogen (USA).", [["T4 ligase", "GENE_OR_GENE_PRODUCT", 24, 33], ["Restriction enzymes", "PROTEIN", 0, 19], ["T4 ligase", "PROTEIN", 24, 33], ["Restriction enzymes", "TEST", 0, 19], ["T4 ligase", "TEST", 24, 33]]], ["The DNA extraction and purification kit was from Qiagen (Germany). pET-28a expression vector was from Novagen (Germany).", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["pET-28a", "GENE_OR_GENE_PRODUCT", 67, 74], ["Novagen", "GENE_OR_GENE_PRODUCT", 102, 109], ["pET-28a expression vector", "DNA", 67, 92], ["The DNA extraction", "TREATMENT", 0, 18], ["purification kit", "TEST", 23, 39], ["pET", "TEST", 67, 70]]], ["The Ni\u2013nitrilotriacetic acid agarose was from Novagen (Germany).", [["Ni\u2013nitrilotriacetic acid", "CHEMICAL", 4, 28], ["Ni\u2013nitrilotriacetic acid", "CHEMICAL", 4, 28], ["Ni\u2013nitrilotriacetic acid", "SIMPLE_CHEMICAL", 4, 28], ["agarose", "SIMPLE_CHEMICAL", 29, 36], ["Novagen", "GENE_OR_GENE_PRODUCT", 46, 53], ["The Ni\u2013nitrilotriacetic acid agarose", "TREATMENT", 0, 36]]], ["Mouse anti-His monoclonal antibody (mAb) was purchased from BD Clontech (USA).", [["Mouse", "ORGANISM", 0, 5], ["anti-His", "GENE_OR_GENE_PRODUCT", 6, 14], ["Mouse anti-His monoclonal antibody", "PROTEIN", 0, 34], ["mAb", "PROTEIN", 36, 39], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse anti-His monoclonal antibody", "TEST", 0, 34]]], ["Horseradish peroxidase (HRP) labeled goat anti-human IgG and anti-mouse IgG were obtained from Zhongshan Biotech (China).", [["Horseradish peroxidase", "SIMPLE_CHEMICAL", 0, 22], ["HRP", "GENE_OR_GENE_PRODUCT", 24, 27], ["goat", "ORGANISM", 37, 41], ["IgG", "GENE_OR_GENE_PRODUCT", 53, 56], ["IgG", "GENE_OR_GENE_PRODUCT", 72, 75], ["Horseradish peroxidase (HRP) labeled goat anti-human IgG", "PROTEIN", 0, 56], ["anti-mouse IgG", "PROTEIN", 61, 75], ["Horseradish", "SPECIES", 0, 11], ["goat", "SPECIES", 37, 41], ["anti-human", "SPECIES", 42, 52], ["anti-mouse", "SPECIES", 61, 71], ["Horseradish", "SPECIES", 0, 11], ["goat", "SPECIES", 37, 41], ["anti-mouse", "SPECIES", 61, 71], ["Horseradish peroxidase (HRP) labeled goat anti-human IgG", "TREATMENT", 0, 56], ["anti-mouse IgG", "TEST", 61, 75]]], ["Complementary DNA encoding full-length S proteins of SARS-CoV was obtained from China CDC.", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["SARS-CoV", "ORGANISM", 53, 61], ["full-length S proteins", "PROTEIN", 27, 49], ["SARS-CoV", "SPECIES", 53, 61], ["Complementary DNA", "PROBLEM", 0, 17], ["SARS", "PROBLEM", 53, 57], ["CoV", "PROBLEM", 58, 61]]], ["Sera from convalescent SARS patients were provided by Beijing Red Cross Blood Center.Construction of the pET28a-S450-650 expression vector ::: Materials and methodsDNA coding for S450-650 was amplified using PCR with SARS-CoV S protein cDNA as template.", [["SARS", "DISEASE", 23, 27], ["S450-650", "CHEMICAL", 179, 187], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["patients", "ORGANISM", 28, 36], ["pET28a", "GENE_OR_GENE_PRODUCT", 105, 111], ["S450-650", "GENE_OR_GENE_PRODUCT", 179, 187], ["pET28a-S450-650 expression vector", "DNA", 105, 138], ["S450", "DNA", 179, 183], ["SARS-CoV S protein cDNA", "DNA", 217, 240], ["patients", "SPECIES", 28, 36], ["SARS-CoV", "SPECIES", 217, 225], ["PCR", "TEST", 208, 211], ["SARS", "PROBLEM", 217, 221], ["CoV S protein cDNA", "TREATMENT", 222, 240]]], ["The sequences of the primers employed in the PCR were 5\u2032CGC GGA TCC ATG CCC TTT GAG AGA GAC ATA TCT 3\u2032 (forward sequence containing a BamHI site) and 5\u2032CCC GAA TTC TTA AAT GTC GCA CTC ATA AGA AGT G 3\u2032 (reverse sequence containing an EcoRI site).Construction of the pET28a-S450-650 expression vector ::: Materials and methodsPCR was performed under the following conditions: 5 min at 95 \u00b0C for full denaturation, 30 s at 95 \u00b0C, 1 min at 50 \u00b0C, 1 min at 72 \u00b0C for 35 circles of amplification, and 10 min at 72 \u00b0C for an additional extension.", [["BamHI", "GENE_OR_GENE_PRODUCT", 134, 139], ["EcoRI", "GENE_OR_GENE_PRODUCT", 233, 238], ["pET28a", "GENE_OR_GENE_PRODUCT", 265, 271], ["forward sequence", "DNA", 104, 120], ["BamHI site", "DNA", 134, 144], ["5\u2032CCC GAA TTC TTA AAT GTC GCA CTC ATA AGA AGT G 3\u2032", "DNA", 150, 200], ["reverse sequence", "DNA", 202, 218], ["EcoRI site", "DNA", 233, 243], ["pET28a-S450-650 expression vector", "DNA", 265, 298], ["the primers", "TEST", 17, 28], ["the PCR", "TEST", 41, 48], ["GGA", "TEST", 60, 63], ["TCC", "TEST", 64, 67], ["ATG", "TEST", 68, 71], ["CCC", "TEST", 72, 75], ["TTT", "TEST", 76, 79], ["GAG", "TEST", 80, 83], ["AGA", "TEST", 84, 87], ["TCT", "TEST", 96, 99], ["a BamHI site", "TREATMENT", 132, 144], ["GAA TTC", "TEST", 156, 163], ["GCA", "TEST", 176, 179], ["an EcoRI site", "TREATMENT", 230, 243], ["full denaturation", "PROBLEM", 393, 410], ["an additional extension", "TREATMENT", 515, 538]]], ["The amplified product was digested with BamHI and EcoRI, and then ligated with cut vector, pET28a.", [["BamHI", "GENE_OR_GENE_PRODUCT", 40, 45], ["EcoRI", "GENE_OR_GENE_PRODUCT", 50, 55], ["pET28a", "GENE_OR_GENE_PRODUCT", 91, 97], ["BamHI", "DNA", 40, 45], ["EcoRI", "DNA", 50, 55], ["cut vector", "DNA", 79, 89], ["pET28a", "DNA", 91, 97], ["BamHI and EcoRI", "TREATMENT", 40, 55]]], ["The resulting plasmid was named pET28a-S450-650.Expression, on-column refolding, and purification of S450-650 ::: Materials and methodsFreshly transformed Escherichia coli BL21 (DE3) cells harboring plasmid pET28a-S450-650 were cultured in 1 L of 2YT medium containing kanamycin (25 \u03bcg/ml) at 37 \u00b0C. When the cell density reached 0.8\u20131.0 (OD600), isopropyl-\u03b2-d-thiogalactopyranoside (IPTG, Sigma) was added to a final concentration of 0.1 mM, and the bacteria were cultured for a further 3.5 h at 37 \u00b0C. The culture was then harvested by centrifugation at 5,000g for 15 min at 4 \u00b0C. The cell pellet was suspended in 100 ml buffer A (Table 1).", [["plasmid", "ANATOMY", 14, 21], ["DE3) cells", "ANATOMY", 178, 188], ["plasmid", "ANATOMY", 199, 206], ["cell", "ANATOMY", 309, 313], ["cell pellet", "ANATOMY", 587, 598], ["pET28a-S450-650", "CHEMICAL", 32, 47], ["S450-650", "CHEMICAL", 101, 109], ["pET28a-S450-650", "CHEMICAL", 207, 222], ["kanamycin", "CHEMICAL", 269, 278], ["isopropyl-\u03b2-d-thiogalactopyranoside", "CHEMICAL", 347, 382], ["IPTG", "CHEMICAL", 384, 388], ["S450-650", "CHEMICAL", 101, 109], ["kanamycin", "CHEMICAL", 269, 278], ["isopropyl-\u03b2-d-thiogalactopyranoside", "CHEMICAL", 347, 382], ["IPTG", "CHEMICAL", 384, 388], ["S450-650", "SIMPLE_CHEMICAL", 101, 109], ["Escherichia coli", "ORGANISM", 155, 171], ["BL21", "ORGANISM", 172, 176], ["DE3) cells", "CELL", 178, 188], ["kanamycin", "SIMPLE_CHEMICAL", 269, 278], ["cell", "CELL", 309, 313], ["isopropyl-\u03b2-d-thiogalactopyranoside", "SIMPLE_CHEMICAL", 347, 382], ["IPTG", "SIMPLE_CHEMICAL", 384, 388], ["Sigma", "SIMPLE_CHEMICAL", 390, 395], ["cell", "CELL", 587, 591], ["pET28a", "DNA", 32, 38], ["S450", "DNA", 39, 43], ["Escherichia coli BL21 (DE3) cells", "CELL_LINE", 155, 188], ["plasmid pET28a-S450-650", "DNA", 199, 222], ["Escherichia coli BL21", "SPECIES", 155, 176], ["Escherichia coli BL21", "SPECIES", 155, 176], ["DE3", "SPECIES", 178, 181], ["Escherichia coli BL21", "TEST", 155, 176], ["cells", "TEST", 183, 188], ["harboring plasmid pET28a", "TEST", 189, 213], ["S450", "TEST", 214, 218], ["kanamycin", "TREATMENT", 269, 278], ["the cell density", "TEST", 305, 321], ["isopropyl-\u03b2-d-thiogalactopyranoside (IPTG", "TREATMENT", 347, 388], ["the bacteria", "PROBLEM", 447, 459], ["The culture", "TEST", 504, 515], ["The cell pellet", "TREATMENT", 583, 598], ["Escherichia coli BL21", "OBSERVATION", 155, 176], ["cell density", "OBSERVATION", 309, 321], ["cell pellet", "OBSERVATION", 587, 598]]], ["After sonication (4 s pulse, 4 s pause, 200 W for 50 times), the lysed cells were centrifuged at 5000g for 15 min at 4 \u00b0C and pellet was resuspended in 100 ml buffer B.Expression, on-column refolding, and purification of S450-650 ::: Materials and methodsThe purified inclusion bodies were solubilized in 40 ml buffer C by incubating at 4 \u00b0C overnight.", [["cells", "ANATOMY", 71, 76], ["bodies", "ANATOMY", 278, 284], ["S450-650", "CHEMICAL", 221, 229], ["S450-650", "CHEMICAL", 221, 229], ["cells", "CELL", 71, 76], ["S450-650", "SIMPLE_CHEMICAL", 221, 229], ["lysed cells", "CELL_LINE", 65, 76], ["the lysed cells", "TREATMENT", 61, 76], ["The purified inclusion bodies", "TREATMENT", 255, 284], ["inclusion bodies", "OBSERVATION", 268, 284]]], ["After centrifugation at 16,000g for 30 min, the supernatant was filtered through a 0.45 \u03bcm membrane and incubated with 4 ml Ni\u2013nitrilotriacetic acid (NTA) agarose at 4 \u00b0C for 1 h.", [["supernatant", "ANATOMY", 48, 59], ["\u03bcm membrane", "ANATOMY", 88, 99], ["Ni\u2013nitrilotriacetic acid", "CHEMICAL", 124, 148], ["NTA", "CHEMICAL", 150, 153], ["Ni\u2013nitrilotriacetic acid", "CHEMICAL", 124, 148], ["NTA", "CHEMICAL", 150, 153], ["membrane", "CELLULAR_COMPONENT", 91, 99], ["Ni\u2013nitrilotriacetic acid", "SIMPLE_CHEMICAL", 124, 148], ["NTA", "SIMPLE_CHEMICAL", 150, 153], ["agarose", "SIMPLE_CHEMICAL", 155, 162], ["centrifugation", "TREATMENT", 6, 20], ["a 0.45 \u03bcm membrane", "TREATMENT", 81, 99], ["4 ml Ni\u2013nitrilotriacetic acid (NTA) agarose", "TREATMENT", 119, 162]]], ["Then, the agarose was poured into a column and washed with 30 ml buffer C at a flow rate of 2 ml/min.", [["agarose", "SIMPLE_CHEMICAL", 10, 17], ["the agarose", "TREATMENT", 6, 17], ["a flow rate", "TREATMENT", 77, 88], ["column", "ANATOMY", 36, 42]]], ["A linear gradient urea buffer D between 8 and 0 M was applied.", [["urea", "CHEMICAL", 18, 22], ["urea", "CHEMICAL", 18, 22], ["urea", "SIMPLE_CHEMICAL", 18, 22], ["A linear gradient urea buffer D", "TREATMENT", 0, 31], ["linear", "OBSERVATION_MODIFIER", 2, 8], ["gradient", "OBSERVATION_MODIFIER", 9, 17]]], ["Finally, the column was washed with 10 ml buffer E, and the recombinant S450-650 was eluted with 15 ml buffer F. The flow rate was maintained at 1 ml/min throughout.", [["S450-650", "CHEMICAL", 72, 80], ["S450-650", "SIMPLE_CHEMICAL", 72, 80], ["the column", "TREATMENT", 9, 19], ["the recombinant S450", "TREATMENT", 56, 76], ["The flow rate", "TEST", 113, 126], ["column", "ANATOMY", 13, 19]]], ["The recombinant S450-650 was adjusted to proper concentration and dialyzed with PBS (pH 7.2) containing 20% glycerol, 5% glucose.Immunization of animals ::: Materials and methodsFemale BALB/c mice of 6\u20138 weeks of age were obtained from Institute of Genetics and Developmental Biology Chinese Academy of Sciences, Beijing, China.", [["S450-650", "CHEMICAL", 16, 24], ["glycerol", "CHEMICAL", 108, 116], ["glucose", "CHEMICAL", 121, 128], ["glycerol", "CHEMICAL", 108, 116], ["glucose", "CHEMICAL", 121, 128], ["glycerol", "SIMPLE_CHEMICAL", 108, 116], ["glucose", "SIMPLE_CHEMICAL", 121, 128], ["BALB/c mice", "ORGANISM", 185, 196], ["mice", "SPECIES", 192, 196], ["mice", "SPECIES", 192, 196], ["The recombinant S450", "TREATMENT", 0, 20], ["PBS", "TEST", 80, 83], ["pH", "TEST", 85, 87], ["20% glycerol", "TREATMENT", 104, 116]]], ["The mice were immunized S.C. with S480-650 (50 \u03bcg/mouse) or PBS emulsified in complete Freund\u2019s adjuvant (CFA, Sigma) at the base of the tail.", [["tail", "ANATOMY", 137, 141], ["S480-650", "CHEMICAL", 34, 42], ["S480-650", "CHEMICAL", 34, 42], ["mice", "ORGANISM", 4, 8], ["S480-650", "SIMPLE_CHEMICAL", 34, 42], ["mouse", "ORGANISM", 50, 55], ["Freund\u2019s adjuvant", "SIMPLE_CHEMICAL", 87, 104], ["CFA", "SIMPLE_CHEMICAL", 106, 109], ["tail", "ORGANISM_SUBDIVISION", 137, 141], ["mice", "SPECIES", 4, 8], ["mouse", "SPECIES", 50, 55], ["mice", "SPECIES", 4, 8], ["mouse", "SPECIES", 50, 55], ["The mice", "TREATMENT", 0, 8], ["PBS emulsified", "TREATMENT", 60, 74], ["base", "ANATOMY_MODIFIER", 125, 129], ["tail", "ANATOMY", 137, 141]]], ["Two more booster immunization was given on days 15 and 29 with Ag mixed with incomplete Freund\u2019s adjuvant (IFA).", [["Ag", "CHEMICAL", 63, 65], ["Ag", "CHEMICAL", 63, 65], ["Freund\u2019s adjuvant", "SIMPLE_CHEMICAL", 88, 105], ["Ag", "PROTEIN", 63, 65], ["Two more booster immunization", "TREATMENT", 0, 29], ["incomplete Freund\u2019s adjuvant", "TREATMENT", 77, 105]]], ["Mouse blood was collected by tail bleeding on day 0, 7, 14, 21, 28, 35, 42, and the sera were kept at \u221280 \u00b0C until use.Western blot assays ::: Materials and methodsThe nitro-cellulose membranes, on which the recombinant S450-650 protein bands had been transferred, were blocked at room temperature for 2 h with blocking solution (5% non-fat dried milk) and then incubated for 2 h at room temperature with the first antibody.", [["blood", "ANATOMY", 6, 11], ["tail", "ANATOMY", 29, 33], ["sera", "ANATOMY", 84, 88], ["milk", "ANATOMY", 347, 351], ["tail bleeding", "DISEASE", 29, 42], ["nitro-cellulose", "CHEMICAL", 168, 183], ["nitro", "CHEMICAL", 168, 173], ["Mouse", "ORGANISM", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["tail", "ORGANISM_SUBDIVISION", 29, 33], ["sera", "ORGANISM_SUBSTANCE", 84, 88], ["fat", "TISSUE", 337, 340], ["milk", "ORGANISM_SUBSTANCE", 347, 351], ["S450", "PROTEIN", 220, 224], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse blood", "TEST", 0, 11], ["tail bleeding", "PROBLEM", 29, 42], ["the sera", "TEST", 80, 88], ["The nitro-cellulose membranes", "TREATMENT", 164, 193], ["blocking solution", "TREATMENT", 311, 328], ["5% non-fat dried milk", "TREATMENT", 330, 351], ["tail", "ANATOMY", 29, 33], ["bleeding", "OBSERVATION", 34, 42], ["cellulose membranes", "OBSERVATION", 174, 193]]], ["After washes in Tris-buffered saline (TBS, pH 8.0) containing 0.05% Tween 20 (TBS-T), the membranes were incubated with HRP-labeled goat anti-human IgG or goat anti-mouse IgG.", [["membranes", "ANATOMY", 90, 99], ["Tris", "CHEMICAL", 16, 20], ["Tween 20", "CHEMICAL", 68, 76], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 16, 36], ["TBS", "SIMPLE_CHEMICAL", 38, 41], ["Tween 20", "SIMPLE_CHEMICAL", 68, 76], ["TBS-T", "SIMPLE_CHEMICAL", 78, 83], ["membranes", "CELLULAR_COMPONENT", 90, 99], ["HRP", "SIMPLE_CHEMICAL", 120, 123], ["goat", "ORGANISM", 132, 136], ["IgG", "GENE_OR_GENE_PRODUCT", 148, 151], ["HRP-labeled goat anti-human IgG", "PROTEIN", 120, 151], ["goat anti-mouse IgG", "PROTEIN", 155, 174], ["goat", "SPECIES", 132, 136], ["goat", "SPECIES", 155, 159], ["anti-mouse", "SPECIES", 160, 170], ["goat", "SPECIES", 132, 136], ["goat", "SPECIES", 155, 159], ["washes in Tris", "TREATMENT", 6, 20], ["buffered saline (TBS", "TREATMENT", 21, 41], ["pH", "TEST", 43, 45], ["HRP", "TEST", 120, 123], ["goat anti-human IgG", "TREATMENT", 132, 151], ["goat anti-mouse IgG", "TREATMENT", 155, 174]]], ["3,3\u2032-diaminobenzidine tetrahydrochloride (DAB, Sigma) was used to visualize the reaction.ELISAs ::: Materials and methodsELISA plates were coated at 4 \u00b0C overnight with recombinant protein (2.5 pmol/well) resuspended in carbonate buffer (pH 9.6).", [["3,3\u2032-diaminobenzidine tetrahydrochloride", "CHEMICAL", 0, 40], ["DAB", "CHEMICAL", 42, 45], ["3,3\u2032-diaminobenzidine tetrahydrochloride", "CHEMICAL", 0, 40], ["DAB", "CHEMICAL", 42, 45], ["carbonate", "CHEMICAL", 220, 229], ["3,3\u2032-diaminobenzidine tetrahydrochloride", "SIMPLE_CHEMICAL", 0, 40], ["DAB", "SIMPLE_CHEMICAL", 42, 45], ["Sigma", "SIMPLE_CHEMICAL", 47, 52], ["carbonate", "SIMPLE_CHEMICAL", 220, 229], ["recombinant protein", "PROTEIN", 169, 188], ["diaminobenzidine tetrahydrochloride (DAB, Sigma)", "TREATMENT", 5, 53], ["the reaction", "PROBLEM", 76, 88], ["Materials and methodsELISA plates", "TREATMENT", 100, 133], ["recombinant protein", "TREATMENT", 169, 188], ["carbonate buffer", "TREATMENT", 220, 236], ["pH", "TEST", 238, 240]]], ["The wells were then incubated with blocking solution (2% BSA in PBS) for 2 h at 37 \u00b0C. After four washes with PBS containing 0.05% Tween 20 (PBS-T), one hundred microliters of diluted sera was added and incubated for 90 min at 37 \u00b0C. After washes with PBS-T, the plates were then incubated with HRP-labeled goat anti-human IgG antibody for 1 h at 37 \u00b0C. OPD (ortho-phenylenediamine) substrate (100 \u03bcl/well) was added after five washes with PBS-T and incubated for 2 min at room temperature.", [["sera", "ANATOMY", 184, 188], ["ortho-phenylenediamine", "CHEMICAL", 359, 381], ["Tween 20", "CHEMICAL", 131, 139], ["OPD (ortho-phenylenediamine", "CHEMICAL", 354, 381], ["BSA", "SIMPLE_CHEMICAL", 57, 60], ["Tween 20", "SIMPLE_CHEMICAL", 131, 139], ["sera", "ORGANISM_SUBSTANCE", 184, 188], ["HRP", "SIMPLE_CHEMICAL", 295, 298], ["goat", "ORGANISM", 307, 311], ["OPD", "SIMPLE_CHEMICAL", 354, 357], ["ortho-phenylenediamine", "SIMPLE_CHEMICAL", 359, 381], ["HRP-labeled goat anti-human IgG antibody", "PROTEIN", 295, 335], ["goat", "SPECIES", 307, 311], ["goat", "SPECIES", 307, 311], ["blocking solution", "TREATMENT", 35, 52], ["2% BSA in PBS", "TREATMENT", 54, 67], ["PBS", "TREATMENT", 110, 113], ["diluted sera", "TREATMENT", 176, 188], ["PBS", "TREATMENT", 252, 255], ["the plates", "TEST", 259, 269], ["HRP", "TEST", 295, 298], ["labeled goat anti-human IgG antibody", "TEST", 299, 335], ["OPD (ortho-phenylenediamine) substrate", "TREATMENT", 354, 392], ["PBS", "TREATMENT", 440, 443]]], ["Fifty microliters of 2 M H2SO4 solution was added to each well to stop the reaction, and the optical density (OD) was immediately read at 492 nm.Cloning and expression of S450-650 in E. coli ::: ResultsAs illustrated in Fig. 1, complementary DNA encoding S450-650 of the S protein of SARS-CoV was inserted into pET28a, a vector for His-tag fusion protein expression under the control of T7 RNA polymerase and lac operator [14], [15].", [["H2SO4", "CHEMICAL", 25, 30], ["S450-650", "CHEMICAL", 171, 179], ["H2SO4", "CHEMICAL", 25, 30], ["S450-650", "GENE_OR_GENE_PRODUCT", 171, 179], ["E. coli", "ORGANISM", 183, 190], ["DNA", "CELLULAR_COMPONENT", 242, 245], ["S450-650", "GENE_OR_GENE_PRODUCT", 255, 263], ["SARS-CoV", "ORGANISM", 284, 292], ["pET28a", "GENE_OR_GENE_PRODUCT", 311, 317], ["S450", "PROTEIN", 171, 175], ["complementary DNA", "DNA", 228, 245], ["S450", "PROTEIN", 255, 259], ["S protein", "PROTEIN", 271, 280], ["SARS-CoV", "DNA", 284, 292], ["pET28a", "DNA", 311, 317], ["His-tag fusion protein", "PROTEIN", 332, 354], ["T7 RNA polymerase", "PROTEIN", 387, 404], ["E. coli", "SPECIES", 183, 190], ["E. coli", "SPECIES", 183, 190], ["SARS-CoV", "SPECIES", 284, 292], ["2 M H2SO4 solution", "TREATMENT", 21, 39], ["the reaction", "PROBLEM", 71, 83], ["complementary DNA", "PROBLEM", 228, 245], ["SARS", "PROBLEM", 284, 288], ["a vector", "TREATMENT", 319, 327], ["His-tag fusion protein expression", "TREATMENT", 332, 365], ["the control of T7 RNA polymerase", "TREATMENT", 372, 404], ["lac operator", "TREATMENT", 409, 421], ["T7", "ANATOMY", 387, 389]]], ["Following IPTG induction (0.1 mM, 37 \u00b0C), the recombinant protein was overexpressed in inclusion bodies of E. coli BL21 cells (Fig. 2), reaching approximate 40% of total bacterial proteins, as estimated by scanning imaging analysis of the SDS\u2013PAGE gels (data not shown).Purification of the recombinant S450-650 ::: Results", [["cells", "ANATOMY", 120, 125], ["IPTG", "CHEMICAL", 10, 14], ["S450-650", "CHEMICAL", 302, 310], ["IPTG", "CHEMICAL", 10, 14], ["E. coli BL21 cells", "CELL", 107, 125], ["Fig. 2", "CELL", 127, 133], ["recombinant protein", "PROTEIN", 46, 65], ["BL21 cells", "CELL_LINE", 115, 125], ["bacterial proteins", "PROTEIN", 170, 188], ["E. coli BL21", "SPECIES", 107, 119], ["E. coli", "SPECIES", 107, 114], ["IPTG induction", "TREATMENT", 10, 24], ["the recombinant protein", "TEST", 42, 65], ["E. coli BL21 cells", "PROBLEM", 107, 125], ["total bacterial proteins", "PROBLEM", 164, 188], ["scanning imaging analysis", "TEST", 206, 231], ["E. coli BL21 cells", "OBSERVATION", 107, 125]]]], "ca2e21e13c3bdcad15372f753031925eb1081476": [["IntroductionHydroxychloroquine (HCQ) is solid oral prescription tablets formulations that have been used for medication of malaria and a wide variety of inflammatory conditions.", [["oral", "ANATOMY", 46, 50], ["Hydroxychloroquine", "CHEMICAL", 12, 30], ["HCQ", "CHEMICAL", 32, 35], ["malaria", "DISEASE", 123, 130], ["Hydroxychloroquine", "CHEMICAL", 12, 30], ["HCQ", "CHEMICAL", 32, 35], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 12, 30], ["HCQ", "SIMPLE_CHEMICAL", 32, 35], ["oral", "ORGANISM_SUBDIVISION", 46, 50], ["IntroductionHydroxychloroquine (HCQ)", "TREATMENT", 0, 36], ["solid oral prescription tablets formulations", "TREATMENT", 40, 84], ["malaria", "PROBLEM", 123, 130], ["a wide variety of inflammatory conditions", "TREATMENT", 135, 176], ["malaria", "OBSERVATION", 123, 130], ["inflammatory", "OBSERVATION", 153, 165]]], ["Moreover, HCQ has in-vitro activity for the treatment of SARS CoV-2, and related coronaviruses problems [1] [2] [3] .In recent days it is proven to have superficial ability and tolerable safety against COVID-19 (coronavirus-2019) related pneumonia in clinical experiments performed in China [4] . patients.", [["HCQ", "CHEMICAL", 10, 13], ["SARS", "DISEASE", 57, 61], ["COVID-19 (coronavirus-2019", "CHEMICAL", 202, 228], ["pneumonia", "DISEASE", 238, 247], ["HCQ", "CHEMICAL", 10, 13], ["HCQ", "SIMPLE_CHEMICAL", 10, 13], ["CoV-2", "ORGANISM", 62, 67], ["[1] [2] [3]", "SIMPLE_CHEMICAL", 104, 115], ["COVID-19", "ORGANISM", 202, 210], ["coronavirus-2019", "ORGANISM", 212, 228], ["patients", "ORGANISM", 297, 305], ["patients", "SPECIES", 297, 305], ["SARS CoV", "SPECIES", 57, 65], ["the treatment", "TREATMENT", 40, 53], ["SARS CoV", "TEST", 57, 65], ["coronaviruses problems", "PROBLEM", 81, 103], ["superficial ability", "PROBLEM", 153, 172], ["COVID", "TEST", 202, 207], ["coronavirus", "PROBLEM", 212, 223], ["pneumonia", "PROBLEM", 238, 247], ["pneumonia", "OBSERVATION", 238, 247]]], ["Based on these conclusions, a conference was organized on 15, February 2020; members 3 including professionals and experts from government and regulatory authorities of clinical trials agreed and approved that HCQ and chloroquine phosphate has effective against COVID-19.", [["HCQ", "CHEMICAL", 210, 213], ["chloroquine phosphate", "CHEMICAL", 218, 239], ["COVID-19", "CHEMICAL", 262, 270], ["HCQ", "CHEMICAL", 210, 213], ["chloroquine phosphate", "CHEMICAL", 218, 239], ["COVID-19", "CHEMICAL", 262, 270], ["HCQ", "SIMPLE_CHEMICAL", 210, 213], ["chloroquine phosphate", "SIMPLE_CHEMICAL", 218, 239], ["HCQ", "TREATMENT", 210, 213], ["chloroquine phosphate", "TREATMENT", 218, 239], ["COVID", "TEST", 262, 267]]], ["Based upon limited available clinical trials data, HCQ is recommending for treatment of COVID-19 infected patients in most of the countries.", [["HCQ", "CHEMICAL", 51, 54], ["COVID-19 infected", "DISEASE", 88, 105], ["HCQ", "CHEMICAL", 51, 54], ["HCQ", "SIMPLE_CHEMICAL", 51, 54], ["COVID-19", "ORGANISM", 88, 96], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["HCQ", "TREATMENT", 51, 54], ["treatment", "TREATMENT", 75, 84], ["COVID", "TREATMENT", 88, 93]]], ["Due to wider accessibility of these HCQ tablets in the United States, it has been administered to hospitalized COVID-19 patients.", [["HCQ", "CHEMICAL", 36, 39], ["HCQ", "CHEMICAL", 36, 39], ["HCQ", "SIMPLE_CHEMICAL", 36, 39], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["these HCQ tablets", "TREATMENT", 30, 47]]], ["It is still under investigation clinical trials for treatment of patients with different stages like mild, moderate, and severe COVID-19.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["treatment", "TREATMENT", 52, 61], ["different stages like mild, moderate, and severe COVID", "PROBLEM", 79, 133], ["mild", "OBSERVATION_MODIFIER", 101, 105], ["moderate", "OBSERVATION_MODIFIER", 107, 115], ["severe", "OBSERVATION_MODIFIER", 121, 127]]], ["The chemical structure of HCQ was shown in Fig. 1 .IntroductionCurrently, most of the countries were looking for HCQ drug product literature and other related information for better understanding, due to the COVID 19 pandemic.", [["HCQ", "CHEMICAL", 26, 29], ["HCQ", "CHEMICAL", 113, 116], ["HCQ", "CHEMICAL", 26, 29], ["HCQ", "CHEMICAL", 113, 116], ["HCQ", "SIMPLE_CHEMICAL", 26, 29], ["HCQ", "SIMPLE_CHEMICAL", 113, 116], ["chemical structure", "OBSERVATION", 4, 22]]], ["It is very important to know the drug product release with respective the time in invitro conditions.", [["the drug product release", "TREATMENT", 29, 53]]], ["The literature survey revealed different types of analytical techniques are used for determination of HCQ to report the information, such as HPLC with PDA detector [5] [6] , HPLC with UV detector [7] [8] [9] [10] [11] , chromatography-tandem mass spectrometry [12] [13] , LC/IT/MS [14] , capillary-LC [15] , Electrochemical study [16] .Chromatographic conditionsThe chromatogram was achieved with in 5 min run time by using Agilent, Zorbax C8, 250 x 4.6 mm i.d., column with isocratic method.", [["HCQ", "CHEMICAL", 102, 105], ["HCQ", "CHEMICAL", 102, 105], ["Zorbax C8", "CHEMICAL", 433, 442], ["HCQ", "SIMPLE_CHEMICAL", 102, 105], ["[7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 196, 217], ["The literature survey", "TEST", 0, 21], ["analytical techniques", "TREATMENT", 50, 71], ["PDA detector", "TEST", 151, 163], ["HPLC", "TEST", 174, 178], ["UV detector", "TEST", 184, 195], ["chromatography", "TEST", 220, 234], ["tandem mass spectrometry", "TEST", 235, 259], ["LC/IT/MS", "TEST", 272, 280], ["capillary-LC", "TEST", 288, 300], ["Electrochemical study", "TEST", 308, 329], ["Chromatographic conditions", "PROBLEM", 336, 362], ["The chromatogram", "TEST", 362, 378], ["Agilent, Zorbax C8", "TREATMENT", 424, 442], ["isocratic method", "TREATMENT", 475, 491]]], ["The Mobile Phase consists 0.01M of 1-pentane sulfonic acid and 0.02% of Ortho phosphoric acid in purified water with acetonitrile and methanol (800: 100: 100 v/v).Chromatographic conditionsThe flow rate was 1.0 mL min -1 and injection volume were 10 \u00b5l.", [["1-pentane sulfonic acid", "CHEMICAL", 35, 58], ["Ortho phosphoric acid", "CHEMICAL", 72, 93], ["acetonitrile", "CHEMICAL", 117, 129], ["methanol", "CHEMICAL", 134, 142], ["1-pentane sulfonic acid", "CHEMICAL", 35, 58], ["Ortho phosphoric acid", "CHEMICAL", 72, 93], ["acetonitrile", "CHEMICAL", 117, 129], ["methanol", "CHEMICAL", 134, 142], ["1-pentane sulfonic acid", "SIMPLE_CHEMICAL", 35, 58], ["Ortho phosphoric acid", "SIMPLE_CHEMICAL", 72, 93], ["water", "SIMPLE_CHEMICAL", 106, 111], ["acetonitrile", "SIMPLE_CHEMICAL", 117, 129], ["methanol", "SIMPLE_CHEMICAL", 134, 142], ["pentane sulfonic acid", "TREATMENT", 37, 58], ["Ortho phosphoric acid", "TREATMENT", 72, 93], ["acetonitrile", "TREATMENT", 117, 129], ["methanol", "TREATMENT", 134, 142], ["Chromatographic conditions", "PROBLEM", 163, 189], ["The flow rate", "TEST", 189, 202], ["injection volume", "TEST", 225, 241]]], ["Detection was made at 254 nm by using dual absorbance detector (DAD).Dissolution conditions and preparation of sample:To evaluate the dissolution of profile of HCQ reference listed product (RLD) (Plaquenil) with respective the time used USP apparatus-II (Paddle) having 50 rpm and 900mL of medium maintained 37.0\u00b0C temp.", [["HCQ", "CHEMICAL", 160, 163], ["Plaquenil", "CHEMICAL", 196, 205], ["HCQ", "CHEMICAL", 160, 163], ["Plaquenil", "CHEMICAL", 196, 205], ["HCQ", "SIMPLE_CHEMICAL", 160, 163], ["RLD", "SIMPLE_CHEMICAL", 190, 193], ["Plaquenil", "SIMPLE_CHEMICAL", 196, 205], ["Dissolution conditions", "PROBLEM", 69, 91], ["HCQ", "TREATMENT", 160, 163], ["RLD) (Plaquenil)", "TREATMENT", 190, 206], ["C temp", "TEST", 313, 319]]], ["After dropping the RLD tablets in to six dissolution vessels collected the samples at different time points. and injected in to HPLC.Anticipated ResultsFor the estimation of HCQ tablets started method development with selection of buffer, we selected %1-pentane sulfonic acid and 0.02%of OPA in purified water.", [["vessels", "ANATOMY", 53, 60], ["samples", "ANATOMY", 75, 82], ["HCQ", "CHEMICAL", 174, 177], ["1-pentane sulfonic acid", "CHEMICAL", 252, 275], ["OPA", "CHEMICAL", 288, 291], ["HCQ", "CHEMICAL", 174, 177], ["1-pentane sulfonic acid", "CHEMICAL", 252, 275], ["OPA", "CHEMICAL", 288, 291], ["vessels", "MULTI-TISSUE_STRUCTURE", 53, 60], ["HCQ", "SIMPLE_CHEMICAL", 174, 177], ["1-pentane sulfonic acid", "SIMPLE_CHEMICAL", 252, 275], ["OPA", "SIMPLE_CHEMICAL", 288, 291], ["the RLD tablets", "TREATMENT", 15, 30], ["HCQ tablets", "TREATMENT", 174, 185], ["selection of buffer", "TREATMENT", 218, 237], ["pentane sulfonic acid", "TREATMENT", 254, 275], ["OPA", "TREATMENT", 288, 291], ["vessels", "ANATOMY", 53, 60]]], ["Mixed the buffer with methanol and acetonitrile in the ratio of 800:100:100 v/v for the better peak shape.", [["methanol", "CHEMICAL", 22, 30], ["acetonitrile", "CHEMICAL", 35, 47], ["methanol", "CHEMICAL", 22, 30], ["acetonitrile", "CHEMICAL", 35, 47], ["methanol", "SIMPLE_CHEMICAL", 22, 30], ["acetonitrile", "SIMPLE_CHEMICAL", 35, 47], ["methanol", "TREATMENT", 22, 30], ["acetonitrile", "TREATMENT", 35, 47], ["peak shape", "OBSERVATION", 95, 105]]], ["Selected, Agilent Zorbax C8, 250 x 4.6 mm i.d column for estimation of HCQ for better system suitability parameters like tailing factor and theoretical plates.", [["HCQ", "CHEMICAL", 71, 74], ["Zorbax C8", "CHEMICAL", 18, 27], ["HCQ", "CHEMICAL", 71, 74], ["HCQ", "SIMPLE_CHEMICAL", 71, 74], ["tailing factor", "PROTEIN", 121, 135], ["Selected, Agilent Zorbax C8", "TREATMENT", 0, 27], ["estimation of HCQ", "TREATMENT", 57, 74], ["tailing factor and theoretical plates", "TREATMENT", 121, 158]]], ["The flow rate of HPLC was set 1.0 mL min -1 and injection volume was 10 \u00b5l.", [["The flow rate", "TEST", 0, 13], ["HPLC", "TEST", 17, 21], ["injection volume", "TEST", 48, 64]]], ["HPLC Detection was made at 254 nm by using dual absorbance detector (DAD).", [["HPLC Detection", "TEST", 0, 14]]], ["Evaluated system suitability parameters (retention time, tailing factor and theoretical plates) at 254 nm by using DAD detector (Fig. 2 ).", [["tailing factor", "PROTEIN", 57, 71], ["tailing factor and theoretical plates", "TREATMENT", 57, 94]]], ["As part of method validation specificity, linearity, precision and recovery parameters were verified.", [["method validation specificity", "TEST", 11, 40], ["recovery parameters", "TEST", 67, 86]]], ["The concentration and area relationships were linear (R 2 > 0.999), over the concentration range of 25 to 300 \u00b5g mL -1 for HCQ.", [["HCQ", "CHEMICAL", 123, 126], ["HCQ", "CHEMICAL", 123, 126], ["HCQ", "SIMPLE_CHEMICAL", 123, 126], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["area", "OBSERVATION_MODIFIER", 22, 26], ["linear", "OBSERVATION_MODIFIER", 46, 52]]], ["The relative standard deviations for precision and intermediate precision were less than 1.5%.", [["standard deviations", "OBSERVATION", 13, 32]]], ["The accuracy for 50% to 150% dissolution were found to more than 97%.", [["The accuracy", "TEST", 0, 12]]], ["The proposed RP-HPLC generic method was applied for analysis of US marketed products successfully.Anticipated ResultsPerformed invitro dissolution profile for the Reference listed drug and in-house formations to compare 6 the product release with respective the specified time intervals.", [["HPLC generic method", "TREATMENT", 16, 35], ["US marketed products", "TREATMENT", 64, 84]]], ["During the dissolution profile we were selected four different media like 0.1N HCl, pH 4.5 acetate buffer, pH 6.8 phosphate buffer to understand the product behaviors in low to high pH conditions.", [["N HCl", "CHEMICAL", 77, 82], ["pH 4.5 acetate", "CHEMICAL", 84, 98], ["phosphate", "CHEMICAL", 114, 123], ["HCl", "CHEMICAL", 79, 82], ["acetate", "CHEMICAL", 91, 98], ["phosphate", "CHEMICAL", 114, 123], ["pH 4.5 acetate buffer", "TREATMENT", 84, 105], ["pH", "TEST", 107, 109], ["phosphate buffer", "TREATMENT", 114, 130]]], ["After that all the media were reached optimum release (Table -1 & Figure 3 ).Conclusion:The hydroxychloroquine is currently recommending for treatment of hospitalized COVID-19 patients in most of the countries in the world.", [["hydroxychloroquine", "CHEMICAL", 92, 110], ["COVID", "DISEASE", 167, 172], ["hydroxychloroquine", "CHEMICAL", 92, 110], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 92, 110], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["all the media", "TREATMENT", 11, 24], ["The hydroxychloroquine", "TREATMENT", 88, 110]]], ["It is very important to understand the drug profiling invitro conditions, Hence a simple HPLC method has been developed successfully for estimation of HCQ dissolution profile in invitro conditions.", [["HCQ", "CHEMICAL", 151, 154], ["HCQ", "CHEMICAL", 151, 154], ["HCQ", "SIMPLE_CHEMICAL", 151, 154], ["a simple HPLC method", "TREATMENT", 80, 100], ["HCQ dissolution profile", "TREATMENT", 151, 174]]], ["The optimized HPLC method used for estimation of dissolution profile of RLD and in-house tablets.", [["RLD", "CHEMICAL", 72, 75], ["RLD", "SIMPLE_CHEMICAL", 72, 75], ["The optimized HPLC method", "TREATMENT", 0, 25]]], ["The optimized method was validated as per the ICH guidelines and the results were found satisfactory.", [["ICH", "DISEASE", 46, 49]]], ["Finally developed method was used in the quality control lab for the analysis of dissolution.", [["method", "TREATMENT", 18, 24]]]], "PMC7361037": [["Dear Editor-in-Chief Mehar S. MankuWe have read with great attention the article \u201cHomocysteine as a potential predictor of cardiovascular risk in patients with COVID-19\u201c, written by colleagues Ponti, Ruini and Tomasi (Authors) in the forthcoming October issue of Medical Hypotheses, published online in the May issue of same Journal [1].", [["cardiovascular", "ANATOMY", 123, 137], ["Homocysteine", "CHEMICAL", 82, 94], ["Homocysteine", "CHEMICAL", 82, 94], ["Homocysteine", "SIMPLE_CHEMICAL", 82, 94], ["cardiovascular", "ANATOMICAL_SYSTEM", 123, 137], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154]]], ["This interesting article evaluates possible relation between hyperhomocysteinemia and cardiovascular risk in patients with COVID-19.", [["cardiovascular", "ANATOMY", 86, 100], ["hyperhomocysteinemia", "DISEASE", 61, 81], ["cardiovascular", "ANATOMICAL_SYSTEM", 86, 100], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["hyperhomocysteinemia", "PROBLEM", 61, 81], ["cardiovascular risk", "PROBLEM", 86, 105], ["COVID", "TEST", 123, 128], ["hyperhomocysteinemia", "OBSERVATION", 61, 81], ["cardiovascular", "ANATOMY", 86, 100]]], ["We welcome the opportunity to make a short comment as well.Dear Editor-in-Chief Mehar S. MankuUndoubtedly, hyperhomocysteinemia has neurotoxic, neuroinflammatory, neurodegenerative, proatherogenic, prothrombotic, and prooxidative effects [2].", [["hyperhomocysteinemia", "DISEASE", 107, 127], ["neurotoxic", "DISEASE", 132, 142], ["hyperhomocysteinemia", "PROBLEM", 107, 127], ["neurotoxic", "PROBLEM", 132, 142], ["neuroinflammatory", "PROBLEM", 144, 161], ["neurodegenerative", "PROBLEM", 163, 180], ["proatherogenic", "PROBLEM", 182, 196], ["prothrombotic", "PROBLEM", 198, 211], ["hyperhomocysteinemia", "OBSERVATION", 107, 127], ["neurotoxic", "OBSERVATION_MODIFIER", 132, 142], ["neuroinflammatory", "OBSERVATION_MODIFIER", 144, 161], ["neurodegenerative", "OBSERVATION_MODIFIER", 163, 180], ["proatherogenic", "OBSERVATION_MODIFIER", 182, 196]]], ["It is linked with the existence of C667T MTHFR mutation, but also with reduced levels of B9 (folic acid) and other B-vitamins [3].", [["folic acid", "CHEMICAL", 93, 103], ["B-vitamins", "CHEMICAL", 115, 125], ["folic acid", "CHEMICAL", 93, 103], ["B-vitamins", "CHEMICAL", 115, 125], ["C667T MTHFR", "GENE_OR_GENE_PRODUCT", 35, 46], ["folic acid", "SIMPLE_CHEMICAL", 93, 103], ["B-vitamins", "SIMPLE_CHEMICAL", 115, 125], ["C667T MTHFR", "PROTEIN", 35, 46], ["C667T MTHFR mutation", "PROBLEM", 35, 55], ["B9 (folic acid)", "TREATMENT", 89, 104], ["other B-vitamins", "TREATMENT", 109, 125]]], ["In our study, we have shown that almost 17% of patients with prothrombotic / proembolic ischemic stroke had non-iatrogenic hyperhomocysteinemia [4].Dear Editor-in-Chief Mehar S. MankuFurthermore, previous reports unveiled that hyperhomocysteinemia contributed alongside many virus-infections including: human hepatitis virus, human papilloma virus, as well as human immunodeficiency virus [5], [6], [7].", [["ischemic stroke", "DISEASE", 88, 103], ["hyperhomocysteinemia", "DISEASE", 123, 143], ["hyperhomocysteinemia", "DISEASE", 227, 247], ["infections", "DISEASE", 281, 291], ["human hepatitis virus", "DISEASE", 303, 324], ["human papilloma virus", "DISEASE", 326, 347], ["human immunodeficiency virus", "DISEASE", 360, 388], ["patients", "ORGANISM", 47, 55], ["human hepatitis virus", "ORGANISM", 303, 324], ["human papilloma virus", "ORGANISM", 326, 347], ["human immunodeficiency virus", "ORGANISM", 360, 388], ["patients", "SPECIES", 47, 55], ["human", "SPECIES", 303, 308], ["hepatitis virus", "SPECIES", 309, 324], ["human", "SPECIES", 326, 331], ["papilloma virus", "SPECIES", 332, 347], ["human immunodeficiency virus", "SPECIES", 360, 388], ["human hepatitis virus", "SPECIES", 303, 324], ["human papilloma virus", "SPECIES", 326, 347], ["human immunodeficiency virus", "SPECIES", 360, 388], ["our study", "TEST", 3, 12], ["prothrombotic / proembolic ischemic stroke", "PROBLEM", 61, 103], ["non-iatrogenic hyperhomocysteinemia", "PROBLEM", 108, 143], ["hyperhomocysteinemia", "PROBLEM", 227, 247], ["many virus", "PROBLEM", 270, 280], ["infections", "PROBLEM", 281, 291], ["human hepatitis virus", "PROBLEM", 303, 324], ["human papilloma virus", "PROBLEM", 326, 347], ["human immunodeficiency virus", "PROBLEM", 360, 388], ["ischemic", "OBSERVATION_MODIFIER", 88, 96], ["stroke", "OBSERVATION", 97, 103], ["hyperhomocysteinemia", "OBSERVATION", 227, 247], ["infections", "OBSERVATION", 281, 291], ["papilloma virus", "OBSERVATION", 332, 347]]], ["Novelty pandemic coronavirus disease (COVID-19) has yet unclear kaleidoscopic presentation.", [["coronavirus disease", "DISEASE", 17, 36], ["coronavirus", "ORGANISM", 17, 28], ["coronavirus", "SPECIES", 17, 28], ["Novelty pandemic coronavirus disease", "PROBLEM", 0, 36], ["COVID", "TEST", 38, 43], ["coronavirus disease", "OBSERVATION", 17, 36]]], ["Also, (co)incidental appearance of hyperhomocysteinemia can make numerous negative effects, but not only in COVID-19 patients.", [["hyperhomocysteinemia", "DISEASE", 35, 55], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["hyperhomocysteinemia", "PROBLEM", 35, 55], ["hyperhomocysteinemia", "OBSERVATION", 35, 55], ["negative effects", "OBSERVATION_MODIFIER", 74, 90]]], ["Unfortunately, there was very poor reliable data of their concomitance according to PubMed survey.Dear Editor-in-Chief Mehar S. MankuLater, follow-up imaging in SARS-CoV-2 patients with pneumonia often demonstrated the disease severity [8].", [["SARS", "DISEASE", 161, 165], ["pneumonia", "DISEASE", 186, 195], ["SARS-CoV-2", "ORGANISM", 161, 171], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["SARS-CoV", "SPECIES", 161, 169], ["imaging", "TEST", 150, 157], ["pneumonia", "PROBLEM", 186, 195], ["the disease severity", "PROBLEM", 215, 235], ["pneumonia", "OBSERVATION", 186, 195], ["disease", "OBSERVATION", 219, 226]]], ["Interestingly, high number of pulmonary embolism was noted in COVID-19 pneumonia patients (20.6%), despite the fact that 90% of them were receiving prophylactic antithrombotic treatment according to the current guidelines.", [["pulmonary", "ANATOMY", 30, 39], ["pulmonary embolism", "DISEASE", 30, 48], ["pneumonia", "DISEASE", 71, 80], ["pulmonary", "ORGAN", 30, 39], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["pulmonary embolism", "PROBLEM", 30, 48], ["COVID", "TEST", 62, 67], ["pneumonia", "PROBLEM", 71, 80], ["prophylactic antithrombotic treatment", "TREATMENT", 148, 185], ["high", "OBSERVATION_MODIFIER", 15, 19], ["number", "OBSERVATION_MODIFIER", 20, 26], ["pulmonary", "ANATOMY", 30, 39], ["embolism", "OBSERVATION", 40, 48], ["pneumonia", "OBSERVATION", 71, 80]]], ["So, failure to identify cardiovascular risk could worsen the prognosis [9].", [["cardiovascular", "ANATOMY", 24, 38], ["cardiovascular risk", "PROBLEM", 24, 43], ["failure", "OBSERVATION", 4, 11]]], ["It is of great importance for early warning of aggravation, which could help clinicians manage quickly and accurately [10].Dear Editor-in-Chief Mehar S. MankuPerhaps, it is necesarry to add-on other medicaments to minimize cardiovascular risk and improve health condition of COVID-19 patients with pneumonia, also with the real possibility of pulmonary embolism.", [["cardiovascular", "ANATOMY", 223, 237], ["pulmonary", "ANATOMY", 343, 352], ["pneumonia", "DISEASE", 298, 307], ["pulmonary embolism", "DISEASE", 343, 361], ["cardiovascular", "ANATOMICAL_SYSTEM", 223, 237], ["patients", "ORGANISM", 284, 292], ["pulmonary", "ORGAN", 343, 352], ["patients", "SPECIES", 284, 292], ["aggravation", "PROBLEM", 47, 58], ["other medicaments", "TREATMENT", 193, 210], ["cardiovascular risk", "PROBLEM", 223, 242], ["pneumonia", "PROBLEM", 298, 307], ["pulmonary embolism", "PROBLEM", 343, 361], ["pneumonia", "OBSERVATION", 298, 307], ["pulmonary", "ANATOMY", 343, 352], ["embolism", "OBSERVATION", 353, 361]]], ["According to studies of Authors as well as Yang et al. (2020) on 40 and 273 COVID-19 patients, levels of homocysteine were significantly higher and also showed predictive value for CT-imaging progressions [1], [11].", [["homocysteine", "CHEMICAL", 105, 117], ["homocysteine", "CHEMICAL", 105, 117], ["patients", "ORGANISM", 85, 93], ["homocysteine", "SIMPLE_CHEMICAL", 105, 117], ["patients", "SPECIES", 85, 93], ["COVID", "TEST", 76, 81], ["levels of homocysteine", "TEST", 95, 117], ["predictive value", "TEST", 160, 176], ["CT-imaging progressions", "TEST", 181, 204]]], ["Our studies show that the intake of B9 vitamin, sometimes with other vitamins in this group, was effective in creating normalized homocysteine levels in patients with ishemic stroke and Parkinson's disease [4], [3].", [["B9 vitamin", "CHEMICAL", 36, 46], ["vitamins", "CHEMICAL", 69, 77], ["homocysteine", "CHEMICAL", 130, 142], ["ishemic stroke", "DISEASE", 167, 181], ["Parkinson's disease", "DISEASE", 186, 205], ["B9 vitamin", "CHEMICAL", 36, 46], ["homocysteine", "CHEMICAL", 130, 142], ["B9 vitamin", "SIMPLE_CHEMICAL", 36, 46], ["vitamins", "SIMPLE_CHEMICAL", 69, 77], ["homocysteine", "SIMPLE_CHEMICAL", 130, 142], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["Our studies", "TEST", 0, 11], ["B9 vitamin", "TREATMENT", 36, 46], ["other vitamins", "TREATMENT", 63, 77], ["creating normalized homocysteine levels", "PROBLEM", 110, 149], ["ishemic stroke", "PROBLEM", 167, 181], ["Parkinson's disease", "PROBLEM", 186, 205], ["stroke", "OBSERVATION", 175, 181]]], ["Furthermore, other studies also prove its quality in lowering hyperhomocysteinemia [12], [13].", [["hyperhomocysteinemia", "DISEASE", 62, 82], ["other studies", "TEST", 13, 26], ["lowering hyperhomocysteinemia", "PROBLEM", 53, 82]]], ["B-vitamins (B2, B3, B6) are identified with the enhancement of the immune system [14].", [["B-vitamins", "CHEMICAL", 0, 10], ["B-vitamins (B2, B3, B6", "CHEMICAL", 0, 22], ["B-vitamins", "SIMPLE_CHEMICAL", 0, 10], ["B2", "SIMPLE_CHEMICAL", 12, 14], ["B2", "PROTEIN", 12, 14], ["B3", "PROTEIN", 16, 18], ["B-vitamins (B2, B3, B6)", "TREATMENT", 0, 23]]], ["Consequently, their prescriptions for COVID-19 patients should continue as per usual in clinical practice [15].Dear Editor-in-Chief Mehar S. MankuWe emphasize that B9 vitamin and other B-vitamins are \u201con the first-line\u201d \u2013 good and safe in reduction levels of homocysteine.", [["B9 vitamin", "CHEMICAL", 164, 174], ["B-vitamins", "CHEMICAL", 185, 195], ["homocysteine", "CHEMICAL", 259, 271], ["B9 vitamin and other B-vitamins", "CHEMICAL", 164, 195], ["homocysteine", "CHEMICAL", 259, 271], ["patients", "ORGANISM", 47, 55], ["B9 vitamin", "SIMPLE_CHEMICAL", 164, 174], ["B-vitamins", "SIMPLE_CHEMICAL", 185, 195], ["homocysteine", "SIMPLE_CHEMICAL", 259, 271], ["patients", "SPECIES", 47, 55], ["COVID", "TREATMENT", 38, 43], ["B9 vitamin", "TREATMENT", 164, 174], ["other B-vitamins", "TREATMENT", 179, 195], ["homocysteine", "TREATMENT", 259, 271], ["homocysteine", "OBSERVATION", 259, 271]]], ["Therefore, B-vitamins can, ad hoc, become the medication of choice in the treatment when harmful hyperhomocysteinemia coexisting with COVID-19.", [["B-vitamins", "CHEMICAL", 11, 21], ["hyperhomocysteinemia", "DISEASE", 97, 117], ["COVID-19", "CHEMICAL", 134, 142], ["B-vitamins", "CHEMICAL", 11, 21], ["COVID-19", "CHEMICAL", 134, 142], ["B-vitamins", "SIMPLE_CHEMICAL", 11, 21], ["B-vitamins", "TREATMENT", 11, 21], ["the treatment", "TREATMENT", 70, 83], ["harmful hyperhomocysteinemia", "PROBLEM", 89, 117], ["COVID", "TEST", 134, 139], ["hyperhomocysteinemia", "OBSERVATION", 97, 117]]]], "452c61775e722f3e196d95d75185e08227b5eba5": [["IntroductionIncursion of animal (usually bat)-derived coronaviruses into the human population has caused several outbreaks of severe disease, starting with severe acute respiratory syndrome (SARS) 3 in 2002 (Menachery et al., 2015) .", [["acute respiratory syndrome", "DISEASE", 163, 189], ["SARS", "DISEASE", 191, 195], ["coronaviruses", "ORGANISM", 54, 67], ["human", "ORGANISM", 77, 82], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["severe disease", "PROBLEM", 126, 140], ["severe acute respiratory syndrome", "PROBLEM", 156, 189], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["disease", "OBSERVATION", 133, 140], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["respiratory syndrome", "OBSERVATION", 169, 189]]], ["In late 2019 a highly infectious illness, with cold-like symptoms progressing to pneumonia and acute respiratory failure, resulting in an estimated 6% overall death rate (Baud et al., 2020) , with higher mortality among the elderly and immunocompromised populations, was identified and confirmed as a pandemic by the WHO on 11 th March 2020.", [["respiratory", "ANATOMY", 101, 112], ["infectious illness", "DISEASE", 22, 40], ["pneumonia", "DISEASE", 81, 90], ["acute respiratory failure", "DISEASE", 95, 120], ["death", "DISEASE", 159, 164], ["a highly infectious illness", "PROBLEM", 13, 40], ["cold-like symptoms", "PROBLEM", 47, 65], ["pneumonia", "PROBLEM", 81, 90], ["acute respiratory failure", "PROBLEM", 95, 120], ["an estimated 6% overall death rate", "PROBLEM", 135, 169], ["immunocompromised populations", "PROBLEM", 236, 265], ["highly", "OBSERVATION_MODIFIER", 15, 21], ["infectious", "OBSERVATION", 22, 32], ["pneumonia", "OBSERVATION", 81, 90], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["respiratory failure", "OBSERVATION", 101, 120], ["immunocompromised", "OBSERVATION", 236, 253]]], ["The etiological agent is a novel coronavirus (SARS-CoV-2) belonging to lineage B betacoronavirus and sharing 88% sequence identity with bat coronaviruses (Lu et al., 2020a) .", [["coronavirus", "ORGANISM", 33, 44], ["SARS-CoV-2", "ORGANISM", 46, 56], ["lineage B betacoronavirus", "CELL", 71, 96], ["bat coronaviruses", "ORGANISM", 136, 153], ["SARS-CoV-2", "SPECIES", 46, 56], ["B betacoronavirus", "SPECIES", 79, 96], ["a novel coronavirus", "PROBLEM", 25, 44]]], ["The heavily glycosylated trimeric surface Spike protein mediates viral entry into the host cell.", [["cell", "ANATOMY", 91, 95], ["host cell", "CELL", 86, 95], ["trimeric surface Spike protein", "PROTEIN", 25, 55], ["host cell", "CELL_TYPE", 86, 95], ["viral entry", "OBSERVATION", 65, 76], ["host cell", "OBSERVATION", 86, 95]]], ["It is a large type I transmembrane glycoprotein (the ectodomain alone comprises over 1200 residues) (Wrapp et al., 2020) .", [["type I transmembrane glycoprotein", "GENE_OR_GENE_PRODUCT", 14, 47], ["type I transmembrane glycoprotein", "PROTEIN", 14, 47], ["ectodomain", "PROTEIN", 53, 63], ["a large type I transmembrane glycoprotein", "TREATMENT", 6, 47], ["the ectodomain alone", "TREATMENT", 49, 69], ["large", "OBSERVATION_MODIFIER", 8, 13]]], ["It is made as a single polypeptide and then cleaved by host proteases to yield an N-terminal S1 region and the C-terminal S2 region.IntroductionSpike exists initially in a pre-fusion state where the domains of S1 cloak the upper portion of the spike with the relatively small (~22 kDa) S1 RBD nestled at the tip.", [["N", "CHEMICAL", 82, 83], ["C-terminal S2", "GENE_OR_GENE_PRODUCT", 111, 124], ["upper", "ORGANISM_SUBDIVISION", 223, 228], ["host proteases", "PROTEIN", 55, 69], ["N-terminal S1 region", "PROTEIN", 82, 102], ["C-terminal S2 region", "PROTEIN", 111, 131], ["Spike", "PROTEIN", 144, 149], ["S1", "PROTEIN", 210, 212], ["RBD", "PROTEIN", 289, 292], ["a single polypeptide", "TREATMENT", 14, 34], ["the spike", "PROBLEM", 240, 249], ["terminal", "ANATOMY_MODIFIER", 84, 92], ["S1", "ANATOMY", 93, 95], ["region", "ANATOMY_MODIFIER", 96, 102], ["-terminal", "ANATOMY_MODIFIER", 112, 121], ["S2", "ANATOMY", 122, 124], ["region", "ANATOMY_MODIFIER", 125, 131], ["upper", "ANATOMY_MODIFIER", 223, 228], ["spike", "OBSERVATION_MODIFIER", 244, 249], ["relatively", "OBSERVATION_MODIFIER", 259, 269], ["small", "OBSERVATION_MODIFIER", 270, 275], ["tip", "OBSERVATION_MODIFIER", 308, 311]]], ["The RBD is predominantly in a 'down' state where the receptor binding site is inaccessible, however it appears that it stochastically flips up with a hinge-like motion transiently presenting the ACE2 receptor binding site (Roy, 2020; Song et al., 2018; Walls et al., 2020; Wrapp et al., 2020) .", [["RBD", "DISEASE", 4, 7], ["ACE2", "GENE_OR_GENE_PRODUCT", 195, 199], ["RBD", "PROTEIN", 4, 7], ["receptor binding site", "PROTEIN", 53, 74], ["ACE2 receptor binding site", "PROTEIN", 195, 221], ["RBD", "OBSERVATION", 4, 7], ["predominantly", "OBSERVATION_MODIFIER", 11, 24]]], ["ACE2 acts as a functional receptor for both SARS-CoV and SARS-CoV-2, binding to the latter with a 10 to 20-fold higher affinity (K D of ~15 nM), possibly contributing to its ease of transmission (Song et al., 2018; Wrapp et al., 2020) .", [["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 44, 52], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["ACE2", "PROTEIN", 0, 4], ["SARS-CoV", "SPECIES", 44, 52], ["ACE2 acts", "TREATMENT", 0, 9], ["a functional receptor", "TREATMENT", 13, 34], ["both SARS", "PROBLEM", 39, 48], ["CoV", "TEST", 49, 52], ["SARS", "TEST", 57, 61], ["CoV", "TEST", 62, 65], ["K D", "TEST", 129, 132], ["possibly contributing to", "UNCERTAINTY", 145, 169]]], ["There is 73% sequence identity between the RBDs of SARS-CoV and SARS-CoV-2 ( Figure S1 ).", [["SARS", "DISEASE", 51, 55], ["SARS-CoV", "ORGANISM", 51, 59], ["SARS-CoV-2", "ORGANISM", 64, 74], ["SARS-CoV", "SPECIES", 51, 59], ["SARS-CoV", "SPECIES", 64, 72], ["73% sequence identity", "PROBLEM", 9, 30], ["SARS", "PROBLEM", 51, 55], ["CoV", "TEST", 56, 59], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72]]], ["When ACE2 locks on it holds the RBD 'up', destabilising the S1 cloak and possibly favouring conversion to a postfusion form where the S2 subunit, through massive conformational changes, propels its fusion domain upwards to engage with the host membrane, casting off S1 in the process (Song et al., 2018; Wrapp et al., 2020) .", [["membrane", "ANATOMY", 244, 252], ["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["S2", "GENE_OR_GENE_PRODUCT", 134, 136], ["membrane", "CELLULAR_COMPONENT", 244, 252], ["ACE2", "PROTEIN", 5, 9], ["RBD", "PROTEIN", 32, 35], ["S1 cloak", "PROTEIN", 60, 68], ["postfusion form", "PROTEIN", 108, 123], ["S2 subunit", "PROTEIN", 134, 144], ["fusion domain", "PROTEIN", 198, 211], ["S1", "PROTEIN", 266, 268], ["ACE2 locks", "TREATMENT", 5, 15], ["massive conformational changes", "PROBLEM", 154, 184], ["its fusion domain", "TREATMENT", 194, 211], ["S1", "ANATOMY", 60, 62]]], ["Structural studies of the RBD in complex with ACE2 (Lan et al., 2020; Wang et al., 2020b; Yan et al., 2020) how that it is recognized by the extracellular peptidase domain (PD) of ACE2 through mainly polar interactions.", [["extracellular", "ANATOMY", 141, 154], ["RBD", "GENE_OR_GENE_PRODUCT", 26, 29], ["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["ACE2", "GENE_OR_GENE_PRODUCT", 180, 184], ["RBD", "PROTEIN", 26, 29], ["ACE2", "PROTEIN", 46, 50], ["extracellular peptidase domain", "PROTEIN", 141, 171], ["PD", "PROTEIN", 173, 175], ["ACE2", "PROTEIN", 180, 184], ["Structural studies", "TEST", 0, 18], ["the extracellular peptidase domain", "TREATMENT", 137, 171], ["ACE2", "TREATMENT", 180, 184], ["RBD", "ANATOMY", 26, 29], ["polar interactions", "OBSERVATION", 200, 218]]], ["The S 4 protein is an attractive candidate for both vaccine development and immunotherapy.", [["S 4", "GENE_OR_GENE_PRODUCT", 4, 7], ["S 4 protein", "PROTEIN", 4, 15], ["both vaccine development", "TREATMENT", 47, 71], ["immunotherapy", "TREATMENT", 76, 89]]], ["Potent nanomolar affinity neutralising human monoclonal antibodies against the SARS-CoV RBD have been identified that attach at the ACE2 receptor binding site (including M396, CR3014 and 80R (Ter Meulen et al., 2006; Sui et al., 2004; Zhu et al., 2007) ).", [["human", "ORGANISM", 39, 44], ["SARS-CoV RBD", "ORGANISM", 79, 91], ["ACE2", "GENE_OR_GENE_PRODUCT", 132, 136], ["human monoclonal antibodies", "PROTEIN", 39, 66], ["SARS-CoV RBD", "PROTEIN", 79, 91], ["ACE2 receptor binding site", "DNA", 132, 158], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["SARS-CoV", "SPECIES", 79, 87], ["Potent nanomolar affinity", "TREATMENT", 0, 25], ["human monoclonal antibodies", "TEST", 39, 66], ["the SARS", "PROBLEM", 75, 83], ["CoV RBD", "PROBLEM", 84, 91], ["CR3014", "TEST", 176, 182]]], ["For example 80R binds with nanomolar affinity, prevents binding to ACE2 and the formation of syncytia in vitro, and inhibits viral replication in vivo (Sui et al., 2004) .", [["syncytia", "ANATOMY", 93, 101], ["80R", "CHEMICAL", 12, 15], ["80R", "GENE_OR_GENE_PRODUCT", 12, 15], ["ACE2", "GENE_OR_GENE_PRODUCT", 67, 71], ["syncytia", "CELL", 93, 101], ["80R", "PROTEIN", 12, 15], ["ACE2", "PROTEIN", 67, 71], ["nanomolar affinity", "PROBLEM", 27, 45], ["ACE2", "TREATMENT", 67, 71], ["syncytia in vitro", "PROBLEM", 93, 110], ["viral replication", "TREATMENT", 125, 142], ["nanomolar affinity", "OBSERVATION", 27, 45], ["syncytia", "OBSERVATION", 93, 101]]], ["However, despite the two viruses sharing the same ACE2 receptor these ACE2 blocking antibodies do not bind SARS-CoV-2 RBD (Wrapp et al., 2020) .", [["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["ACE2 receptor", "PROTEIN", 50, 63], ["ACE2 blocking antibodies", "PROTEIN", 70, 94], ["RBD", "PROTEIN", 118, 121], ["the two viruses", "PROBLEM", 17, 32], ["ACE2 blocking antibodies", "TEST", 70, 94], ["CoV", "TEST", 112, 115]]], ["In contrast CR3022, a SARS-CoV-specific monoclonal selected from a single chain Fv phage display library constructed from lymphocytes of a convalescent SARS patient and reconstructed into IgG1 format (Ter Meulen et al., 2006) , has been reported to cross-react strongly, binding to the RBD of SARS-CoV-2 with a K D of 6.3 nM (Tian et al., 2020) , whilst not competing with the binding of ACE2 (Ter Meulen et al., 2006) .", [["lymphocytes", "ANATOMY", 122, 133], ["CR3022", "CHEMICAL", 12, 18], ["SARS", "DISEASE", 152, 156], ["SARS", "DISEASE", 293, 297], ["K", "CHEMICAL", 311, 312], ["CR3022", "SIMPLE_CHEMICAL", 12, 18], ["SARS-CoV", "ORGANISM", 22, 30], ["lymphocytes", "CELL", 122, 133], ["patient", "ORGANISM", 157, 164], ["IgG1", "GENE_OR_GENE_PRODUCT", 188, 192], ["SARS-CoV-2", "ORGANISM", 293, 303], ["K D", "SIMPLE_CHEMICAL", 311, 314], ["ACE2", "GENE_OR_GENE_PRODUCT", 388, 392], ["CR3022", "PROTEIN", 12, 18], ["SARS-CoV-specific monoclonal", "PROTEIN", 22, 50], ["lymphocytes", "CELL_TYPE", 122, 133], ["IgG1", "PROTEIN", 188, 192], ["RBD", "PROTEIN", 286, 289], ["ACE2", "PROTEIN", 388, 392], ["patient", "SPECIES", 157, 164], ["SARS-CoV", "SPECIES", 22, 30], ["SARS-CoV", "SPECIES", 293, 301], ["a SARS", "TEST", 20, 26], ["a single chain Fv phage", "TREATMENT", 65, 88], ["a convalescent SARS", "PROBLEM", 137, 156], ["CoV", "TEST", 298, 301], ["a K D", "TEST", 309, 314]]], ["Furthermore, although SARS-CoV escape mutations could be readily generated for ACE2blocking CR3014, no escape mutations could be generated for CR3022, preventing mapping of its epitope (Ter Meulen et al., 2006) .", [["CR3022", "CHEMICAL", 143, 149], ["SARS-CoV", "ORGANISM", 22, 30], ["ACE2blocking CR3014", "DNA", 79, 98], ["SARS-CoV", "SPECIES", 22, 30], ["SARS", "PROBLEM", 22, 26], ["CoV escape mutations", "PROBLEM", 27, 47], ["ACE2blocking CR3014", "TREATMENT", 79, 98], ["escape mutations", "PROBLEM", 103, 119]]], ["Furthermore a natural mutation of SARS-CoV-2 has now been detected at residue 495 (Y N) (GISAID (Shu and McCauley, 2017) : Accession ID: EPI_ISL_429783 Wienecke-Baldacchino et al., 2020), which forms part of the ACE2 binding epitope.", [["SARS", "DISEASE", 34, 38], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 34, 44], ["ACE2", "GENE_OR_GENE_PRODUCT", 212, 216], ["SARS-CoV-2", "DNA", 34, 44], ["ACE2 binding epitope", "PROTEIN", 212, 232], ["SARS-CoV", "SPECIES", 34, 42], ["a natural mutation of SARS", "PROBLEM", 12, 38], ["CoV", "TEST", 39, 42], ["the ACE2 binding epitope", "PROBLEM", 208, 232]]], ["Finally, CR3022 and CR3014 act synergistically to neutralise SARS-CoV with extreme potency (Ter Meulen et al., 2006) .", [["CR3022", "CHEMICAL", 9, 15], ["CR3014", "CHEMICAL", 20, 26], ["CR3022", "CHEMICAL", 9, 15], ["CR3014", "CHEMICAL", 20, 26], ["CR3022", "SIMPLE_CHEMICAL", 9, 15], ["CR3014", "SIMPLE_CHEMICAL", 20, 26], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 61, 69], ["SARS-CoV", "SPECIES", 61, 69], ["CR3022", "TEST", 9, 15]]], ["Whilst this work was being prepared for publication a paper reporting that CR3022 does not neutralise SARS-CoV-2 and describing the structure of the complex with the RBD at 3.1 \u00c5 resolution was published (Yuan et al., 2020) .", [["CR3022", "CHEMICAL", 75, 81], ["SARS", "DISEASE", 102, 106], ["CR3022", "CHEMICAL", 75, 81], ["CR3022", "SIMPLE_CHEMICAL", 75, 81], ["RBD", "PROTEIN", 166, 169]]], ["Here we extend the structure analysis to significantly higher resolution and, using a different neutralisation assay, show that CR3022 does neutralise SARS-CoV-2, but via a mechanism that would not be detected by the method of Yuan et al (Yuan et al., 2020) .", [["CR3022", "CHEMICAL", 128, 134], ["CR3022", "SIMPLE_CHEMICAL", 128, 134], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 151, 161], ["a different neutralisation assay", "TEST", 84, 116], ["significantly", "OBSERVATION_MODIFIER", 41, 54], ["higher", "OBSERVATION_MODIFIER", 55, 61], ["resolution", "OBSERVATION_MODIFIER", 62, 72]]], ["We use cryo-EM analysis of the interaction of CR3022 with the full Spike ectodomain to confirm 5 this mechanism.", [["CR3022", "GENE_OR_GENE_PRODUCT", 46, 52], ["CR3022", "PROTEIN", 46, 52], ["Spike ectodomain", "PROTEIN", 67, 83], ["cryo-EM analysis", "TEST", 7, 23], ["the full Spike ectodomain", "TREATMENT", 58, 83]]], ["Taken together these observations suggest that the CR3022 epitope should be a major target for therapeutic antibodies.CR3022 binds tightly to the RBD and allosterically perturbs ACE2 bindingTo understand how CR3022 works we first investigated the interaction of CR3022 Fab with isolated recombinant SARS-CoV-2 RBD, both alone and in the presence of ACE2.", [["CR3022", "CHEMICAL", 118, 124], ["CR3022 epitope", "GENE_OR_GENE_PRODUCT", 51, 65], ["CR3022", "SIMPLE_CHEMICAL", 118, 124], ["RBD", "GENE_OR_GENE_PRODUCT", 146, 149], ["ACE2", "GENE_OR_GENE_PRODUCT", 178, 182], ["CR3022", "GENE_OR_GENE_PRODUCT", 208, 214], ["Fab", "GENE_OR_GENE_PRODUCT", 269, 272], ["SARS-CoV-2 RBD", "GENE_OR_GENE_PRODUCT", 299, 313], ["ACE2", "GENE_OR_GENE_PRODUCT", 349, 353], ["CR3022 epitope", "PROTEIN", 51, 65], ["therapeutic antibodies", "PROTEIN", 95, 117], ["CR3022", "PROTEIN", 118, 124], ["RBD", "PROTEIN", 146, 149], ["ACE2", "PROTEIN", 178, 182], ["CR3022", "PROTEIN", 208, 214], ["CR3022 Fab", "PROTEIN", 262, 272], ["recombinant SARS-CoV-2 RBD", "PROTEIN", 287, 313], ["ACE2", "PROTEIN", 349, 353], ["the CR3022 epitope", "PROBLEM", 47, 65], ["therapeutic antibodies", "PROBLEM", 95, 117], ["CR", "TEST", 262, 264], ["Fab", "TEST", 269, 272], ["isolated recombinant SARS", "PROBLEM", 278, 303], ["CoV-2 RBD", "PROBLEM", 304, 313]]], ["Surface plasmon resonance (SPR) measurements (Methods and Figure S2 ) confirmed that CR3022 binding to RBD is strong (although weaker than the binding reported to SARS-CoV (Ter Meulen et al., 2006) ), with a slight variation according to whether CR3022 or RBD is used as the analyte (K D = 30 nM and 15 nM respectively, derived from the kinetic data in Table S1 ).CR3022 binds tightly to the RBD and allosterically perturbs ACE2 bindingAn independent measure using Bio-Layer Interferometry (BLI) with RBD as analyte gave a K D of 19 nM (Methods and Figure S2 ).", [["CR3022", "CHEMICAL", 85, 91], ["CR3022", "CHEMICAL", 246, 252], ["K", "CHEMICAL", 284, 285], ["CR3022", "CHEMICAL", 364, 370], ["CR3022", "CHEMICAL", 85, 91], ["CR3022", "CHEMICAL", 246, 252], ["CR3022", "CHEMICAL", 364, 370], ["CR3022", "SIMPLE_CHEMICAL", 85, 91], ["CR3022", "SIMPLE_CHEMICAL", 246, 252], ["CR3022", "SIMPLE_CHEMICAL", 364, 370], ["ACE2", "GENE_OR_GENE_PRODUCT", 424, 428], ["CR3022", "PROTEIN", 85, 91], ["RBD", "PROTEIN", 103, 106], ["CR3022", "PROTEIN", 246, 252], ["RBD", "PROTEIN", 256, 259], ["CR3022", "PROTEIN", 364, 370], ["RBD", "PROTEIN", 392, 395], ["ACE2", "PROTEIN", 424, 428], ["RBD", "PROTEIN", 501, 504], ["Surface plasmon resonance", "TEST", 0, 25], ["Figure S2 )", "TEST", 58, 69], ["SARS", "TEST", 163, 167], ["a slight variation", "PROBLEM", 206, 224], ["RBD", "PROBLEM", 256, 259], ["the analyte", "TEST", 271, 282], ["K D", "TEST", 284, 287], ["a K D", "TEST", 521, 526], ["strong", "OBSERVATION_MODIFIER", 110, 116], ["slight", "OBSERVATION_MODIFIER", 208, 214]]], ["These values are quite similar to those reported by Tian et al. (Tian et al., 2020 ) (6.6 nM), whereas weaker binding (K D ~ 115 nM) was reported recently by Yuan et al. (Yuan et al., 2020) .", [["weaker binding", "PROBLEM", 103, 117], ["K D", "TEST", 119, 122]]], ["Using SPR to perform a competition assay revealed that the binding of ACE2 to the RBD is perturbed by the presence of CR3022 ( Figure S3 ).", [["CR3022", "CHEMICAL", 118, 124], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["RBD", "GENE_OR_GENE_PRODUCT", 82, 85], ["ACE2", "PROTEIN", 70, 74], ["RBD", "PROTEIN", 82, 85], ["a competition assay", "TEST", 21, 40], ["RBD", "OBSERVATION", 82, 85]]], ["The presence of ACE2 slows the binding of CR3022 to RBD and accelerates the dissociation.", [["RBD", "DISEASE", 52, 55], ["CR3022", "CHEMICAL", 42, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 16, 20], ["CR3022", "GENE_OR_GENE_PRODUCT", 42, 48], ["ACE2", "PROTEIN", 16, 20], ["CR3022", "PROTEIN", 42, 48], ["RBD", "PROTEIN", 52, 55], ["ACE2", "PROBLEM", 16, 20], ["the dissociation", "PROBLEM", 72, 88], ["ACE2", "OBSERVATION", 16, 20], ["slows", "OBSERVATION_MODIFIER", 21, 26], ["dissociation", "OBSERVATION", 76, 88]]], ["Similarly, the release of ACE2 from RBD is accelerated by the presence of CR3022.", [["RBD", "DISEASE", 36, 39], ["CR3022", "CHEMICAL", 74, 80], ["CR3022", "CHEMICAL", 74, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["RBD", "GENE_OR_GENE_PRODUCT", 36, 39], ["CR3022", "SIMPLE_CHEMICAL", 74, 80], ["ACE2", "PROTEIN", 26, 30], ["RBD", "PROTEIN", 36, 39], ["RBD", "OBSERVATION", 36, 39]]], ["These observations are suggestive of an allosteric effect between ACE2 and CR3022.CR3022 neutralises SARS-CoV-2A plaque reduction neutralisation test using SARS-CoV-2 virus and CR3022 showed an ND50 of 1:201 for a starting concentration of 2mg/mL (calculated according to Grist (Grist, 1966) ), superior to that of MERS convalescent serum (ND50 of 1:149) used as a NIBSC 6 international standard positive control (see Methods and Table S2 ).", [["serum", "ANATOMY", 333, 338], ["CR3022", "CHEMICAL", 82, 88], ["CR3022", "CHEMICAL", 75, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 66, 70], ["CR3022", "GENE_OR_GENE_PRODUCT", 75, 81], ["CR3022", "SIMPLE_CHEMICAL", 82, 88], ["SARS-CoV-2A", "ORGANISM", 101, 112], ["SARS-CoV-2 virus", "ORGANISM", 156, 172], ["CR3022", "ORGANISM", 177, 183], ["serum", "ORGANISM_SUBSTANCE", 333, 338], ["ACE2", "PROTEIN", 66, 70], ["CR3022", "PROTEIN", 75, 81], ["CoV-2 virus", "SPECIES", 161, 172], ["SARS-CoV-2 virus", "SPECIES", 156, 172], ["an allosteric effect", "PROBLEM", 37, 57], ["ACE2", "TEST", 66, 70], ["CR3022", "TEST", 82, 88], ["neutralises", "TEST", 89, 100], ["SARS", "TEST", 101, 105], ["CoV", "TEST", 106, 109], ["2A plaque reduction", "TREATMENT", 110, 129], ["neutralisation test", "TEST", 130, 149], ["SARS", "TEST", 156, 160], ["CoV", "TEST", 161, 164], ["CR3022", "TEST", 177, 183], ["a starting concentration", "TREATMENT", 212, 236], ["MERS convalescent serum", "TEST", 315, 338], ["a NIBSC", "TREATMENT", 363, 370], ["suggestive of", "UNCERTAINTY", 23, 36], ["allosteric effect", "OBSERVATION", 40, 57]]], ["This corresponds to 50% neutralisation at ~70 nM (~10.5 ug/mL).", [["neutralisation", "TEST", 24, 38]]], ["This is similar to the neutralising concentration (50% neutralisation at 11 ug/mL) reported by Ter Meulen et al. (Ter Meulen et al., 2006) for SARS-CoV, however, as discussed below, it is in apparent disagreement with the result reported recently by Yuan et al. (Yuan et al., 2020) .Structure determination of RBD-CR3022 Fab complexWe determined the crystal structure of the SARS-CoV-2 RBD-CR3022 Fab complex (see Methods and Table S3 ) to investigate the relationship between the binding epitopes of ACE2 and CR3022.", [["SARS-CoV", "DISEASE", 143, 151], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 143, 151], ["ACE2", "GENE_OR_GENE_PRODUCT", 501, 505], ["CR3022", "GENE_OR_GENE_PRODUCT", 510, 516], ["RBD", "PROTEIN", 310, 313], ["CR3022 Fab complexWe", "PROTEIN", 314, 334], ["SARS-CoV-2 RBD", "PROTEIN", 375, 389], ["CR3022 Fab complex", "PROTEIN", 390, 408], ["binding epitopes", "PROTEIN", 481, 497], ["ACE2", "PROTEIN", 501, 505], ["CR3022", "PROTEIN", 510, 516], ["SARS-CoV", "SPECIES", 143, 151], ["the neutralising concentration", "TREATMENT", 19, 49], ["SARS", "PROBLEM", 143, 147], ["RBD", "TEST", 310, 313], ["Fab complexWe", "TEST", 321, 334], ["the SARS", "TEST", 371, 379], ["CoV", "TEST", 380, 383], ["ACE2", "TEST", 501, 505]]], ["Crystals grew rapidly and consistently.", [["Crystals", "ORGANISM_SUBSTANCE", 0, 8], ["Crystals", "TEST", 0, 8], ["grew", "OBSERVATION_MODIFIER", 9, 13], ["rapidly", "OBSERVATION_MODIFIER", 14, 21]]], ["Two crystal forms grew in the same drop.", [["Two crystal forms", "TEST", 0, 17], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["same", "OBSERVATION_MODIFIER", 30, 34], ["drop", "OBSERVATION_MODIFIER", 35, 39]]], ["The solvent content of the crystal form solved first was unusually high (ca 87%) with the ACE2 binding site exposed to large continuous solvent channels within the crystal lattice ( Figure S4 ).", [["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["ACE2", "PROTEIN", 90, 94], ["ca", "TEST", 73, 75], ["the ACE2 binding site", "PROBLEM", 86, 107], ["large continuous solvent channels", "TREATMENT", 119, 152], ["solvent content", "OBSERVATION", 4, 19], ["high", "OBSERVATION_MODIFIER", 67, 71], ["large", "OBSERVATION_MODIFIER", 119, 124], ["continuous", "OBSERVATION_MODIFIER", 125, 135], ["solvent channels", "OBSERVATION", 136, 152], ["crystal lattice", "OBSERVATION", 164, 179]]], ["These crystals therefore offer a promising vehicle for crystallographic screening to identify potential therapeutics that could act to block virus attachment.", [["crystallographic screening", "TEST", 55, 81], ["block virus attachment", "PROBLEM", 135, 157]]], ["The current analysis of this crystal form is at 4.4 \u00c5 resolution and so, to avoid overfitting, refinement used a novel real-space refinement algorithm to optimise the phases (Vagabond, HMG unpublished, see Methods).", [["HMG", "PROTEIN", 185, 188], ["overfitting", "PROBLEM", 82, 93], ["a novel real-space refinement algorithm", "TREATMENT", 111, 150]]], ["This, together with the favourable observation to parameter ratio resulting from the exceptionally high solvent content, meant that the map was of very high quality, allowing reliable structural interpretation ( Figure S5 , Methods).", [["parameter ratio", "TEST", 50, 65], ["the exceptionally high solvent content", "PROBLEM", 81, 119]]], ["Full interpretation of the detailed interactions between CR3022 and the RBD was enabled by the second crystal form which diffracted to high resolution, 2.4 \u00c5, and the structure of which was refined to give an R-work/R-free of 0.213/0.239 and good stereochemistry (Methods, Table S3, Figure S5 ).CR3022 binding epitope is highly conserved and inaccessible in prefusion S protein 7The high-resolution structure is shown in Figure 1a .", [["CR3022", "CHEMICAL", 295, 301], ["CR3022", "CANCER", 57, 63], ["CR3022", "SIMPLE_CHEMICAL", 295, 301], ["prefusion S protein 7", "GENE_OR_GENE_PRODUCT", 358, 379], ["CR3022", "PROTEIN", 57, 63], ["RBD", "PROTEIN", 72, 75], ["CR3022 binding epitope", "PROTEIN", 295, 317], ["prefusion S protein 7", "PROTEIN", 358, 379], ["prefusion S protein", "TEST", 358, 377], ["high", "OBSERVATION_MODIFIER", 135, 139], ["resolution", "OBSERVATION_MODIFIER", 140, 150]]], ["There are two complexes in the crystal asymmetric unit with residues 331-529 in one RBD, 332-445 and 448-532 in the other RBD well defined, whilst residues133-136 of the CR3022 heavy chains are disordered.", [["residues 331-529", "CHEMICAL", 60, 76], ["332-445 and 448-532", "CHEMICAL", 89, 108], ["RBD", "PROTEIN", 84, 87], ["RBD", "PROTEIN", 122, 125], ["CR3022 heavy chains", "PROTEIN", 170, 189], ["two", "OBSERVATION_MODIFIER", 10, 13], ["complexes", "OBSERVATION", 14, 23], ["crystal", "OBSERVATION_MODIFIER", 31, 38], ["asymmetric", "OBSERVATION_MODIFIER", 39, 49]]], ["The RBD has a very similar structure to that seen in the complex of SARS-CoV-2 RBD with ACE2, rmsd for 194 Ca atoms of 0.6 \u00c5 2 (PDB, 6M0J (Lan et al., 2020) ), and an rmsd of 1.1 \u00c5 2 compared to the SARS CoV RBD (PDB, 2AJF (Li et al., 2005) ).", [["SARS", "DISEASE", 68, 72], ["Ca", "CHEMICAL", 107, 109], ["Ca", "CHEMICAL", 107, 109], ["ACE2", "GENE_OR_GENE_PRODUCT", 88, 92], ["RBD", "PROTEIN", 4, 7], ["SARS-CoV-2 RBD", "PROTEIN", 68, 82], ["ACE2", "PROTEIN", 88, 92], ["SARS CoV", "SPECIES", 199, 207], ["CoV", "TEST", 73, 76], ["ACE2", "TEST", 88, 92], ["rmsd", "TEST", 94, 98], ["Ca atoms", "TEST", 107, 115], ["PDB", "TEST", 128, 131], ["an rmsd", "TEST", 164, 171], ["the SARS", "TEST", 195, 203], ["PDB", "TEST", 213, 216], ["RBD", "OBSERVATION", 4, 7], ["very", "OBSERVATION_MODIFIER", 14, 18], ["similar", "OBSERVATION_MODIFIER", 19, 26], ["structure", "OBSERVATION", 27, 36], ["SARS", "OBSERVATION", 68, 72], ["PDB", "ANATOMY", 213, 216]]], ["Only minor conformational changes are introduced by binding to CR3022, at residues 381-390.", [["CR3022", "CHEMICAL", 63, 69], ["CR3022", "GENE_OR_GENE_PRODUCT", 63, 69], ["CR3022", "PROTEIN", 63, 69], ["minor conformational changes", "PROBLEM", 5, 33], ["minor", "OBSERVATION_MODIFIER", 5, 10], ["conformational", "OBSERVATION", 11, 25]]], ["The RBD was deglycosylated (Methods) to leave a single saccharide unit at each of the N-linked glycosylation sites clearly seen at N331 and N343 ( Figure S5 ).", [["saccharide", "CHEMICAL", 55, 65], ["N", "CHEMICAL", 86, 87], ["RBD", "PROTEIN", 4, 7], ["N-linked glycosylation sites", "PROTEIN", 86, 114], ["N331", "PROTEIN", 131, 135], ["a single saccharide unit", "TREATMENT", 46, 70], ["the N-linked glycosylation sites", "TREATMENT", 82, 114]]], ["CR3022 attaches to the RBD surface orthogonal to the ACE2 receptor binding site.", [["surface", "ANATOMY", 27, 34], ["CR3022", "CHEMICAL", 0, 6], ["CR3022", "CHEMICAL", 0, 6], ["CR3022", "SIMPLE_CHEMICAL", 0, 6], ["ACE2", "GENE_OR_GENE_PRODUCT", 53, 57], ["CR3022", "PROTEIN", 0, 6], ["RBD", "PROTEIN", 23, 26], ["ACE2 receptor binding site", "DNA", 53, 79], ["ACE2", "ANATOMY", 53, 57], ["receptor", "OBSERVATION", 58, 66], ["binding site", "OBSERVATION", 67, 79]]], ["There is no overlap between the epitopes and indeed both the Fab and ACE2 ectodomain can bind without clashing ( Figure 1d ) (Tian et al., 2020) .", [["Fab", "GENE_OR_GENE_PRODUCT", 61, 64], ["ACE2", "GENE_OR_GENE_PRODUCT", 69, 73], ["epitopes", "PROTEIN", 32, 40], ["Fab", "PROTEIN", 61, 64], ["ACE2 ectodomain", "PROTEIN", 69, 84], ["overlap between the epitopes", "PROBLEM", 12, 40], ["no", "UNCERTAINTY", 9, 11], ["epitopes", "OBSERVATION", 32, 40]]], ["Such independence of the ACE2 binding site has been reported recently for another SARS-CoV-2 neutralising antibody, 47D11 .", [["ACE2", "GENE_OR_GENE_PRODUCT", 25, 29], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 82, 92], ["47D11", "SIMPLE_CHEMICAL", 116, 121], ["ACE2 binding site", "DNA", 25, 42], ["SARS-CoV-2 neutralising antibody", "PROTEIN", 82, 114], ["47D11", "PROTEIN", 116, 121], ["the ACE2 binding site", "PROBLEM", 21, 42], ["another SARS", "TEST", 74, 86], ["CoV", "TEST", 87, 90], ["neutralising antibody", "TEST", 93, 114]]], ["The Fab complex interface buries 990 \u00c5 2 of surface area (600 and 390 \u00c5 2 by the heavy and light chains respectively, Figure 2a and Figure S6 ), somewhat more than the RBD-ACE2 interface which covers 850 \u00c5 2 (PDB 6M0J (Lan et al., 2020) ).", [["surface area", "ANATOMY", 44, 56], ["Fab", "GENE_OR_GENE_PRODUCT", 4, 7], ["ACE2", "GENE_OR_GENE_PRODUCT", 172, 176], ["Fab complex", "PROTEIN", 4, 15], ["heavy and light chains", "PROTEIN", 81, 103], ["S6", "PROTEIN", 139, 141], ["RBD", "PROTEIN", 168, 171], ["ACE2", "PROTEIN", 172, 176], ["The Fab complex interface buries", "TEST", 0, 32], ["surface area", "TEST", 44, 56]]], ["Typical of a Fab complex, the interaction is mediated by the antibody CDR loops, which fit well into the rather sculpted surface of the RBD (Figure 1b , c).", [["surface", "ANATOMY", 121, 128], ["RBD", "DISEASE", 136, 139], ["Fab", "GENE_OR_GENE_PRODUCT", 13, 16], ["Fab complex", "PROTEIN", 13, 24], ["antibody CDR loops", "PROTEIN", 61, 79], ["RBD", "PROTEIN", 136, 139], ["Figure 1b , c)", "PROTEIN", 141, 155], ["a Fab complex", "PROBLEM", 11, 24], ["Fab complex", "OBSERVATION_MODIFIER", 13, 24], ["RBD", "ANATOMY", 136, 139]]], ["The heavy chain CDR1, 2 and 3 make contacts to residues from \u03b1 2, \u03b2 2 and \u03b1 3 (residues 369-386), while two of the light chain CDRs (1 and 2) interact mainly with residues from the \u03b2 2-\u03b13 loop, \u03b1 3 (380-392) and the \u03b1 5-\u03b24 loop (427-430) (Figures 1, S1, S7).", [["CDR1", "GENE_OR_GENE_PRODUCT", 16, 20], ["2", "GENE_OR_GENE_PRODUCT", 22, 23], ["3", "GENE_OR_GENE_PRODUCT", 28, 29], ["\u03b1 2", "GENE_OR_GENE_PRODUCT", 61, 64], ["\u03b2 2", "GENE_OR_GENE_PRODUCT", 66, 69], ["\u03b1 3", "GENE_OR_GENE_PRODUCT", 74, 77], ["369-386", "AMINO_ACID", 88, 95], ["2", "GENE_OR_GENE_PRODUCT", 139, 140], ["\u03b1 3", "GENE_OR_GENE_PRODUCT", 194, 197], ["heavy chain CDR1, 2 and 3", "PROTEIN", 4, 29], ["\u03b1 2", "PROTEIN", 61, 64], ["\u03b1 3", "PROTEIN", 74, 77], ["light chain CDRs", "PROTEIN", 115, 131], ["\u03b2 2-\u03b13 loop", "PROTEIN", 181, 192], ["\u03b1 3", "PROTEIN", 194, 197], ["S1", "PROTEIN", 250, 252], ["S7", "PROTEIN", 254, 256], ["Figures", "TEST", 239, 246], ["heavy", "OBSERVATION_MODIFIER", 4, 9], ["chain CDR1", "OBSERVATION", 10, 20]]], ["A total of 16 residues from the heavy chain and 14 from the light chain cement the interaction with 26 residues from the RBD.", [["RBD", "DISEASE", 121, 124], ["heavy chain", "PROTEIN", 32, 43], ["RBD", "PROTEIN", 121, 124], ["A total of 16 residues from the heavy chain", "TREATMENT", 0, 43], ["the light chain cement", "TREATMENT", 56, 78], ["26 residues from the RBD", "PROBLEM", 100, 124], ["total", "OBSERVATION_MODIFIER", 2, 7], ["RBD", "OBSERVATION", 121, 124]]], ["For the heavy chain these potentially form 7 H-bonds and 3 salt bridges, the latter from D55 and E57 (CDR2) to K378 of the RBD.CR3022 binding epitope is highly conserved and inaccessible in prefusion S protein 7Whilst the light chain interface comprises 6 H-bonds and a single salt bridge between E61CR3022 binding epitope is highly conserved and inaccessible in prefusion S protein 7(CDR2) and K386 of the RBD.", [["RBD", "DISEASE", 123, 126], ["CR3022", "CHEMICAL", 127, 133], ["E61CR3022", "CHEMICAL", 297, 306], ["RBD", "DISEASE", 407, 410], ["H", "CHEMICAL", 45, 46], ["K378", "CHEMICAL", 111, 115], ["H", "CHEMICAL", 256, 257], ["H-bonds", "SIMPLE_CHEMICAL", 45, 52], ["3 salt bridges", "SIMPLE_CHEMICAL", 57, 71], ["D55", "SIMPLE_CHEMICAL", 89, 92], ["CR3022", "SIMPLE_CHEMICAL", 127, 133], ["E61CR3022", "SIMPLE_CHEMICAL", 297, 306], ["prefusion S protein 7", "GENE_OR_GENE_PRODUCT", 363, 384], ["CDR2", "GENE_OR_GENE_PRODUCT", 385, 389], ["D55", "PROTEIN", 89, 92], ["E57", "PROTEIN", 97, 100], ["CDR2", "PROTEIN", 102, 106], ["RBD", "PROTEIN", 123, 126], ["CR3022 binding epitope", "PROTEIN", 127, 149], ["prefusion S protein", "PROTEIN", 190, 209], ["E61CR3022 binding epitope", "PROTEIN", 297, 322], ["prefusion S protein 7", "PROTEIN", 363, 384], ["CDR2", "PROTEIN", 385, 389], ["K386", "PROTEIN", 395, 399], ["RBD", "PROTEIN", 407, 410], ["3 salt bridges", "TREATMENT", 57, 71], ["D55", "TREATMENT", 89, 92], ["E57 (CDR2", "TREATMENT", 97, 106], ["the RBD", "PROBLEM", 119, 126], ["prefusion S protein", "TEST", 190, 209], ["a single salt bridge", "TREATMENT", 268, 288], ["prefusion S protein", "TEST", 363, 382], ["CDR2", "TEST", 385, 389], ["the RBD", "PROBLEM", 403, 410], ["RBD", "OBSERVATION", 123, 126], ["RBD", "OBSERVATION", 407, 410]]], ["The binding is consolidated by a number of hydrophobic 8 interactions ( Figure S7b ).", [["consolidated", "OBSERVATION", 15, 27]]], ["Of the 26 residues involved in the interaction 23 are conserved between SARS-CoV and SARS-CoV-2 ( Figure 2b and Figure S1 ).", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 72, 80], ["SARS-CoV", "SPECIES", 72, 80], ["SARS-CoV", "SPECIES", 85, 93], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80], ["SARS", "TEST", 85, 89], ["CoV", "TEST", 90, 93], ["26 residues", "OBSERVATION_MODIFIER", 7, 18]]], ["The CR30222 epitope is much more conserved than that of the receptor blocking anti-SARS-CoV antibody 80R for which only 13 of the 29 interacting residues are conserved (Hwang et al., 2006) , in-line with the lack of cross reactivity observed for the latter.CR3022 binding epitope is highly conserved and inaccessible in prefusion S protein 7The reason for the conservation of the CR3022 epitope becomes clear in the context of the complete pre-fusion S structure (PDB IDs: 6VSB (Wrapp et al., 2020) , 6VXX, 6VYB (Walls et al., 2020) ) where the epitope is inaccessible ( Figure 3 ).", [["CR3022", "CHEMICAL", 257, 263], ["CR30222", "GENE_OR_GENE_PRODUCT", 4, 11], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 78, 91], ["CR3022", "SIMPLE_CHEMICAL", 257, 263], ["prefusion S protein 7", "GENE_OR_GENE_PRODUCT", 320, 341], ["CR30222 epitope", "PROTEIN", 4, 19], ["anti-SARS-CoV antibody 80R", "PROTEIN", 78, 104], ["CR3022 binding epitope", "PROTEIN", 257, 279], ["prefusion S protein 7", "PROTEIN", 320, 341], ["CR3022 epitope", "PROTEIN", 380, 394], ["pre-fusion S structure", "PROTEIN", 440, 462], ["The CR30222 epitope", "TEST", 0, 19], ["the receptor blocking anti-SARS", "TEST", 56, 87], ["CoV antibody", "TEST", 88, 100], ["cross reactivity", "PROBLEM", 216, 232], ["prefusion S protein", "TEST", 320, 339], ["the CR3022 epitope", "TREATMENT", 376, 394], ["clear", "OBSERVATION", 403, 408]]], ["When the RBD is in the 'down'CR3022 binding epitope is highly conserved and inaccessible in prefusion S protein 7configuration the CR3022 epitope is packed tightly against another RBD of the trimer and the N-terminal domain (NTD) of the neighbouring protomer.", [["N-", "CHEMICAL", 206, 208], ["RBD", "GENE_OR_GENE_PRODUCT", 9, 12], ["RBD", "PROTEIN", 9, 12], ["CR3022 binding epitope", "PROTEIN", 29, 51], ["prefusion S protein 7configuration", "PROTEIN", 92, 126], ["CR3022 epitope", "PROTEIN", 131, 145], ["RBD", "PROTEIN", 180, 183], ["trimer", "PROTEIN", 191, 197], ["N-terminal domain", "PROTEIN", 206, 223], ["NTD", "PROTEIN", 225, 228], ["neighbouring protomer", "PROTEIN", 237, 258], ["prefusion S protein", "TEST", 92, 111], ["RBD", "OBSERVATION", 9, 12]]], ["In the structure of the pre-fusion form of trimeric Spike the majority of RBDs are 'down', although presumably stochastically one may be 'up' (Walls et al., 2020; Wrapp et al., 2020) .", [["Spike", "GENE_OR_GENE_PRODUCT", 52, 57], ["RBDs", "GENE_OR_GENE_PRODUCT", 74, 78], ["trimeric Spike", "PROTEIN", 43, 57], ["RBDs", "PROTEIN", 74, 78], ["trimeric Spike", "PROBLEM", 43, 57], ["trimeric Spike", "OBSERVATION", 43, 57], ["majority", "OBSERVATION_MODIFIER", 62, 70]]], ["The structure of a SARS-CoV complex with ACE2 ectodomain shows that this 'up' configuration is competent to bind receptor, and that there are a family of 'up' orientations with significantly different hinge angles (Song et al., 2018) .", [["SARS", "DISEASE", 19, 23], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 19, 27], ["ACE2", "GENE_OR_GENE_PRODUCT", 41, 45], ["SARS-CoV complex", "PROTEIN", 19, 35], ["ACE2", "PROTEIN", 41, 45], ["a SARS-CoV complex", "PROBLEM", 17, 35], ["ACE2 ectodomain", "TEST", 41, 56]]], ["However, the CR3022 epitope remains largely inaccessible even in the 'up' configuration.", [["CR3022 epitope", "GENE_OR_GENE_PRODUCT", 13, 27], ["CR3022 epitope", "PROTEIN", 13, 27], ["largely", "OBSERVATION_MODIFIER", 36, 43], ["inaccessible", "OBSERVATION", 44, 56]]], ["Modelling the rotation of the RBD required to enable Fab interaction in the context of the Spike trimer, showed a rotation corresponding to a > 60\u00b0 further declination from the central vertical axis was required, beyond that observed previously (Walls et al., 2020; Wrapp et al., 2020) (Figure 3i ), although this might be partly mitigated by more complex movements of the RBD and if more than one RBD is in the 'up' configuration this requirement would be relaxed somewhat.", [["RBD", "DISEASE", 30, 33], ["RBD", "DISEASE", 373, 376], ["RBD", "DISEASE", 398, 401], ["Fab", "GENE_OR_GENE_PRODUCT", 53, 56], ["Spike", "GENE_OR_GENE_PRODUCT", 91, 96], ["RBD", "PROTEIN", 30, 33], ["Fab", "PROTEIN", 53, 56], ["Spike trimer", "PROTEIN", 91, 103], ["RBD", "PROTEIN", 373, 376], ["RBD", "PROTEIN", 398, 401], ["the RBD", "PROBLEM", 26, 33], ["the RBD", "PROBLEM", 369, 376], ["central", "OBSERVATION_MODIFIER", 177, 184], ["vertical axis", "OBSERVATION", 185, 198], ["RBD", "OBSERVATION", 373, 376]]], ["Since locking the up state by receptor blocking antibodies is thought to destabilise the pre-fusion state (Walls et al., 2019) binding of CR3022 presumably introduces further destabilisation, leading to a premature conversion to the post-fusion state, inactivating the virus.", [["CR3022", "CHEMICAL", 138, 144], ["CR3022", "GENE_OR_GENE_PRODUCT", 138, 144], ["receptor blocking antibodies", "PROTEIN", 30, 58], ["CR3022", "PROTEIN", 138, 144], ["receptor blocking antibodies", "TEST", 30, 58], ["the pre-fusion state", "PROBLEM", 85, 105], ["further destabilisation", "PROBLEM", 167, 190], ["a premature conversion to the post-fusion state", "PROBLEM", 203, 250], ["the virus", "PROBLEM", 265, 274]]], ["CR3022 and ACE2 blocking antibodies can bind 9 independently but both induce an 'up' conformation, presumably explaining the observed synergy between binding at the two sites (Ter Meulen et al., 2006) .Mechanism of neutralisation of SARS-CoV-2 by CR3022 confirmed by cryo-EMTo test if CR3022 binding destabilises the prefusion state of Spike, the ectodomain construct described previously (Wrapp et al., 2020) was used to produce glycosylated protein in HEK cells (Methods).", [["HEK cells", "ANATOMY", 454, 463], ["CR3022", "CHEMICAL", 0, 6], ["SARS", "DISEASE", 233, 237], ["CR3022", "CHEMICAL", 285, 291], ["CR3022", "CHEMICAL", 285, 291], ["CR3022", "SIMPLE_CHEMICAL", 0, 6], ["ACE2", "GENE_OR_GENE_PRODUCT", 11, 15], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 233, 243], ["CR3022", "SIMPLE_CHEMICAL", 247, 253], ["CR3022", "SIMPLE_CHEMICAL", 285, 291], ["Spike", "GENE_OR_GENE_PRODUCT", 336, 341], ["HEK cells", "CELL", 454, 463], ["CR3022", "PROTEIN", 0, 6], ["ACE2", "PROTEIN", 11, 15], ["antibodies", "PROTEIN", 25, 35], ["CR3022", "PROTEIN", 285, 291], ["Spike", "PROTEIN", 336, 341], ["glycosylated protein", "PROTEIN", 430, 450], ["HEK cells", "CELL_LINE", 454, 463], ["SARS-CoV", "SPECIES", 233, 241], ["CR3022", "TEST", 0, 6], ["ACE2 blocking antibodies", "TREATMENT", 11, 35], ["the observed synergy between binding", "PROBLEM", 121, 157], ["neutralisation of SARS", "PROBLEM", 215, 237], ["CoV", "TEST", 238, 241], ["cryo-EMTo test", "TEST", 267, 281], ["CR3022 binding", "PROBLEM", 285, 299], ["Spike", "PROBLEM", 336, 341], ["the ectodomain construct", "PROBLEM", 343, 367], ["glycosylated protein in HEK cells", "PROBLEM", 430, 463], ["neutralisation", "OBSERVATION", 215, 229], ["HEK cells", "OBSERVATION", 454, 463]]], ["Cryo-EM screening showed that the protein was in the trimeric prefusion conformation.", [["trimeric prefusion conformation", "PROTEIN", 53, 84], ["Cryo-EM screening", "TEST", 0, 17], ["the protein", "TEST", 30, 41], ["prefusion conformation", "OBSERVATION", 62, 84]]], ["Spike was then mixed with an excess of CR3022 Fab and incubated at room temperature, with aliquots being taken at 50 minutes and 3 hours.", [["CR3022", "CHEMICAL", 39, 45], ["Fab", "GENE_OR_GENE_PRODUCT", 46, 49], ["CR3022 Fab", "PROTEIN", 39, 49], ["Spike", "PROBLEM", 0, 5], ["CR3022 Fab", "TREATMENT", 39, 49], ["aliquots", "TREATMENT", 90, 98]]], ["Aliquots were immediately applied to cryo-EM grids and frozen (Methods).", [["Aliquots", "ANATOMY", 0, 8], ["Aliquots", "ORGANISM_SUBSTANCE", 0, 8], ["Aliquots", "TREATMENT", 0, 8], ["cryo-EM grids", "TREATMENT", 37, 50]]], ["For the 50 minutes incubation, collection of a substantial amount of data allowed unbiased particle picking and 2D classification which revealed two major structural classes with a similar number in each, (i) the prefusion conformation, and (ii) a radically different conformation (Methods , Table S4 and Figure S8 ).Mechanism of neutralisation of SARS-CoV-2 by CR3022 confirmed by cryo-EMDetailed analysis of the prefusion conformation led to a structure at a nominal resolution of 3.4 \u00c5 (FSC = 0.143), based on a broad distribution of orientations, that revealed the same predominant RBD pattern (one 'up' and two 'down') previously seen (Wrapp et al., 2020) with no evidence of CR3022 binding (Figure 4a , Figure S9 ).", [["SARS", "DISEASE", 348, 352], ["CR3022", "CHEMICAL", 362, 368], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 348, 358], ["CR3022", "SIMPLE_CHEMICAL", 362, 368], ["CR3022", "SIMPLE_CHEMICAL", 681, 687], ["RBD", "PROTEIN", 586, 589], ["CR3022", "PROTEIN", 681, 687], ["SARS-CoV", "SPECIES", 348, 356], ["2D classification", "TEST", 112, 129], ["neutralisation of SARS", "PROBLEM", 330, 352], ["CoV", "TEST", 353, 356], ["the prefusion conformation", "PROBLEM", 410, 436], ["FSC", "TEST", 490, 493], ["the same predominant RBD pattern", "PROBLEM", 565, 597], ["CR3022 binding", "PROBLEM", 681, 695], ["substantial", "OBSERVATION_MODIFIER", 47, 58], ["amount", "OBSERVATION_MODIFIER", 59, 65], ["similar", "OBSERVATION_MODIFIER", 181, 188], ["number", "OBSERVATION_MODIFIER", 189, 195], ["prefusion conformation", "OBSERVATION", 213, 235], ["neutralisation", "OBSERVATION", 330, 344], ["prefusion conformation", "OBSERVATION", 414, 436], ["predominant", "OBSERVATION_MODIFIER", 574, 585], ["RBD pattern", "OBSERVATION", 586, 597], ["no evidence of", "UNCERTAINTY", 666, 680]]], ["Analysis of the other major particle class revealed strong preferential orientation of the particles on the grid ( Figure S10a ).", [["strong", "OBSERVATION_MODIFIER", 52, 58], ["preferential", "OBSERVATION_MODIFIER", 59, 71], ["orientation", "OBSERVATION_MODIFIER", 72, 83]]], ["Despite this a reconstruction with a nominal resolution of 3.9 \u00c5 within the plane of the grid, and perhaps 7 \u00c5 resolution in the perpendicular direction ( Figure S10b ), could be produced which allowed the unambiguous fitting of the CR3022-RBD complex (Figure 4b ).Mechanism of neutralisation of SARS-CoV-2 by CR3022 confirmed by cryo-EMNote that in addition there is less well defined density attached to the RBD, in a suitable position to correspond to the Spike N-terminal domain (Wrapp et al., 2020) .", [["SARS", "DISEASE", 296, 300], ["N", "CHEMICAL", 465, 466], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 296, 306], ["CR3022", "ORGANISM", 310, 316], ["RBD", "GENE_OR_GENE_PRODUCT", 410, 413], ["CR3022", "PROTEIN", 233, 239], ["RBD complex", "PROTEIN", 240, 251], ["Figure 4b", "PROTEIN", 253, 262], ["RBD", "PROTEIN", 410, 413], ["Spike N-terminal domain", "PROTEIN", 459, 482], ["SARS-CoV", "SPECIES", 296, 304], ["this a reconstruction", "TREATMENT", 8, 29], ["neutralisation of SARS", "PROBLEM", 278, 300], ["CoV", "TEST", 301, 304], ["resolution", "OBSERVATION_MODIFIER", 111, 121], ["neutralisation", "OBSERVATION", 278, 292], ["less", "OBSERVATION_MODIFIER", 368, 372], ["well defined", "OBSERVATION_MODIFIER", 373, 385], ["density", "OBSERVATION", 386, 393], ["RBD", "OBSERVATION", 410, 413], ["Spike", "OBSERVATION_MODIFIER", 459, 464]]], ["These structures are no longer trimeric, rather two complexes associate to form an approximately symmetric dimer (however, application of this symmetry in the reconstruction process did not improve 1 0 the resolution).", [["an approximately symmetric dimer", "PROBLEM", 80, 112], ["this symmetry in the reconstruction process", "TREATMENT", 138, 181], ["no longer", "UNCERTAINTY", 21, 30], ["approximately", "OBSERVATION_MODIFIER", 83, 96], ["symmetric", "OBSERVATION_MODIFIER", 97, 106], ["dimer", "OBSERVATION", 107, 112]]], ["The interactions responsible for dimerisation involve the ACE2 binding site on the RBD and the elbow of the Fab, however the interaction does not occur in our lowresolution crystal form and is therefore probably extremely weak and not biologically significant.", [["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["elbow", "ORGANISM_SUBDIVISION", 95, 100], ["Fab", "GENE_OR_GENE_PRODUCT", 108, 111], ["ACE2 binding site", "PROTEIN", 58, 75], ["RBD", "PROTEIN", 83, 86], ["Fab", "PROTEIN", 108, 111], ["the ACE2 binding site", "PROBLEM", 54, 75], ["extremely weak", "PROBLEM", 212, 226], ["elbow", "ANATOMY", 95, 100]]], ["Since conversion to the post-fusion conformation leads to dissociation of S1Mechanism of neutralisation of SARS-CoV-2 by CR3022 confirmed by cryo-EM(which includes the N-terminal domain and RBD) these results confirm that CR3022 destabilises the prefusion Spike conformation.", [["SARS", "DISEASE", 107, 111], ["CR3022", "CHEMICAL", 222, 228], ["N-", "CHEMICAL", 168, 170], ["CR3022", "CHEMICAL", 222, 228], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 107, 117], ["CR3022", "SIMPLE_CHEMICAL", 121, 127], ["CR3022", "SIMPLE_CHEMICAL", 222, 228], ["S1Mechanism", "PROTEIN", 74, 85], ["CR3022", "PROTEIN", 121, 127], ["N-terminal domain", "PROTEIN", 168, 185], ["RBD", "PROTEIN", 190, 193], ["CR3022", "PROTEIN", 222, 228], ["prefusion Spike conformation", "PROTEIN", 246, 274], ["the post-fusion conformation", "TREATMENT", 20, 48], ["SARS", "PROBLEM", 107, 111], ["CoV", "TEST", 112, 115], ["the N-terminal domain and RBD", "PROBLEM", 164, 193], ["the prefusion Spike conformation", "PROBLEM", 242, 274], ["neutralisation", "OBSERVATION", 89, 103], ["prefusion Spike", "OBSERVATION", 246, 261]]], ["By this point there were no intact trimers remaining and a heterogeneous range of oligomeric assemblies had appeared, which we were not able to interpret in detail but which are consistent with the lateral assembly of Fab/RBD complexes ( Figure S11 ).", [["Fab", "GENE_OR_GENE_PRODUCT", 218, 221], ["Fab", "PROTEIN", 218, 221], ["RBD complexes", "PROTEIN", 222, 235], ["Figure S11", "PROTEIN", 238, 248], ["intact trimers", "PROBLEM", 28, 42], ["a heterogeneous range of oligomeric assemblies", "PROBLEM", 57, 103], ["Fab/RBD complexes", "PROBLEM", 218, 235], ["no", "UNCERTAINTY", 25, 27], ["intact", "OBSERVATION_MODIFIER", 28, 34], ["trimers", "OBSERVATION", 35, 42], ["heterogeneous", "OBSERVATION_MODIFIER", 59, 72], ["oligomeric assemblies", "OBSERVATION", 82, 103], ["consistent with", "UNCERTAINTY", 178, 193]]], ["Note that the relatively slow kinetics will not be representative of events in vivo, where the conversion might be accelerated by the elevated temperature and the absence of the mutations which were added to this construct to stabilise the prefusion state (Kirchdoerfer et al., 2018; Pallesen et al., 2017; Wrapp et al., 2020) .DiscussionUntil now the only documented mechanism of neutralisation of coronaviruses has been through blocking receptor attachment.", [["coronaviruses", "ORGANISM", 399, 412], ["the relatively slow kinetics", "PROBLEM", 10, 38], ["the elevated temperature", "PROBLEM", 130, 154], ["the mutations", "PROBLEM", 174, 187], ["neutralisation of coronaviruses", "PROBLEM", 381, 412], ["elevated", "OBSERVATION", 134, 142], ["neutralisation", "OBSERVATION", 381, 395], ["coronaviruses", "OBSERVATION", 399, 412]]], ["In the case of SARS-CoV this is achieved by presentation of the RBD of the Spike in an 'up' conformation.DiscussionAlthough not yet confirmed for SARS-CoV-2 it is very likely that a similar mechanism can apply.", [["SARS", "DISEASE", 15, 19], ["SARS", "DISEASE", 146, 150], ["SARS-CoV", "ORGANISM", 15, 23], ["SARS-CoV-2", "ORGANISM", 146, 156], ["RBD", "PROTEIN", 64, 67], ["Spike", "PROTEIN", 75, 80], ["SARS-CoV", "SPECIES", 15, 23], ["SARS-CoV", "SPECIES", 146, 154], ["SARS", "PROBLEM", 15, 19], ["the Spike", "PROBLEM", 71, 80], ["SARS", "PROBLEM", 146, 150], ["SARS", "OBSERVATION", 15, 19], ["very likely", "UNCERTAINTY", 163, 174]]], ["Here we define a second class of neutralisers, that bind a highly conserved epitope ( Figure S1 ) and can therefore act against both SARS-CoV and SARS-CoV-2 (CR3022 was first identified as a neutralising antibody against SARS-CoV (Ter Meulen et al., 2006) ).", [["SARS-CoV", "ORGANISM", 133, 141], ["SARS-CoV-2", "ORGANISM", 146, 156], ["CR3022", "ORGANISM", 158, 164], ["SARS-CoV", "ORGANISM", 221, 229], ["neutralising antibody", "PROTEIN", 191, 212], ["SARS-CoV", "SPECIES", 133, 141], ["SARS-CoV", "SPECIES", 146, 154], ["SARS-CoV", "SPECIES", 221, 229], ["neutralisers", "TREATMENT", 33, 45], ["both SARS", "PROBLEM", 128, 137], ["CoV", "TEST", 138, 141], ["SARS", "TEST", 146, 150], ["CoV", "TEST", 151, 154], ["a neutralising antibody", "TEST", 189, 212], ["SARS", "PROBLEM", 221, 225]]], ["We find that binding of CR3022 to the isolated RBD is tight (~20 nM) and the crystal structure of the complex reveals the atomic detail of the interaction.", [["CR3022", "CHEMICAL", 24, 30], ["RBD", "DISEASE", 47, 50], ["CR3022", "CHEMICAL", 24, 30], ["CR3022", "GENE_OR_GENE_PRODUCT", 24, 30], ["CR3022", "PROTEIN", 24, 30], ["RBD", "PROTEIN", 47, 50], ["RBD", "OBSERVATION", 47, 50], ["tight", "OBSERVATION_MODIFIER", 54, 59]]], ["Despite the spatial separation of the CR3022 and ACE2 epitopes we find an allosteric effect between the two binding events.", [["CR3022", "GENE_OR_GENE_PRODUCT", 38, 44], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["CR3022 and ACE2 epitopes", "PROTEIN", 38, 62], ["the CR3022 and ACE2 epitopes", "TREATMENT", 34, 62], ["an allosteric effect", "PROBLEM", 71, 91], ["allosteric effect", "OBSERVATION", 74, 91]]], ["The role of the 1 1 CR3022 epitope in stabilising the prefusion Spike trimer explains why it has, to date, proved impossible to generate mutations that escape binding of the antibody (Ter Meulen et al., 2006) .DiscussionWhilst in our assay CR3022 neutralises SARS-CoV-2, a recent paper (Yuan et al., 2020) reported an alternative assay that did not detect neutralisation.", [["CR3022", "CHEMICAL", 240, 246], ["CR3022", "GENE_OR_GENE_PRODUCT", 20, 26], ["CR3022", "SIMPLE_CHEMICAL", 240, 246], ["SARS-CoV-2", "ORGANISM", 259, 269], ["1 1 CR3022 epitope", "PROTEIN", 16, 34], ["prefusion Spike trimer", "PROTEIN", 54, 76], ["1 CR3022 epitope", "TREATMENT", 18, 34], ["an alternative assay", "TEST", 315, 335], ["neutralisation", "PROBLEM", 356, 370], ["neutralisation", "OBSERVATION", 356, 370]]], ["The difference is likely due to their removal of the antibody/virus mix after adsorption to the indicator cells, before incubating to allow cytopathic effect (CPE) to develop.", [["cells", "ANATOMY", 106, 111], ["cells", "CELL", 106, 111], ["antibody", "PROTEIN", 53, 61], ["indicator cells", "CELL_TYPE", 96, 111], ["their removal", "TREATMENT", 32, 45], ["the antibody/virus mix", "TREATMENT", 49, 71], ["cytopathic effect (CPE)", "PROBLEM", 140, 163], ["likely due to", "UNCERTAINTY", 18, 31]]], ["This would be in-line with the distinction previously seen between neutralisation tests for influenza virus by antibodies which bind the stem of hemagglutinin and therefore do not block receptor binding (Thomson et al., 2012) .", [["influenza virus", "DISEASE", 92, 107], ["influenza virus", "ORGANISM", 92, 107], ["antibodies", "PROTEIN", 111, 121], ["hemagglutinin", "PROTEIN", 145, 158], ["influenza virus", "SPECIES", 92, 107], ["neutralisation tests", "TEST", 67, 87], ["influenza virus", "PROBLEM", 92, 107], ["hemagglutinin", "TREATMENT", 145, 158]]], ["These antibodies did not appear to be neutralising when tested with the standard WHO neutralisation assay, in which a similar protocol is used to that adopted by Yuan et al, in which the inoculum of virus/antibody is washed out before development of CPE.DiscussionNeutralisation was observed, however, when the antibodies were left in the assay during incubation to produce CPE.", [["antibodies", "PROTEIN", 6, 16], ["antibodies", "PROTEIN", 311, 321], ["the standard WHO neutralisation assay", "TEST", 68, 105], ["a similar protocol", "TREATMENT", 116, 134], ["virus/antibody", "TREATMENT", 199, 213], ["CPE", "PROBLEM", 250, 253], ["the antibodies", "TEST", 307, 321], ["CPE", "PROBLEM", 374, 377], ["CPE", "OBSERVATION", 250, 253]]], ["By analogy we would expect antibodies to the RBD that block attachment to ACE2 to behave in a similar way to antibodies against the globular head of HA, whilst antibodies such as CR3022, that neutralise by an alternative mechanism to blocking receptor attachment, may need to be present throughout the incubation period with the indicator cells to reveal neutralisation.", [["head", "ANATOMY", 141, 145], ["cells", "ANATOMY", 339, 344], ["CR3022", "CHEMICAL", 179, 185], ["RBD", "GENE_OR_GENE_PRODUCT", 45, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 74, 78], ["head", "ORGAN", 141, 145], ["HA", "GENE_OR_GENE_PRODUCT", 149, 151], ["CR3022", "GENE_OR_GENE_PRODUCT", 179, 185], ["cells", "CELL", 339, 344], ["antibodies", "PROTEIN", 27, 37], ["RBD", "PROTEIN", 45, 48], ["ACE2", "PROTEIN", 74, 78], ["antibodies", "PROTEIN", 109, 119], ["antibodies", "PROTEIN", 160, 170], ["CR3022", "PROTEIN", 179, 185], ["antibodies", "PROBLEM", 27, 37], ["the RBD", "PROBLEM", 41, 48], ["ACE2", "TREATMENT", 74, 78], ["the globular head of HA", "PROBLEM", 128, 151], ["neutralisation", "PROBLEM", 355, 369], ["neutralisation", "OBSERVATION", 355, 369]]], ["This agrees with our observation that, in the absence of ACE2, the CR3022 Fab destroys the prefusion-stabilised trimer (T 1/2 ~1h at room temperature as measured by cryo-EM).DiscussionWith monoclonal antibodies now recognised as potential antivirals (Lu et al., 2020b; Salazar et al., 2017) our results suggest that CR3022 may be of immediate utility, since the mechanism of neutralisation will be unusually resistant to virus escape.", [["CR3022", "CHEMICAL", 316, 322], ["ACE2", "GENE_OR_GENE_PRODUCT", 57, 61], ["CR3022 Fab", "GENE_OR_GENE_PRODUCT", 67, 77], ["CR3022", "SIMPLE_CHEMICAL", 316, 322], ["ACE2", "PROTEIN", 57, 61], ["CR3022 Fab", "PROTEIN", 67, 77], ["prefusion-stabilised trimer", "PROTEIN", 91, 118], ["monoclonal antibodies", "PROTEIN", 189, 210], ["ACE2", "TEST", 57, 61], ["monoclonal antibodies", "TEST", 189, 210], ["neutralisation", "PROBLEM", 375, 389], ["virus escape", "PROBLEM", 421, 433]]], ["In contrast antibodies which compete with ACE2 (whose epitope on SARS-CoV-2 is reported to have already 1 2Discussionshown mutation at residue 495 (GISAID: Accession ID: EPI_ISL_429783 Wienecke-Baldacchino et al., 2020 (Shu and McCauley, 2017) ), are likely to be susceptible to escape.DiscussionFurthermore, with knowledge of the detailed structure of the epitope presented here a higher affinity version of CR3022 might be engineered.", [["CR3022", "CHEMICAL", 409, 415], ["ACE2", "GENE_OR_GENE_PRODUCT", 42, 46], ["SARS-CoV-2", "ORGANISM", 65, 75], ["CR3022", "SIMPLE_CHEMICAL", 409, 415], ["antibodies", "PROTEIN", 12, 22], ["ACE2", "PROTEIN", 42, 46], ["epitope", "PROTEIN", 357, 364], ["CR3022", "PROTEIN", 409, 415], ["a higher affinity version of CR3022", "TREATMENT", 380, 415], ["likely to be", "UNCERTAINTY", 251, 263], ["escape", "OBSERVATION", 279, 285]]], ["Alternatively, since the same mechanism of neutralisation is likely to be used by other antibodies, a more potent monoclonal antibody targeting the same epitope might be found (for instance by screening for competition with CR3022).", [["CR3022", "CHEMICAL", 224, 230], ["antibodies", "PROTEIN", 88, 98], ["monoclonal antibody", "PROTEIN", 114, 133], ["CR3022", "PROTEIN", 224, 230], ["neutralisation", "PROBLEM", 43, 57], ["other antibodies", "PROBLEM", 82, 98], ["a more potent monoclonal antibody", "PROBLEM", 100, 133], ["neutralisation", "OBSERVATION", 43, 57]]], ["Additionally, since this epitope is sterically and functionally independent of the well-established receptor-blocking neutralising antibody epitope there is considerable scope for therapeutic synergy between antibodies targeting the two epitopes (indeed this type ofBio-layer interferometryTo further validate the SPR results the K D of Fab CR3022 for RBD was also measured by bio-layer interferometry.", [["K D", "GENE_OR_GENE_PRODUCT", 330, 333], ["Fab CR3022", "GENE_OR_GENE_PRODUCT", 337, 347], ["neutralising antibody epitope", "PROTEIN", 118, 147], ["antibodies", "PROTEIN", 208, 218], ["epitopes", "PROTEIN", 237, 245], ["Fab CR3022", "PROTEIN", 337, 347], ["RBD", "PROTEIN", 352, 355], ["receptor-blocking neutralising antibody epitope", "TREATMENT", 100, 147], ["therapeutic synergy", "PROBLEM", 180, 199], ["antibodies", "TREATMENT", 208, 218], ["Bio-layer interferometry", "TREATMENT", 266, 290], ["the SPR", "TEST", 310, 317], ["the K D of Fab CR3022", "TEST", 326, 347], ["RBD", "PROBLEM", 352, 355]]], ["Kinetic assays were performed on an Octet Red 96e (ForteBio) at 30 \u2103 with a shake speed of 1000 rpm.", [["Octet Red 96e", "SPECIES", 36, 49], ["Kinetic assays", "TEST", 0, 14]]], ["Fab CR3022 was immobilized onto amine reactive 2nd generation (AR2G) biosensors (ForteBio) and serially diluted RBD (80\uff0c40\uff0c20\uff0c10 and 5 nM) was used as analyte.", [["CR3022", "CHEMICAL", 4, 10], ["amine", "CHEMICAL", 32, 37], ["amine", "CHEMICAL", 32, 37], ["Fab", "GENE_OR_GENE_PRODUCT", 0, 3], ["AR2G", "SIMPLE_CHEMICAL", 63, 67], ["ForteBio", "SIMPLE_CHEMICAL", 81, 89], ["Fab CR3022", "TEST", 0, 10], ["amine reactive 2nd generation (AR2G) biosensors", "TREATMENT", 32, 79], ["serially diluted RBD", "TEST", 95, 115]]], ["PBS (pH 7.4) was used as the assay buffer.", [["PBS", "SIMPLE_CHEMICAL", 0, 3], ["PBS", "TEST", 0, 3], ["pH", "TEST", 5, 7], ["the assay buffer", "TREATMENT", 25, 41]]], ["Recorded data were analysed using the Data Analysis Software HT v11.1 (Fortebio), with a global 1:1 fitting model.NeutralisationNeutralising virus titres were measured in serum samples that had been heat-inactivated at 56 \u00b0C for 30 minutes.", [["serum samples", "ANATOMY", 171, 184], ["serum samples", "ORGANISM_SUBSTANCE", 171, 184], ["the Data Analysis", "TEST", 34, 51], ["Software HT v", "TEST", 52, 65], ["NeutralisationNeutralising virus titres", "TREATMENT", 114, 153], ["serum samples", "TEST", 171, 184]]], ["SARS-CoV-2 (strain Victoria/1/2020 at cell passage 3 (Caly et al., 2020) ) was diluted to a concentration of 1.4E+03 pfu/mL (70 pfu/50 \u00b5l) and mixed 50:50 in 1% FCS/MEM containing 25 mM HEPES buffer with doubling serum dilutions from 1:10 to 1:320 in a 96-well V-bottomed plate.8The plate was incubated at 37 \u00b0C in a humidified box for 1 hour to allow the antibody in the serum samples to neutralise the virus.", [["cell", "ANATOMY", 38, 42], ["serum", "ANATOMY", 213, 218], ["serum samples", "ANATOMY", 372, 385], ["SARS", "DISEASE", 0, 4], ["HEPES", "CHEMICAL", 186, 191], ["SARS-CoV-2", "ORGANISM", 0, 10], ["cell", "CELL", 38, 42], ["serum", "ORGANISM_SUBSTANCE", 213, 218], ["serum samples", "ORGANISM_SUBSTANCE", 372, 385], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["25 mM HEPES buffer", "TREATMENT", 180, 198], ["doubling serum dilutions", "TEST", 204, 228], ["a humidified box", "TREATMENT", 315, 331], ["the antibody", "TEST", 352, 364], ["the serum samples", "TEST", 368, 385], ["the virus", "PROBLEM", 400, 409], ["plate", "OBSERVATION_MODIFIER", 283, 288]]], ["CR3022 (pH7.2) at a starting concentration of 2 mg/mL was diluted 1 in 10.", [["CR3022", "CHEMICAL", 0, 6], ["CR3022", "CHEMICAL", 0, 6], ["CR3022", "SIMPLE_CHEMICAL", 0, 6], ["a starting concentration", "TREATMENT", 18, 42]]], ["The dilutions were then made 2-fold up to 320.", [["The dilutions", "TEST", 0, 13]]], ["The neutralised virus was transferred into the wells of a twice DPBS-washed plaque assay 24-well plate that had been seeded with Vero/hSLAM the previous day at 1.5E+05 cells per well in 10% FCS/MEM.", [["plaque", "ANATOMY", 76, 82], ["E+05 cells", "ANATOMY", 163, 173], ["E+05 cells", "CELL", 163, 173], ["The neutralised virus", "PROBLEM", 0, 21], ["a twice DPBS", "TREATMENT", 56, 68], ["plaque assay", "TEST", 76, 88], ["Vero/hSLAM", "TREATMENT", 129, 139], ["virus", "OBSERVATION", 16, 21]]], ["Neutralised virus was allowed to adsorb at 37 \u00b0C for a further hour, and overlaid with plaque assay overlay media (1X MEM/1.5% CMC/4% FCS final).", [["plaque", "ANATOMY", 87, 93], ["Neutralised virus", "PROBLEM", 0, 17], ["plaque assay overlay media", "TREATMENT", 87, 113], ["plaque", "OBSERVATION", 87, 93]]], ["After 5 days incubation at 37 \u00b0C in a humified box, the plates were fixed, stained and plaques counted.8Dilutions and controls were performed in duplicate.", [["plaques", "ANATOMY", 87, 94], ["a humified box", "TREATMENT", 36, 50], ["the plates", "TEST", 52, 62], ["plaques", "PROBLEM", 87, 94], ["plaques", "OBSERVATION", 87, 94]]], ["Median neutralising titres (ND50) were determined using the Spearman-Karber formula (K\u00e4rber, 1931) relative to virus only control wells.Crystallization, data collection and X-ray structure determinationPurified and deglycosylated RBD and CR3022 Fab were concentrated to 8.3 mg/mL and 11 mg/mL respectively, and then mixed in an approximate molar ratio of 1:1.", [["X", "PROTEIN", 173, 174], ["deglycosylated RBD", "PROTEIN", 215, 233], ["CR3022 Fab", "PROTEIN", 238, 248], ["Median neutralising titres (ND50)", "TREATMENT", 0, 33], ["Crystallization", "TEST", 136, 151], ["data collection", "TEST", 153, 168], ["X-ray structure", "TEST", 173, 188], ["deglycosylated RBD", "TEST", 215, 233], ["CR", "TEST", 238, 240], ["Fab", "TEST", 245, 248], ["an approximate molar ratio", "TREATMENT", 325, 351]]], ["Crystallization screen experiments were carried out using the nanolitre sitting-drop vapour diffusion method in 96-well plates as previously described (Walter et al., 2003 (Walter et al., , 2005 transmission).", [["Crystallization screen experiments", "TEST", 0, 34], ["the nanolitre sitting", "TEST", 58, 79], ["vapour diffusion method", "TEST", 85, 108]]], ["The data set of 720\u00b0 was collected from a single frozen crystal to 4.4 \u00c5 resolution with 52-fold redundancy.", [["The data", "TEST", 0, 8], ["a single frozen crystal", "TREATMENT", 40, 63], ["52-fold redundancy", "PROBLEM", 89, 107], ["-fold", "OBSERVATION_MODIFIER", 91, 96], ["redundancy", "OBSERVATION", 97, 107]]], ["The crystal belongs to space group P4 1 2 1 2 with unit cell dimensions a = b = 150.5 \u00c5 and c = 241.6 \u00c5.", [["cell", "ANATOMY", 56, 60], ["The crystal belongs to space group P4", "TEST", 0, 37], ["unit cell dimensions", "TEST", 51, 71], ["c", "TEST", 92, 93]]], ["The structure was determined by molecular replacement with PHASER (McCoy et al., 2007) using search models of human germline antibody Fabs 5-51/O12 (PDB ID, 4KMT (Teplyakov et al., 2014) ) heavy chain and IGHV3-23/IGK4-1 (PDB ID, 5I1D (Teplyakov et al., 2016) ) light chain, and RBD of SARS-CoV-2 RBD/ACE2 complex (PDB ID, 6M0J (Lan et al., 2020) ).", [["human", "ORGANISM", 110, 115], ["IGK4-1", "GENE_OR_GENE_PRODUCT", 214, 220], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 286, 296], ["ACE2", "GENE_OR_GENE_PRODUCT", 301, 305], ["human germline antibody Fabs 5-51", "PROTEIN", 110, 143], ["O12", "PROTEIN", 144, 147], ["IGHV3", "PROTEIN", 205, 210], ["IGK4", "PROTEIN", 214, 218], ["Teplyakov et al., 2016) ) light chain", "PROTEIN", 236, 273], ["RBD", "PROTEIN", 279, 282], ["SARS-CoV-2 RBD", "PROTEIN", 286, 300], ["ACE2 complex", "PROTEIN", 301, 313], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["SARS-CoV", "SPECIES", 286, 294], ["search models", "TEST", 93, 106], ["human germline antibody Fabs", "TEST", 110, 138], ["PDB ID", "TEST", 149, 155], ["heavy chain", "TEST", 189, 200], ["IGHV3", "TEST", 205, 210], ["IGK4", "TEST", 214, 218], ["light chain", "TEST", 262, 273], ["SARS", "TEST", 286, 290], ["CoV", "TEST", 291, 294]]], ["There is one RBD/CR3022 complex in the crystal asymmetric unit, resulting in a crystal solvent content of ~87%.Crystallization, data collection and X-ray structure determinationDuring optimization of the crystallization conditions, a second crystal form was found to grow in the same condition with similar morphology.", [["CR3022", "CHEMICAL", 17, 23], ["RBD", "PROTEIN", 13, 16], ["CR3022 complex", "PROTEIN", 17, 31], ["a crystal solvent content", "TEST", 77, 102], ["Crystallization", "TEST", 111, 126], ["data collection", "TEST", 128, 143], ["X-ray structure", "TREATMENT", 148, 163], ["the crystallization conditions", "PROBLEM", 200, 230], ["one", "OBSERVATION_MODIFIER", 9, 12], ["RBD", "OBSERVATION", 13, 16], ["crystal", "OBSERVATION_MODIFIER", 39, 46], ["asymmetric", "OBSERVATION_MODIFIER", 47, 57], ["crystal", "OBSERVATION_MODIFIER", 79, 86], ["solvent content", "OBSERVATION", 87, 102], ["similar morphology", "OBSERVATION", 299, 317]]], ["A data set of 720\u00b0 rotation with data extending to 2.4 \u00c5 was collected on beamline I03 of Diamond from one of these crystals (exposure time 0.004 s per 0.1\u00b0 frame, beam size 80\u00d720 \u03bc m and 100% beam transmission).Crystallization, data collection and X-ray structure determinationThe crystal also belongs to space group P4 1 2 1 2 but with significantly different unit cell dimensions (a = b = 163.1 \u00c5 and c = 189.1 \u00c5).", [["cell", "ANATOMY", 367, 371], ["cell", "CELL", 367, 371], ["A data", "TEST", 0, 6], ["beam size", "TEST", 164, 173], ["Crystallization", "TEST", 212, 227], ["data collection", "TEST", 229, 244], ["X-ray structure determination", "TEST", 249, 278], ["space group P4", "TEST", 306, 320], ["c", "TEST", 404, 405]]], ["There were two RBD/CR3022 complexes in the asymmetric unit and a solvent content of ~74%.X-ray crystallographic refinement and electron density map generationThe initial structure was determined using the lower resolution data from the first crystal form.", [["CR3022", "CHEMICAL", 19, 25], ["electron", "SIMPLE_CHEMICAL", 127, 135], ["RBD", "PROTEIN", 15, 18], ["CR3022 complexes", "PROTEIN", 19, 35], ["a solvent content", "TEST", 63, 80], ["X-ray crystallographic refinement", "TREATMENT", 89, 122], ["electron density map generation", "TREATMENT", 127, 158], ["two", "OBSERVATION_MODIFIER", 11, 14], ["RBD", "OBSERVATION", 15, 18], ["asymmetric", "OBSERVATION_MODIFIER", 43, 53], ["solvent content", "OBSERVATION", 65, 80]]], ["Data were excluded at a resolution below 35 \u00c5 as these fell under the beamstop shadow.", [["beamstop shadow", "OBSERVATION", 70, 85]]], ["One cycle of REFMAC5 (Murshudov et al., 2011) was used to refine atomic coordinates after manual correction in COOT (Emsley and Cowtan, 2004) Figure S5 ).", [["REFMAC5", "TREATMENT", 13, 20]]], ["The final refined structure had an R work of 0.331 (R free , 0.315) for all data to 4.36 \u00c5 resolution.", [["an R work", "TEST", 32, 41], ["all data", "TEST", 72, 80]]], ["This structure was later used to determine the structure of the second crystal form, which has been refined with PHENIX (Liebschner et al., 2019) to R work = 0.213 and R free = 0.239 for all data to 2.42 \u00c5 resolution.", [["all data", "TEST", 187, 195]]], ["This refined modelX-ray crystallographic refinement and electron density map generationrevealed the presence of one extra residue at each heavy chain N-terminus and 3 extra residues at the N-terminus of one RBD from the signal peptide.", [["N", "CHEMICAL", 150, 151], ["N", "CHEMICAL", 189, 190], ["heavy chain N-terminus", "PROTEIN", 138, 160], ["N-terminus", "PROTEIN", 189, 199], ["RBD", "PROTEIN", 207, 210], ["This refined modelX", "TEST", 0, 19], ["electron density map", "TEST", 56, 76], ["one extra residue", "PROBLEM", 112, 129], ["3 extra residues", "TREATMENT", 165, 181], ["extra residue", "OBSERVATION", 116, 129]]], ["There is well ordered density for a single glycan at each of the glycosylation sites at N331 and N343 in one RBD, and only one at N343 in the second RBD.1Data collection and structure refinement statistics are given in Table S3 .", [["RBD", "DISEASE", 149, 152], ["glycosylation sites", "PROTEIN", 65, 84], ["N331", "PROTEIN", 88, 92], ["N343", "PROTEIN", 97, 101], ["RBD", "PROTEIN", 109, 112], ["N343", "PROTEIN", 130, 134], ["RBD", "PROTEIN", 149, 152], ["a single glycan", "TREATMENT", 34, 49], ["the glycosylation sites", "TREATMENT", 61, 84], ["density", "OBSERVATION", 22, 29], ["RBD", "OBSERVATION", 149, 152]]], ["Structural comparisons used SHP (Stuart et al., 1979) , residues forming the RBD/Fab interface were identified with PISA (Krissinel and Henrick, 2007) , figures were prepared with PyMOL (The PyMOL Molecular Graphics System, Version 1.2r3pre, Schr\u00f6dinger, LLC).CR3022 Fab complex preparation and cryo-EM data collectionPurified spike protein was buffer exchanged into 2 mM Tris pH 8.0, 200 mM NaCl, 0.02 % NaN3 buffer using a desalting column (Zeba, Thermo Fisher \u03bc m and at a nominal magnification of x105,000, corresponding to a calibrated pixel size of 0.83 \u00c5/pixel, see Table S4 .CR3022 Fab complex preparation and cryo-EM data collectionCryo-EM data processing 2 2CR3022 Fab complex preparation and cryo-EM data collectionFor both the 50 minute and 3 h incubation datasets, motion correction and alignment of 2x binned super-resolution movies was performed using Relion3.1.", [["CR3022", "CHEMICAL", 260, 266], ["NaCl", "CHEMICAL", 392, 396], ["NaCl", "CHEMICAL", 392, 396], ["NaN3", "CHEMICAL", 405, 409], ["SHP", "GENE_OR_GENE_PRODUCT", 28, 31], ["Fab", "GENE_OR_GENE_PRODUCT", 81, 84], ["NaN3", "SIMPLE_CHEMICAL", 405, 409], ["SHP", "PROTEIN", 28, 31], ["RBD", "PROTEIN", 77, 80], ["CR3022 Fab complex", "PROTEIN", 260, 278], ["cryo-EM data collectionPurified spike protein", "PROTEIN", 295, 340], ["Relion3", "PROTEIN", 867, 874], ["cryo-EM data", "TEST", 295, 307], ["spike protein", "PROBLEM", 327, 340], ["Tris pH", "TEST", 372, 379], ["NaCl", "TEST", 392, 396], ["NaN3 buffer", "TREATMENT", 405, 416], ["a desalting column", "TREATMENT", 423, 441], ["a calibrated pixel size", "TEST", 528, 551], ["CR", "TEST", 583, 585], ["Fab complex preparation", "TREATMENT", 590, 613], ["cryo-EM data collection", "TEST", 618, 641], ["Fab complex preparation", "TREATMENT", 675, 698], ["cryo-EM data collection", "TEST", 703, 726], ["motion correction", "TREATMENT", 778, 795], ["LLC", "ANATOMY", 255, 258]]], ["CTF-estimation with GCTF (v1.06) (Zhang, 2016) and non-template-driven particle picking was then performed within cryoSPARC v2.14.1-live followed by multiple rounds of 2D classification (Punjani et al., 2017) .CR3022 Fab complex preparation and cryo-EM data collectionFor the 50 minutes dataset.", [["CTF", "PROTEIN", 0, 3], ["cryoSPARC v2.14.1", "CELL_LINE", 114, 131], ["CTF", "TEST", 0, 3], ["GCTF", "TEST", 20, 24], ["non-template", "TREATMENT", 51, 63], ["cryoSPARC", "TEST", 114, 123], ["CR", "TEST", 210, 212], ["cryo-EM data collection", "TEST", 245, 268]]], ["Both structures were then sharpened in cryoSPARC.", [["cryoSPARC", "TEST", 39, 48], ["structures", "ANATOMY_MODIFIER", 5, 15], ["sharpened", "OBSERVATION_MODIFIER", 26, 35]]], ["Data processing and refinement statistics are given in Table S4 .CR3022 Fab complex preparation and cryo-EM data collectionAn initial model for the spike (structure-A) was generated using PDB ID, 6VYB (Walls et al., 2020) and rigid body fitted into the final map using COOT (Emsley and Cowtan, 2004) .CR3022 Fab complex preparation and cryo-EM data collectionThe model was further refined in real space with PHENIX (Liebschner et al., 2019) which resulted in a correlation coefficient of 0.84.", [["body", "ANATOMY", 232, 236], ["body", "ORGANISM_SUBDIVISION", 232, 236], ["CR3022 Fab complex", "PROTEIN", 301, 319], ["CR", "TEST", 65, 67], ["cryo-EM data", "TEST", 100, 112], ["CR", "TEST", 301, 303], ["Fab complex preparation", "TREATMENT", 308, 331], ["cryo-EM data collection", "TEST", 336, 359]]], ["Two copies of RBD-CR3022 were fitted into structure-B in the same manner.", [["RBD-CR3022", "GENE_OR_GENE_PRODUCT", 14, 24], ["RBD", "PROTEIN", 14, 17], ["CR3022", "DNA", 18, 24], ["RBD", "TEST", 14, 17], ["CR3022", "TEST", 18, 24], ["RBD", "OBSERVATION", 14, 17]]], ["Because of the strongly anisotropic resolution the overall correlation coefficient vs the model was lower (0.47).CR3022 Fab complex preparation and cryo-EM data collectionFor the 3 h incubation dataset, particles were extracted with a larger box size (686 pixels as compared to 540 pixels), and, following multiple rounds of 2D classification, 2D class averages from 'blob-picked' particles showing signs of complete 'flower-like' structures were selected for ab initio reconstruction.", [["flower", "ANATOMY", 418, 424], ["CR3022 Fab complex", "PROTEIN", 113, 131], ["cryo-EM data collection", "TEST", 148, 171], ["the 3 h incubation dataset", "TREATMENT", 175, 201], ["'blob", "TEST", 367, 372], ["complete 'flower-like' structures", "PROBLEM", 408, 441], ["ab initio reconstruction", "TREATMENT", 460, 484], ["larger", "OBSERVATION_MODIFIER", 235, 241], ["size", "OBSERVATION_MODIFIER", 246, 250]]]], "PMC7154517": [["Physical activity guidelinesCurrent guidelines on physical activity for children and adolescents aged 5\u201317 years generally recommend at least 60 min daily of the following moderate- to vigorous-intensity physical activities:7\u2022Aerobic activities: Most of the daily activities should be moderate- to vigorous-intensity aerobic activities, such as bicycling, playing sports and active games, and brisk walking.\u2022Strength training: The program should include muscle-strengthening activities at least 3 days a week, such as performing calisthenics, weight-bearing activities, and weight training.\u2022Bone strengthening: Bone-strengthening activities should also be included at least 3 days a week, such as jumping rope, playing tennis or badminton, and engaging in other hopping-type activities.", [["muscle", "ANATOMY", 454, 460], ["Bone", "ANATOMY", 591, 595], ["Bone", "ANATOMY", 611, 615], ["children", "ORGANISM", 72, 80], ["muscle", "ORGAN", 454, 460], ["Bone", "TISSUE", 591, 595], ["Bone", "TISSUE", 611, 615], ["children", "SPECIES", 72, 80], ["adolescents", "SPECIES", 85, 96], ["weight training", "TREATMENT", 574, 589], ["muscle", "ANATOMY", 454, 460], ["Bone", "ANATOMY", 611, 615]]]]}